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Abstract 
Methionine is one of the seven essential amino-acids for humans and is also used in 
feed supplements, predominantly for poultry and felines. Thus there is commercial 
interest in producing this nutrient. The final step in the biological synthesis of 
methionine is the addition of a methyl group to the sulphur of homocysteine; two 
enzymes can perform this step. They are referred to as the cobalamin-dependent and 
cobalamin-independent enzymes. Cobalamin-dependent Methionine Synthase (cdMS) 
catalyzes the transfer of a methyl group from methyl-tetrahydrofolate (MTHF) via the 
(corrin-bound) cobalt of cobalamin to homocysteine to form methionine and 
tetrahydrofolate.  During the catalytic cycle of the B12-dependent methionine synthase 
the cobalt ion shunts between Co1+ and Co3+ states, but occasionally the cobalt ion 
becomes derailed due to oxidative stress to the Co2+ state.  
The bacterium of interest in this study, Corynebacterium glutamicum, possesses a 
genome which encodes genes for both a cobalamin independent and cobalamin 
dependent methionine synthase. However, it does not possess a methionine synthase 
reductase (MSR) remotely similar to those of Escherichia coli or Homo sapiens, both of 
which utilise a flavin to reduce the Co2+ centrally-ligated cobalt of cobalamin to Co1+ 
during reactivation. The investigations into this unknown methionine synthase reductase 
lead to the identification of three ferredoxins, FdxA, B and C, of which FdxC was 
identified as a potential MSR by complementation studies. This ferredoxin is unlike any 
encoded for by E. coli and further lead to the identification of a ferredoxin reductase in 
C. glutamicum which was capable of reducing the highly electronegative 2[4Fe4S] 
clusters contained within itself and FdxA, which are highly similar. Further assay-based 
studies by HPLC-MS, HPLC-MS/MS and EPR revealed that despite their similarities, 
only FdxC could act in the role of MSR with any great efficacy. 
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1: Introduction 
Amino acids are a class of chemical comprising of an amine group and a carboxylic 
acid group linked by a central carbon with a further side chain present, depending on the 
amino acid in question. There are 20 amino acids used for protein synthesis, thus 
playing a role throughout all cells, but that is not the limit of amino acids. Others 
include selenocysteine, selenomethionine or ethionine, which are analogs of those 
amino acids used in the synthesis of proteins. Of the 20 amino acids required to 
synthesise proteins, 8 are ‘essential’ for humans and other animals and cannot be 
synthesised de novo. Five of these are derived from aspartate, and two contain sulphur. 
Many other substrates and cofactors (such as S-adenosyl methionine, SAM) within 
normal cellular processes are derived from amino acids. For these reasons, there is great 
interest in the biotechnological production of amino acids. Chemical synthesis of amino 
acids utilises the Strecker syntheses (Groger 2003) to produce amino acids. This is one 
of the simplest methods of chemical synthesis of amino acids but is still inferior to a 
well optimised biological synthesis mechanism. 
 
1.1: Methionine 
Methionine is a hydrophobic, non-polar amino-acid. Alongside histidine, lysine and 
threonine, methionine is derived from aspartate (Neway 1989). It is the first of two 
sulphur-containing amino-acids, the second of which, cysteine, can be derived from 
methionine (Hullo et al. 2007). As a sulphur containing amino acid, synthesis is 
significantly more challenging, not least of all because a source of sulphur is usually 
fairly limited within biological systems. Methionine has many roles within the cell. 
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1.1.1: The role of methionine in the cell 
As one of the twenty universal amino-acids, methionine plays a role in protein synthesis 
in all prokaryotes and eukaryotes from the smallest of bacteria to the largest mammals. 
It is coded for in the DNA by a single triplet codon, ATG, which acts as the ‘start’ 
codon for all proteins. It is, therefore, absolutely essential in all protein synthesis 
regardless of whether the N-terminal of the protein is cleaved post-translation. Because 
of this, a large amount of research has gone into studying synthesis, utilisation and 
breakdown in multiple organisms for potential exploitation in the biotechnology 
industry. As the final precursor to S-adenosylmethionine (SAM) methionine also has a 
critical role all of the functions that SAM carries out in a cell; methyl-group donation in 
varying mechanisms – including the reactivation (Dixon et al. 1996) of cobalamin-
dependent Methionine Synthase itself – to the one-carbon metabolism and generation of 
a source of radicals when required (Sofia et al. 2001). Lacking the complexity of plants 
and animals, bacteria really only utilise methionine in the methods described above. 
Some bacteria can utilise SAM in a method that other organisms cannot – SAM is used, 
again, as a methyl donor for the safe elimination of toxic metalloids such as arsenic 
(Bentley and Chasteen 2002).  
 
In plants, methionine is the essential precursor for the plant hormone ethylene (Yang et 
al. 1966) which causes fruit ripening (Yang 1967). For animals, methionine is 
frequently used as a feed supplement for cattle and poultry, particularly broiler-farmed 
chickens. It helps to increase muscle mass (Zhan 2005), and aids in proper development 
of feathers due to high levels of cysteine (Guichard 2008). Finally, as humans – and 
other mammals – cannot synthesise methionine de novo in the way that bacteria or 
plants are able, the specific roles of methionine in these organisms tends to revolve 
around what happens when there is a lack of methionine. There has been no clinical 
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evidence that great excess of free methionine is toxic unless there are reduced levels of 
the vitamins B6, B9 and B12 (Toborek 1996) which causes increased homocysteine load, 
which itself can lead to atherosclerosis. There is evidence, limited though it is, that 
supplementation of dietary methionine can be useful in treating urinary tract infections 
(Funfstuck et al. 1997), acetaminophen poisoning (Neuvonen et al. 1985) and 
improving the immune function of HIV compromised individuals (Van Brummelen 
2006). 
 
1.1.2: Synthesis of methionine 
Methionine is synthesised by all plants and bacteria, but is not synthesised de novo by 
any mammals. Most mammals possess a cobalamin-dependent Methionine Synthase – 
they usually lack the genes for intermediate steps in the methionine synthesis pathway. 
The cyclic nature of the relationship between methionine, SAM, S-adenosyl 
homocysteine (SAH) and homocysteine is likely why this has occurred; allowing 
recycling of SAM. 
 
The final step in the pathway from aspartate (Fig. 1.1, point [7]) is arguably the most 
important. Methylation occurs via one of two gene products; the first, metE is the 
cobalamin-independent methionine synthase. While this does not require cobalamin, its 
rate of turnover is much slower than the cobalamin-dependent methionine synthase (the 
metH gene product). Any bacterium unable to synthesise cobalamin, must obtain it from 
the environment in order to utilise the metH gene product for methionine synthesis. The 
question of cobalamin import into cells is an interesting one in itself – cobalamin is 
arguably the largest and most complex of all the biologically produced molecules, and 
the mechanism of transport into a cell must be a significant biological challenge. The 
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investigation of cobalamin transport into the cell is outside the scope of this 
investigation, however. 
Figure 1.1: Biosynthesis of methionine in C. glutamicum (Ruckert et al. 2003). [1] 
Aspatate kinase, [2] aspartaldehyde dehydrogenase, [3] homoserine dehydrogenase, [4] 
homoserine O-acetyletransferase, [5] O-acetylhomoserine (thiol)-lyase (cystathionine g-
synthase), [6] cystathionine g-lyase, [7] homocysteine S-methyltransferase (metE-
encoded vitamin B12 independent or metH-encoded, vitamin B12 dependent), [8] 
homoserine kinase, [9] threonine synthase. 
 
Most of the understanding of methionine synthase comes from the E. coli cobalamin-
dependent methionine synthase, the structure of which has been partially solved 
(Drennan et al. 1994; Amaratunga et al. 1996; Dixon et al. 1996; Datta et al. 2008). The 
C. glutamicum cobalamin-dependent methionine synthase (metH gene product) is 
approximately 135kDa in size, and while the structure has been hypothesised by 
similarity to E. coli metH it has not been solved. 
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In the simplest terms, the metH gene product is a methyltransferase. The breadth and 
variety of the group of proteins described as methyltransferases is not to be 
underestimated (Schubert et al. 2003) where five distinct protein folds have been 
identified. They range from cobalamin-dependent and independent methionine 
synthases (Gonzalez et al. 1992), to salicylic acid carboxyl methyltransferase 
(Hendricks et al. 2004), the uroporphyrinogen III methyltransferase CobA, part of the 
cobalamin biosynthetic operon (Vevodova et al. 2004) to the cobalt-precorrin-4 
methyltransferase CbiF and cobalamin C20 methyltransferase CbiL (Frank et al. 2005; 
Frank et al. 2007). 
 
Cobalamin-dependent methionine synthase (cdMS) catalyses the transfer of a methyl 
group from methyl-tetrahydrofolate (MTHF) via cobalamin to homocysteine, resulting 
in the products methionine and tetrahydrofolate (THF). It can also be described by the 
systematic name 5-methyltetrahydrofolate homocysteine methyltransferase. Unlike the 
metE (cobalamin independent methionine synthase) gene product, the metH product 
sometimes ‘derails’ every 200-1000 cycles (Wolthers and Scrutton 2007) this is because 
the process involves the cycling of tetrapyrrole-bound cobalt from its Co1+ form to its 
Co3+ form, which occasionally fails at the methylation step due to oxidative stress 
(Figure 1.2).  
This causes the cobalamin to move to a Co2+ state, which cannot be used in the 
methylation of homocysteine. In E. coli, the reduction of the cob(II)alamin back to the 
cob(I)alamin form is carried out using flavodoxin and SAM (Hoover et al. 1997; Hall et 
al. 2000; Hall et al. 2001; Wolthers and Scrutton 2009).  
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Figure 1.2: The methionine synthesis cycle for cobalamin-dependent methionine 
synthase, focussing on cobalamin oxidation states, based upon the cycle in E. coli. The 
highlighted section in the red is the main part of the cycle (normal turnover). The black 
section is the reactivation pathway. The question marks indicate the unknown (in C. 
glutamicum) reducing agent. 
 
1.1.3: Cobalamin dependent Methionine Synthase 
Cobalamin dependent methionine synthase has four main domains in the protein. The 
first, the homocysteine S-methyltransferase binding domain allows the methylation of 
homocysteine by methyl-cobalamin to form methionine and stretches from amino acid 
residues 2-295. The second stretches from residues 344-596, and provides MTHF with a 
site to remethylate the cob(I)alamin during normal turnover. The third, the cobalamin 
binding domain runs from residues 643-860, with an Asp-x-His-x-x-Gly cobalamin 
binding motif – the histidine residue coordinates the cobalt at the centre of the 
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tetrapyrrole. Site directed mutagenesis of this histidine all but destroys enzymatic 
activity in the E. coli cdMS (Bandarian et al. 2002). The fourth domain at residues 903-
1196 is involved in the reactivation of cobalamin when the pathway is derailed from its 
main cycle and is termed the reactivation domain, binding MSR and SAM. Domains 
3+4 are shown in Figure 1.3. There is no crystal structure of the full-length protein as it 
is too flexible and mobile; steps have been taken to create conformation-locked mutants 
(Datta et al. 2008) but they have not yet yielded full crystal structures. 
 
Figure 1.3: X-ray crystallographic structure of the cobalamin-binding domain and the 
reactivation domain of cdMS from E. coli, with the Asp-His-Gly motif highlighted in 
red showing how the protein binds cobalamin. The movement of the DMB lower axial 
ligand away from the central cobalt is evident in this structure. PDB accession code: 
1K98 (Bandarian et al. 2002). 
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The cobalamin cofactor is sandwiched between an α-helical domain contacting the 
upper face of the cobalamin and an α/β (Rossman) domain interacting with the lower 
face (Drennan et al. 1994; Datta et al. 2008). Correct folding of the methionine synthase 
in E. coli appears to require the presence of cobalamin in the binding domain. There is 
also some evidence that tertiary structure of C. glutamicum cdMS is affected by binding 
of cobalamin. 
 
A non-radioactive methionine synthase assay was developed by Drummond et al., 
(Drummond et al. 1995) based on an assay described by Rode and Balinska (Rode and 
Balinska 1985) and has been modified for the purposes of this project (Section 2.4.10). 
It involves providing the metH gene product with excesses of hydroxy-cobalamin, 
MTHF and S-adenosyl-L-methionine (SAM) and allowing it to react for a known length 
of time. It is superior to the previous radioactive assay (Garras et al. 1991; Jarrett et al. 
1997) in terms of time, equipment required and ease of preparation, but due to the 
nature of the species examined by the reaction, brings its own issues to assaying 
methionine synthase. 
 
1.1.4: Methionine synthesis and regulation differs between organisms 
Different bacteria use subtly different pathways for the synthesis of methionine. With 
biotechnological interest being focussed on maximum output with minimal expenditure, 
the identification of bacteria utilising simpler pathways is of significant use. The less 
self-regulation that a bacterium has over a system, the more successful the creation of 
mutant strains which produce enhanced levels of an amino acid will be. As an already 
widely used bacterium in biotechnological production of amino acids, C. glutamicum is 
immediately an obvious candidate for producing any amino acid. 
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For the success of an amino acid overproducing strain, thorough understanding of the 
regulation of cellular processes is of great importance. It is frequently less a case of 
over-expressing a single protein and more a case of successfully inhibiting the feedback 
systems that regulate the synthesis of the amino acid. In many organisms the feedback 
inhibition, gene regulation and other control mechanisms are so varied and complex that 
it makes developments of this nature next to impossible. For this reason, the simpler the 
regulatory system the more favourable it is for both the bacterium and for the potential 
development of an over-producing strain.  
 
E. coli possess a considerably more complex feedback inhibition system for the 
methionine synthesis pathway than C. glutamicum or other actinobacteria (Kumar and 
Gomes 2005). This is likely due to the environmental pressures in which the bacterium 
finds itself – the more amino acid scarce the environment that the bacterium 
experiences, the more control the bacterium needs over biosynthesis of amino acids in 
relation to its rate of growth. As one of the many intestinal microflora present in 
humans, E. coli need to maintain tight control over the use of environmentally 
scavenged chemicals and energy. In contrast, soil, the native environment for C. 
glutamicum is extremely rich in potential food sources. 
 
While more complex organisms such as Lactobacilli and some yeasts have been 
assessed for methionine production (Odunfa et al. 2001; Kumar and Gomes 2005) in 
general the more complex the organism is, the more intricate the regulatory mechanisms 
are. Wild-type strains are rarely suitable for methionine production due to this tight 
regulatory system. Engineered strains of varying organisms have been studied and 
reporting, including Saccharomyces cerevisiae (Cherest et al. 1973; Cherest et al. 1973; 
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Surdin-Kerjan et al. 1973) Saccharomycopsis lipolytica (Morzycka et al. 1976) Bacillus 
megaterium (Roy 1989) and Kluyveromyces lactis (Kitamoto 1994). 
 
Corynebacterium diphtheriae has another mechanism at its disposal for methionine 
biosynthesis – along with evidence that C. glutamicum can utilise the same method; 
using methanethiol (which is highly toxic) and O-acetylhomoserine (a mid pathway 
intermediate of methionine biosynthesis) via direct sulphydrylation to bypass the need 
for trans-sulphuration by the metB and metC gene products and the late-stage 
intermediate cystathionine (Hwang et al. 2002). 
 
Methionine synthesis is part of the same broad pathway as cysteine, isoleucine, lysine 
and threonine synthesis. In C. glutamicum this pathway is inhibited at the aspartate to 
aspartyl phosphate step by lysine and threonine and at the aspartate semialdehyde to 
homoserine step by threonine and methionine. In comparison with this two-stage 
suppression mechanism in C. glutamicum (Fig. 1.4) the E. coli methionine synthesis 
pathway (Fig. 1.5) is repressed in two locations and inhibited in one by the desired 
product, methionine, repressed in two essential methionine synthesis steps by lysine, 
one step by both threonine and isoleucine, and finally repressed in two steps by 
threonine. This eight stage suppression of methionine synthesis by chemicals other than 
the desired product makes E. coli a poor potential target for biotechnological 
production, while the simpler suppression system utilised by C. glutamicum is favoured. 
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Figure 1.4: Pathway of methionine synthesis (Kumar and Gomes 2005) showing the 
simpler inhibition and repression systems used by C. glutamicum. Blue arrows indicate 
inhibition and dotted arrows indicate repression. 
 
Figure 1.5: Pathway of methionine synthesis (Kumar and Gomes 2005) showing the 
inhibition and repression systems used in E. coli. Blue arrows indicate inhibition and 
dotted arrows indicate repression. 
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1.1.5: Cellular cycling of methionine 
Methionine is part of a tightly closed loop in cellular biosynthesis. Setting aside the role 
of methionine as an amino acid, it is after adenosylation that most of its intermediate 
roles occur, as a methyl donor. The produce of this methyl donation by SAM is SAH, 
which is then hydrolysed by SAH1. SAH1 is one of the most highly conserved proteins 
across all kingdoms of life (Tehlivets et al. 2004) which forms homocysteine again for 
cysteine or methionine synthesis (Fig 1.6). The many roles of SAM within the cell 
contribute further in making methionine possibly the most essential amino acid in any 
biological system. 
 
Figure 1.6: diagram illustrating the cyclic nature of the methionine biosynthetic 
pathway. The enzymes involved are: 1; homocysteine methyltransferase (cobalamin 
independent, MetE, or cobalamin dependent, MetH), 2; methionine adenosyltransferase, 
3; any metabolic system that requires methyl donation from SAM, for example 
cobalamin dependent methionine synthase, 4; SAH hydrolase, 5; cystathionine beta 
synthase, cystathionine gamma lyase, 6; adenosylmethionine decarboxylase. 
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1.2: Corynebacterium glutamicum 
C. glutamicum is a Gram-positive soil-native bacterium used extensively in the 
biotechnology industry for amino-acid production since it was isolated (Kinoshita 
1959). It was originally used to make monosodium glutamate (MSG, a flavour 
enhancer) by treating L-glutamate with sodium hydroxide and so it enjoys favour in 
biotechnological applications where it is used in large scale production of amino acids. 
It is now used to produce glutamate and lysine as well as the less industrially important 
amino acids such as alanine, isoleucine, proline, threonine and tryptophan (Eikmanns et 
al. 1993). A member of the actinobacteria, it is related to several significant human 
pathogens, such as C. diphtheriae, and Mycobacterium tuberculosis. It possesses a 
curious method of ‘snapping’ division which brought about the idea that it formed 
‘Chinese letters’ (Eggeling and Bott 2005) which look particularly reminiscent of these 
(Figure 1.7 and 1.8). 
 
Figure 1.7: Phase contrast microscope image of C. glutamicum, illustrating the 
‘Chinese letters’ characteristic of the division of Corynebacterium (Eggeling and Bott 
2005). 
Chapter 1 
 - 36 - 
 
 
Figure 1.8: scanning electron micrograph of C. glutamicum cells on a nucleopore 
membrane (Eggeling and Bott 2005). Again, the ‘V’ shapes caused by snap division are 
evident. 
 
There are two completed genome sequences for C. glutamicum, the first of which 
(Nakagawa, 2001, unpublished) lacks annotation on several genes that the second 
(Kalinowski et al. 2003) details. The second has several of the cobalamin operon genes 
required for the aerobic synthesis of cobalamin present; CobQ, a truncated CobG, 
CobL, CobA, CobU, CobT and CobS, the last two of which are two components in the 
complex of proteins which chelates cobalt into the contracted tetrapyrrole ring during 
cobalamin synthesis (Heldt et al. 2005). This is significant due to C. glutamicum 
containing both a cobalamin-dependent and cobalamin-independent Methionine 
Synthase – it appears as if Corynebacterium was able to synthesise cobalamin in the 
past, but has lost the selection pressure for this genetic burden. Literature presents the 
fact that some close relatives of C. glutamicum, such as Corynebacterium simplex and 
Corynebacterium diphtheriae are capable of synthesising cobalt-porphyrins (Fujii et al. 
1974) or cobalamin-like compounds (Pawelkiewicz and Zodrow 1957; Pawelkiewicz 
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and Zodrow 1957). These bacteria, as pathogens, are under even greater selective 
pressure to only maintain those systems necessary. It is likely they are also in the 
process of loss of the cobalamin biosynthetic pathway. 
 
1.3: Unknown systems for reactivation of cobalamin-dependent 
Methionine Synthase 
The mechanism for reduction – or rather, the enzyme that is capable of playing the role 
of methionine synthase reductase (MSR) in Corynebacterium is currently uncertain, but 
it is known that it does not utilise flavodoxin (Schroeder, H, private communication).  
 
Due to the unknown nature of the methionine synthase reductase in C. glutamicum, 
studies of the redox-capable enzymes and cofactors must be undertaken. The two most 
common redox mechanisms for electron transport are flavins and iron-sulphur (FeS) 
clusters, for example the flavin cofactor in E. coli flavodoxin which acts as methionine 
synthase reductase. 
 
1.4: Redox proteins 
Redox proteins are ubiquitous in all organisms for their essential role in all cellular 
metabolisms. Free electrons are a dangerous thing in a biological environment, so redox 
proteins with their varied cofactors neatly control all electron transfer systems. Redox 
cofactors range from organic, such as nucleotide-based cofactors like nicotinamide 
adenine dinucleotide (NAD), nicotinamide adenine dinucleotide phosphate (NADP), 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and quinones to 
cytochromes (containing a bound haem cofactor) (Sone et al. 2001), iron-sulphur 
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clusters (Hall et al. 1975) and other metal cofactors such as the copper in non-
cytochrome-based nitrite reductases (Suzuki et al. 2000). 
 
While the flavodoxin that acts as methionine synthase reductase for the E. coli 
cobalamin-dependent methionine synthase contains FAD, many iron-sulphur cluster 
redox proteins are presented with electrons via other redox proteins containing flavins, 
which in turn obtain electrons from either NADH or NADPH (the reduced forms of 
NAD and NADP respectively). 
 
1.4.1: Flavodoxins 
Flavin dependent redox enzymes contain either a bound FAD or FMN (Fig. 1.9) 
cofactor both of which are a bright yellow colour when oxidised. They are capable of 
two-electron transport, although systems such as CobR donate only a single electron 
(Lawrence et al. 2008) and when partially reduced (a state known as a semiquinone) can 
be either blue or red. In some remarkable systems, flavins can exhibit both states, as 
demonstrated by the D-amino acid oxidase present in eukaryotes from yeast to humans 
(Yagi et al. 1972). When fully reduced they are colourless. Flavodoxins are used as 
redox proteins in a wide variety of pathways, from the E. coli methionine synthase 
(Hoover et al. 1997; Hall et al. 2000) to ferredoxin reductases (Fischer et al. 2002; 
Girardini et al. 2005). It is for both of these roles that flavodoxins are of interest to this 
study. A semiquinone is the only state of flavin which is detectable by EPR, as they are 
the only state which has a single unpaired electron to be detected. There are two 
different semiquinones, named from the colours that they exhibit – red and blue 
semiquinones (Fig. 1.10). 
Chapter 1 
 - 39 - 
 
Figure 1.9: diagram of the structure of flavin mononucleotide (FMN) and flavin 
adenine dinucleotide (FAD) both of which are common cofactors in redox enzymes. 
 
Figure 1.10: Different redox states of flavin: the redox cycle of flavin by 1- and 2-
electron reduction. 
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1.4.2: Ferredoxins 
Ferredoxins are redox active proteins which contain iron as their redox centre (Bruschi 
and Guerlesquin 1988). The first ferredoxin was originally purified from Clostridium 
pasteurianum (Valentine 1964) and provided the beginning of an entirely new branch of 
enzymatic biochemistry. Ferredoxins show significant variation, from single iron 
clusters of rubredoxin to the more complex 4Fe4S clusters demonstrated by proteins 
such as uracil-DNA glycosylase (Hinks et al. 2002) or the extremely complex carbon 
monoxide dehydrogenase which utilises a Ni4Fe5S centre and two distinct 4Fe4S 
clusters (Craft et al. 2002). They vary from aconitases, where they play a role as 
hydrolases, to oxidoreductases such as sulphite reductase, methane monooxygenase 
(Lieberman and Rosenzweig 2005), formate dehydrogenase (Ferry 1990; Khangulov et 
al. 1998) and bacterial nitrate reductase (Moreno-Vivian et al. 1999). 
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1.4.2.1: Single Iron Clusters 
While not really an iron sulphur cluster, it can carry out a similar role within a redox 
protein for electron transport, and so is worth a short comparison. The rubredoxin type 
(Fig. 1.11) is characterised by a high spin Fe3+ which can be reduced to high spin Fe2+.  
A high spin system is one where the energy required for electrons to move from a low 
energy shell to a higher energy shell is small, so in accordance with Hund’s rules 
(Wothers et al. 2001), each of the d orbitals are filled before any electron pairing occurs. 
It has a tetrahedral coordination with the ligating cysteine residues. Study by EPR gives 
a signal a significant distance from other iron proteins at approximately g=4.3, as shown 
in Fig. 1.16. 
 
Figure 1.11: schematic diagram of a single Fe redox centre, such as the one found in 
Pseudomonas aeruginosa rubredoxin (Hagelueken et al. 2007). 
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1.4.2.2: 2Fe2S Clusters 
2Fe2S clusters were first isolated from the leaves of higher plants (Davenport and Hill 
1952) and were subsequently identified in a wide range of species of plants and algae 
(Hall et al. 1975) where ferredoxin has a well defined role for carrying electrons from 
Photosystem I to NADP via the flavoprotein ferredoxin-NADP reductase. There are two 
broad types of 2Fe2S cluster, the plant ferredoxin type, and the adrenodoxin type, 
differentiated between by their EPR spectra (Fig. 1.4.2.7.1) although the construction of 
the cluster remains the same, with a ‘saddle’ formed by the ligation of the iron to 
coordinating cysteine residues (Fig. 1.12). When oxidised, 2Fe2S clusters can show 
significant Fe-Fe antiferromagnetic coupling (where electron spins are ordered in 
opposing orientations). Rieske centres, a special type of 2Fe2S cluster, demonstrate 
different iron coordination by the use of two histidine residues to coordinate one of the 
iron atoms of the cluster (Rieske et al. 1964).  Serine can also be used to ligate iron 
sulphur clusters in place of cysteine or histidine (Cheng et al. 1994). 
 
 
Figure 1.12: schematic diagram of a 2Fe2S redox centre, demonstrating the ‘saddle’ 
shape of a 2Fe2S cluster. 
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1.4.2.3: 4Fe4S Clusters 
Cubic in shape, 4Fe4S clusters are the most often observed example of iron sulphur 
clusters, exhibiting one of the fastest electron transfer rate constants in bioinorganic 
chemistry as the cluster undergoes little reorganisation in the process of oxidation or 
reduction. 4Fe4S iron-sulphur clusters have a diverse range of variations (Hans et al. 
2008) supporting redox pairs of Fe2+/Fe3+ or Fe1+/Fe2+, dependent on whether or not 
they were ‘classical’ 4Fe4S clusters (Fig. 1.13) or of the HiPIP (high potential iron-
sulphur protein) type as exhibited by Chromatium vinosum (Gaillard et al. 1992). The 
Azotobacter vinelandii nitrogenase has been reported to support an all ferrous 4Fe4S 
cluster (Watt and Reddy 1994) which had been previously thought impossible. 
 
 
 
Figure 1.13: schematic diagram of a 4Fe4S redox centre, showing the cubic 
arrangement of the cluster. 
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1.4.2.4: 3Fe4S Clusters 
The existence of functional 3Fe4S clusters have been debated hotly for many years, 
with many considering those occasions where they had been isolated to be a remnant of 
a broken 4Fe4S cluster. With the isolation and characterisation of the Desulfovibrio 
gigas ferredoxin (Chaoliang et al. 1993; Goodfellow et al. 1999) the existence of a real 
3Fe4S cluster was accepted (Papaefthymiou et al. 1987). Structurally, they are similar to 
a 4Fe4S cluster with a single Fe missing - hence the early idea that they were damaged 
4Fe4S clusters (Fig. 1.14). Differently to other FeS clusters, a 3Fe4S cluster shows its 
distinctive EPR spectrum (Fig. 1.16) when oxidised rather than when reduced. 
 
Figure 1.14: schematic diagram of a 3Fe4S cluster, showing the sulphur from cysteine 
residues acting as ligation points for the iron atoms of the cluster. 
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1.4.2.5: 7Fe8S Clusters 
Much in the same way as 3Fe4S centres, 7Fe8S clusters were widely considered to be 
‘broken’ 8Fe8S (2[4Fe4S]) clusters until proved otherwise (Trower et al. 1990; Ricagno 
et al. 2007) (Fig. 1.15). 
 
Figure 1.15: X-ray crystal structure of Mycobacterium smegmatis ferredoxin A, a 
7Fe8S ferredoxin. Note that in the upper iron sulphur cluster an iron atom is missing – if 
present it would be ligated to the cysteine 42 residue. 
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1.4.2.6: 8Fe8S Clusters 
8Fe8S iron sulphur clusters could potentially be better described as 2[4Fe4S] iron 
sulphur clusters, as they are twinned 4Fe4S clusters, rather than a more complex 
polyhedral arrangement. 2[4Fe4S] clusters usually possess midpoint redox potentials 
more negative than other iron sulphur cluster arrangements (Guerrini et al. 2008).  
 
1.4.2.7: Iron sulphur spectroscopy 
Unlike cytochromes and flavoproteins, which have very obvious UV/Visible spectra, 
iron-sulphur proteins (along with quinones and copper proteins) have fairly 
inconspicuous optical absorption spectra, so studies of these have benefitted from 
alternative spectroscopic techniques. Reduced iron-sulphur clusters, due to possessing 
an unpaired electron, lend themselves well to electron paramagnetic resonance (EPR) 
spectroscopy. Reduced ferredoxins (with the exception of 3Fe4S clusters, which gives a 
signal when oxidised) tend to give rise to signals in the g=1.94 region, but the different 
types of iron-sulphur clusters can be identified by the lineshape and temperature 
dependence of the signal (for example the loss of signal of a 2Fe2S cluster when 
temperatures increase beyond approximately 50ºK) as well as by altering the redox 
potential of the sample (Cammack 1976). Figure 1.16 illustrates some of the more 
common iron-sulphur EPR spectra – of particular interest are the adrenodoxin-type 
2Fe2S spectrum, and the Clostridium pasteurianum and Chromatium-type 8Fe8S 
spectra. 
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Figure 1.16: Compilation of EPR spectra of different types from different organisms, 
adapted from Hall (Hall et al. 1975) with addition of D. gigas ferredoxin. 
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1.5: Work leading up to the project 
Details of the work carried out by BASF and partners prior to the beginning of this 
project were not shared beyond strains of C. glutamicum and some of the broad 
objectives. BASF generated a dual Methionine Synthase deficient (∆metE ∆metH) C. 
glutamicum strain along with C. glutamicum specific plasmids containing cobalamin-
dependent Methionine Synthase under the control of either constitutive or inducible 
promoters.  
 
1.6: Aims and objectives 
The broad aims of the investigation at the start of the project were: 
 
1. Purification and characterisation of C. glutamicum cobalamin-dependent 
Methionine Synthase 
Beyond the sequence of the protein, little detail was known about the C. glutamicum 
cdMS, particularly when compared to the work carried out on the E. coli cdMS. The 
first step in being able to manipulate a protein in a predetermined way, for example for 
superior performance, (in this case, production of methionine) is the ability to purify 
and characterise said protein. Once the protein is characterised, site-directed mutations 
can be utilised in an attempt to improve activity or protein quantity, or reduce product 
or feedback inhibition. While the traditional technique of cellular growth in the presence 
of toxic substrate or product analogues (de Graaf et al. 2001; Mampel et al. 2005) can 
result in improved enzyme activity or reduced sensitivity to feedback inhibition, modern 
biotechnological processes call for a more refined approach. 
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2. Increasing yield of methionine or ease of extraction from C. glutamicum 
Primarily, this follows directly from the first aim; by characterising cdMS it becomes 
easier to design a mutant strain capable of producing increased levels of methionine. 
Extraction of methionine would follow a different path – characterising and 
overexpressing membrane-bound methionine exporter protein complexes (Trotschel et 
al. 2005) would be necessary to make methionine easier to extract, as it could be 
obtained from the extracellular medium, rather than once cells have been lysed. 
 
3. Gain insight into the unknown reactivation mechanism of C. glutamicum 
cobalamin-dependent Methionine Synthase 
The C. glutamicum cdMS, like the E. coli and H. sapiens cdMS, suffers from a 
cobalamin cofactor which is vulnerable to oxidative derailment from its normal cycling 
between Co1+ and Co3+. While the human and E. coli cdMS reactivation systems have 
been identified (Hall et al. 2000; Yamada et al. 2006), the C. glutamicum methionine 
synthase reductase, or protein acting in that role, has not been. Determining the protein 
utilised for reductive reactivation of cdMS in C. glutamicum would be a significant step 
in increasing knowledge of the methionine production within this biotechnologically 
important bacterium. 
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2: Materials and Methods 
2.1: Materials 
2.1.1: Chemicals 
Most chemicals, DEAE-sephacel and antibiotics were purchased from Sigma-Aldrich 
Ltd. Other materials were purchased from manufacturers as follows: IPTG and 
ampicillin from Melford Laboratories Ltd; disposable and empty PD10 columns from 
Amersham Biosciences; MiniEluteTM Gel extraction Kit, QIAprep Spin Miniprep Kit 
and QIAquick Gel Extraction Kit from QIAGEN GmbH; restriction enzymes from 
Promega; cloning vectors from Novagen; tryptone, yeast, bacterial agar from Oxoid 
Ltd, QuickChange II Site-Directed Mutagenesis Kit from Stratagene; Roche FastStart 
High Fidelity PCR System from Roche Diagnostics GmbH. Methyl-tetrahydrofolate 
and S-adenosyl L-Methionine were either provided by Dr. H. Schroeder, BASF, 
Ludwigshafen, Germany, or purchased from Schircks Laboratories, Jona, Switzerland 
or Sigma-Aldritch respectively. 
 
2.1.2: Bacterial strains 
E. coli bacterial strains were purchased from Novagen, Invitrogen or Promega. Strains 
of C. glutamicum were provided by Dr. H. Schroeder, BASF, Ludwigshafen, Germany. 
Corynebacterial plasmids were provided by Dr. H. Schroeder, BASF, Ludwigshafen, 
Germany. E. coli strain MTD23 was the generous gift of Prof. R. G. Matthews, 
University of Michigan, Ann Arbor, Michigan. Wild type C. glutamicum was purchased 
from the American Tissue Culture Collection, to verify the validity of the wild type 
provided by BASF. Strains are summarised in Table 2.1. 
 
Chapter 2 
 - 52 - 
Strains Genotypic background Description Reference 
C. glutamicum 
ATCC 13032 Wild type  LGC 
Promochem 
Lu1479 Wild type  BASF 
Lu1479 H170 Wild type Contains 
constitutively 
controlled metH on 
plasmid along with 
genomic copy 
BASF 
OM246 M2014 ∆metE ∆metH  Double knockout 
“zero” strain 
BASF 
OM257 M2014 ∆metE ∆metH 
with IPTG inducible 
metH plasmid pH586 
Double knockout 
“zero” strain 
producing cdMS 
when induced 
BASF 
OM246 H589 M2014 ∆metE ∆metH 
with IPTG inducible 
metH plasmid pH589 
Double knockout 
“zero” strain 
producing MetH 
when induced 
BASF 
OM246 H588 M2014 ∆metE ∆metH 
with IPTG inducible 
metH plasmid pH588 
(has C.glutamicum rare 
codons – GGG mutated 
to GGC) 
Double knockout 
“zero” strain 
increased production 
of MetH due to 
removal of rare 
codons 
BASF 
E. coli 
JM109 endA1 recA1 gyrA96, 
thi hsdR17(rK-, mk+) 
relA1 supE44  ∆(lac-
proAB) [F′, traD36 
proAB lacIqZ∆M15] 
 Promega 
BL21 (DE3) pLysS F- ompT hsdSB (rB-, 
mB-) gal dcm (DE3) 
pLysS (CmR) 
 Novagen 
Rosetta (DE3) pLysS F- ompT hsdSB (rB-, 
mB-) gal dcm lacY1 
(DE3) pLysSRARE 
(CmR) 
IPTG inducible T7 
promotor, rare codon 
tRNA: AUA, AGG, 
AGA, CUA, CCC, 
GGA 
Novagen 
BL21 StarTM (DE3) F- ompT hsdSB (rB-
mB-) gal dcm rne131 
(DE3) 
Contains a mutation 
in the gene encoding 
RNaseE (rne131), 
which is one of the 
major sources of 
mRNA degradation, 
improving stability of 
mRNAs increasing 
protein expression 
yield from T7 
promoter-based 
vectors 
Invitrogen 
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BL21 StarTM (DE3) 
pLysS 
F- ompT hsdSB (rB-
mB-) gal dcm rne131 
(DE3)pLysS (CmR) 
Lower basal-level 
expression of 
heterologous genes 
than BL21 
Star™(DE3) 
Invitrogen 
XL1-Blue recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 
rel A1 lac [F’ proAB 
lacqZ∆M15 Tn10 
(TetR)] 
 Stratagene 
MTD23 ∆metE, ∆metH Methionine 
auxotroph by in-
frame deletions 
within metE and 
metH genes 
Prof. R. 
Matthews 
DH5α F- φ80lacZ∆M15 
∆(lacZYA-argF)U169 
deoR recA1 endA1 
hsdR17(rk-, mk+) phoA 
supE44 thi-1 gyrA96 
relA1 λ- 
 Invitrogen 
MTD23 pBAD 
metH 
Constitutive promoter 
controlled metH  
CmR This study 
MTD23 pUC fdxA Constitutive promoter 
controlled fdxA 
AmpR This study 
MTD23 pUC fdxB Constitutive promoter 
controlled fdxB 
AmpR This study 
MTD23 pUC fdxC Constitutive promoter 
controlled fdxC 
AmpR This study 
MTD23 pET metH IPTG inducible metH AmpR This study 
MTD23 pLysS-ED 
fdxA 
IPTG inducible fdxA CmR This study 
MTD23 pLysS-ED 
fdxB 
IPTG inducible fdxB CmR This study 
MTD23 pLysS-ED 
fdxC 
IPTG inducible fdxC CmR This study 
MTD23 pET metH-
fprA 
IPTG inducible metH 
and IPTG inducible 
fprA 
AmpR This study 
Table 2.1: Bacterial strains used in this study. 
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2.1.3: Plasmids 
A list of all plasmids used during this study are listed in Table 2.2. 
Name/Plasmid Plasmid type, gene, 
cloning sites 
Description Reference 
pGEM-T Easy  PCR cloning vector 
system, T7 and SP6 RNA 
polymerase promoters 
flanking a multiple 
cloning region, linearized 
and containing 3’-T 
overhangs, AmpR  
Novagen 
pET-3a  Over-expression vector 
with T7 promoter, AmpR 
Novagen 
pET-14b  Over-expression N-
terminal His-tag fusion 
protein vector with T7 
promoter, AmpR 
Novagen 
pET-23b  Over-expression C-
terminal His-tag fusion 
protein vector with T7 
promoter, AmpR 
Novagen 
pET-25b  Over-expression N-
terminal periplasm 
localisation tag, C-
terminal His-tag fusion 
protein vector with T7 
promoter, AmpR 
Novagen 
pLysS  contains T7 lysozyme 
gene, used in λDE3 
lysogenic hosts to 
suppress basal expression 
from the T7 promoter, 
CmR 
Novagen 
pLysS-ED  Multiple-cloning site 
altered to contain Nde1 
and HindIII sites, contains 
T7 lysozyme gene, used in 
λDE3 lysogenic hosts to 
suppress basal expression 
from the T7 promoter, 
CmR 
Dr. E. 
Deery 
pBAD-33  Constitutive expression 
vector, CmR 
LGC 
Promochem 
pUC-18  Constitutive expression 
vector, AmpR 
Novagen 
pG(click) C. glu  Constitutive expression 
shuttle vector between E. 
coli & C. glutamicum, 
KmR 
BASF 
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pH170 C. glu metH,  Sal1/Xba1 Constitutive expression, 
KmR 
BASF 
pH586 C. glu metH,  Sal1/Xba1 Inducible expression, KmR BASF 
pH587 C. glu metH,  Sal1/Xba1 Inducible expression, KmR BASF 
pH588 C. glu metH,  Sal1/Xba1 Constitutive expression, 
C. glutamicum rare codon 
‘GGG’ removed and 
replaced by GGC in all 
instances, KmR 
BASF 
pH589 C. glu metH,  Sal1/Xba1 Constitutive expression, 
KmR 
BASF 
pH633 C. glu pQE-30, fdxA, 
BamH1/Pst1 
N-terminal Hex-His tag 
fusion of fdxA, AmpR 
BASF 
pH635 C. glu pQE-30, fdxB, 
BamH1/Pst1 
N-terminal Hex-His tag 
fusion of fdxB, AmpR 
BASF 
pH634 C. glu pQE-30, fdxC, 
BamH1/Pst1 
N-terminal Hex-His tag 
fusion of fdxC, AmpR 
BASF 
pH633.2 C. glu pQE-30, fdxA, 
BamH1/Pst1 
Corrected version of 
pH633, N-terminal Hex-
His tag fusion of fdxA, 
AmpR 
BASF 
pH635.2 C. glu pQE-30, fdxB, 
BamH1/Pst1 
Corrected version of 
pH635, N-terminal Hex-
His tag fusion of fdxB, 
AmpR 
BASF 
pRBS01 pET-14b, fdxA, 
Nde1/BamH1 
WT fdxA, N-terminal hex-
His tag, AmpR 
This study 
pRBS02 pET-14b, fdxB, 
Nde1/BamH1 
WT fdxB, N-terminal hex-
His tag, AmpR 
This study 
pRBS03 pET-14b, fdxC, 
Nde1/BamH1 
WT fdxC, N-terminal hex-
His tag, AmpR 
This study 
pRBS04 pET-23b, fdxA, 
Nde1/BamH1 
WT fdxA, AmpR This study 
pRBS05 pET-23b, fdxB, 
Nde1/BamH1 
WT fdxB, AmpR This study 
pRBS06 pET-23b, fdxC, 
Nde1/BamH1 
WT fdxC, AmpR This study 
pRBS07 pET-23b, fdxA, 
Nde1/BamH1 
WT fdxA, STP codon 
removed, C-terminal hex-
His tag, AmpR 
This study 
pRBS08 pET-23b, fdxB, 
Nde1/BamH1 
WT fdxB, STP codon 
removed, C-terminal hex-
His tag, AmpR 
This study 
pRBS09 pET-23b, fdxC, 
Nde1/BamH1 
WT fdxC, STP codon 
removed, C-terminal hex-
His tag, AmpR 
This study 
pRBS10 pET-3a, fdxA, 
Nde1/BamH1 
WT fdxA, AmpR This study 
pRBS11 pET-3a, fdxB, 
Nde1/BamH1 
WT fdxB, AmpR This study 
pRBS12 pET-3a, fdxC, WT fdxC, AmpR This study 
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Nde1/BamH1 
pRBS13 pLysS, fdxA, 
Nde1/BamH1 
WT fdxA, CmR This study 
pRBS14 pLysS, fdxB, 
Nde1/BamH1 
WT fdxB, CmR This study 
pRBS15 pLysS, fdxC, 
Nde1/BamH1 
WT fdxC, CmR This study 
pRBS16 pUC-18, fdxA, 
Nde1/BamH1 
WT fdxA, AmpR This study 
pRBS17 pUC-18, fdxB, 
Nde1/BamH1 
WT fdxB, AmpR This study 
pRBS18 pUC-18, fdxC, 
Nde1/BamH1 
WT fdxC, AmpR This study 
pRBS19 pBAD-33, metH, 
Sal1/Kpn1 
metH subcloned from 
pH588, CmR 
This study 
pRBS20 C. glu pH588, metH, 
Nde1/Xba1 
Introduction of Nde1 site 
to start of metH gene in 
pH588, KmR 
This study 
pRBS21 pET-14b, metH, 
Nde1/Xba1 
metH subcloned from 
pRBS20, AmpR 
This study 
pRBS22 pET-14b, fdxC, 
Nde1/BamH1 
C9A mutant, AmpR This study 
pRBS23 pET-14b, fdxC, 
Nde1/BamH1 
C17A mutant, AmpR This study 
pRBS24 pET-14b, fdxC, 
Nde1/BamH1 
C21A mutant, AmpR This study 
pRBS25 pET-14b, fdxC, 
Nde1/BamH1 
C25A mutant, AmpR This study 
pRBS26 pET-14b, fdxC, 
Nde1/BamH1 
C40A mutant, AmpR This study 
pRBS27 pET-14b, fdxC, 
Nde1/BamH1 
C43A mutant, AmpR This study 
pRBS28 pET-14b,  fdxC, 
Nde1/BamH1 
C46A mutant, AmpR This study 
pRBS29 pET-14b, fdxC, 
Nde1/BamH1 
C50A mutant, AmpR This study 
pRBS30 pET-14b, fdxB, 
Nde1/BamH1 
C40A mutant, AmpR This study 
pRBS31 pET-14b, fdxB, 
Nde1/BamH1 
C46A mutant, AmpR This study 
pRBS32 pET-14b, fdxB, 
Nde1/BamH1 
C49A mutant, AmpR This study 
pRBS33 pET-14b, fdxB, 
Nde1/BamH1 
C82A mutant, AmpR This study 
pRBS34 pET-14b, fdxB, 
Nde1/BamH1 
C87A mutant, AmpR This study 
pRBS35 pET-14b, fdxA, 
Nde1/BamH1 
C9A mutant, AmpR This study 
pRBS36 pET-14b, fdxA, 
Nde1/BamH1 
C17A mutant, AmpR This study 
pRBS37 pET-14b, fdxA, C21A mutant, AmpR This study 
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Nde1/BamH1 
pRBS38 pET-14b, fdxA, 
Nde1/BamH1 
C25A mutant, AmpR This study 
pRBS39 pET-14b, fdxA, 
Nde1/BamH1 
C40A mutant, AmpR This study 
pRBS40 pET-14b, fdxA, 
Nde1/BamH1 
C43A mutant, AmpR This study 
pRBS41 pET-14b, fdxA, 
Nde1/BamH1 
C46A mutant, AmpR This study 
pRBS42 pET-14b, fdxA, 
Nde1/BamH1 
C50A mutant, AmpR This study 
pRBS43 pET-14b, fdxC, 
Nde1/BamH1 
C9A, C50A mutant, AmpR This study 
pRBS44 pET-14b, fdxC, 
Nde1/BamH1 
C21A, C43A mutant, 
AmpR 
This study 
pRBS45 pET-14b, fdxA, 
Nde1/BamH1 
C9A, C50A mutant, AmpR This study 
pRBS46 pET-14b, fdxA, 
Nde1/BamH1 
C21A, C43A mutant, 
AmpR 
This study 
pRBS47 pET-14b, fprA, 
Nde1/BamH1 
WT fprA, AmpR This study 
pRBS48 pET-14b, fprA, 
Nde1/BamH1 
WT fprA, AmpR This study 
pRBS49 pET-14b, metH, fprA,  WT metH, WT fprA, 
AmpR 
This study 
pRBS50 pBAD-33, metH, fprA,  WT metH, WT fprA, CmR This study 
Table 2.2: Plasmids. Unless specified C. glu with plasmid name, plasmid specific to E. 
coli. 
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2.1.4: Primers 
A list of all primers used in this study can be found in Table 2.3. All primers were 
obtained from Invitrogen Life Technologies. Nucleotide bases in red refer to the 
enzyme restriction sites. The corresponding restriction enzymes are listed in the last 
column of the table. For mutagenesis primers red bases indicate the target point 
mutations. Overlapping restriction sites are red or blue. 
Primer name Sequence 
Enzyme 
restriction 
site 
fdxA Fwd TCCATATGACCTACACAATCGCCCAG Nde1 
fdxA Rvr 
(14b) 
TCGGATCCCTAGTTCTGGTTCTGTGG BamH1 
fdxA Rvr 
(23b) 
TCGGATCCGTTCTGGTTCTGTGG BamH1 
fdxC Fwd TCCATATGACATACACAATCGCAGAG Nde1 
fdxC Rvr 
(14b) 
TCGGATCCTTATGCCTGAGGCGGCAG BamH1 
fdxC Rvr 
(23b) 
TCGGATCCTGCCTGAGGCGGCAG BamH1 
fdxB Fwd TCCATATGTCTACTATTCATTTCATT Nde1 
fdxB Rvr 
(14b) 
TCGGATCCTCACACTTGCGTTTCTGG BamH1 
fdxB Rvr 
(23b) 
TCGGATCCCACTTGCGTTTCTGG BamH1 
metH Fwd TCCATATGTTGATCGGCGACGGCGCCATG Nde1 
metH Rvr 
(14b) 
AGTCTAGATTAGACGTTAAAGTACTTTGC BglII 
metH Rvr 
(23b) 
AGTCTAGAGACGTTAAAGTACTTTGCCTC BglII 
metH 1&2 Rvr TCCATATGCTGAACCCTGCTGCACGCCAGGTTCTT
AACTCTGTGTTCC 
Nde1 
metH 3&4 
Fwd 
TCAGATCTTTAGCCGAAGGAAATATTGGACAGACC
CAGGGTGG 
BglII 
fprA Fwd TCCATATGTCTCGCCCTTTGCGTGTTGC Nde1 
fprA Rvr TCGGATCCTTAGATGTCGTATTCTGGACG BamH1 
fprA Fwd 
D255N 
GCTACGCGATGCGCGATCCTAAGGGCG D→N 
codon alt. 
fprA Rvr 
D255N 
CGCCCTTAGGATCGCGCATCGCGTAGC D→N 
codon alt. 
fdxA Fwd 
C9A 
CAATCGCCCAGCCCGCCGTTGATGTCCTG C→A 
codon alt. 
fdxA Rvr C9A CAGGACATCAACGGCGGGCTGGGCGATTG C→A 
codon alt. 
fdxA Fwd 
C17A 
CTGGATCGAGCCGCCGTCGAGGAATGTC C→A 
codon alt. 
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fdxA Rvr 
C17A 
GACATTCCTCGACGGCGGCTCGATCCAG C→A 
codon alt. 
fdxA Fwd 
C21A 
GCGTCGAGGAAGCTCCCGTGGACTGC C→A 
codon alt. 
fdxA Rvr 
C21A 
GCAGTCCACGGGAGCTTCCTCGACGC C→A 
codon alt. 
fdxA Fwd 
C25A 
GTCCCGTGGACGCCATCTACGAGGGC C→A 
codon alt. 
fdxA Rvr 
C25A 
GCCCTCGTAGATGGCGTCCACGGGAC C→A 
codon alt. 
fdxA Fwd 
C40A 
CACCCCGATGAGGCCGTCGACTGCGG C→A 
codon alt. 
fdxA Rvr 
C40A 
CCGCAGTCGACGGCCTCATCGGGGTG C→A 
codon alt. 
fdxA Fwd 
C43A 
GAGTGCGTCGACGCCGGTGCCTGCGAG C→A 
codon alt. 
fdxA Rvr 
C43A 
CTCGCAGGCACCGGCGTCGACGCACTC C→A 
codon alt. 
fdxA Fwd 
C46A 
CTGCGGTGCCGCCGAGCCCGTCTGC C→A 
codon alt. 
fdxA Rvr 
C46A 
GCAGACGGGCTCGGCGGCACCGCAG C→A 
codon alt. 
fdxA Fwd 
C50A 
GCGAGCCCGTCGCCCCGGTTGAAGC C→A 
codon alt. 
fdxA Rvr 
C50A 
GCTTCAACCGGGGCGACGGGCTCGC C→A 
codon alt. 
fdxB Fwd 
C40A 
GGAATTGTTGCTGAAGCCGGCGGTTCCTTATCG C→A 
codon alt. 
fdxB Rvr 
C40A 
CGATAAGGAACCGCCGGCTTCAGCAACAATTCC C→A 
codon alt. 
fdxB Fwd 
C46A 
GGTTCCTTATCGGCTGCAACCTGC C→A 
codon alt. 
fdxB Rvr 
C46A 
GCAGGTTGCAGCCGATAAGGAACC C→A 
codon alt. 
fdxB Fwd 
C49A 
CGTGTGCAACCGCCCATGTGTTTGTTG C→A 
codon alt. 
fdxB Rvr 
C49A 
CAACAAACACATGGGCGGTTGCACACG C→A 
codon alt. 
fdxB Fwd 
C82A 
GACCGTGAGGATGCCTCCCGTTTG C→A 
codon alt. 
fdxB Rvr 
C82A 
CAAACGGGAGGCATCCTCACGGTC C→A 
codon alt. 
fdxB Fwd 
C87A 
CCGTTTGTCTGCCCAAATCAAGGTC C→A 
codon alt. 
fdxB Rvr 
C87A 
GACCTTGATTTGGGCAGACAAACGG C→A 
codon alt. 
fdxC Fwd 
C9A 
CGCACAGCCCGCCGTTGACGTCTTG C→A 
codon alt. 
fdxC Rvr C9A CAAGACGTCAACGGCGGGCTGTGCG C→A 
codon alt. 
fdxC Fwd GGATCGTGCCGCCGTTGAAGAATGC C→A 
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C17A codon alt. 
fdxC Rvr 
C17A 
GCATTCTTCAACGGCGGCACGATCC C→A 
codon alt. 
fdxC Fwd 
C21A 
GCGTTGAAGAAGCCCCAGTAGATTGC C→A 
codon alt. 
fdxC Rvr 
C21A 
GCAATCTACTGGGGCTTCTTCAACGC C→A 
codon alt. 
fdxC Fwd 
C25A 
GCCCAGTAGATGCCATCTACGAAGG C→A 
codon alt. 
fdxC Rvr 
C25A 
CCTTCGTAGATGGCATCTACTGGGC C→A 
codon alt. 
fdxC Fwd 
C40A 
CACCCGGATGAGGCCGTTGACTGTGG C→A 
codon alt. 
fdxC Rvr 
C40A 
CCACAGTCAACGGCCTCATCCGGGTG C→A 
codon alt. 
fdxC Fwd 
C43A 
GAGTGCGTTGACGCTGGTGCATGTGAG C→A 
codon alt. 
fdxC Rvr 
C43A 
CTCACATGCACCAGCGTCAACGCACTC C→A 
codon alt. 
fdxC Fwd 
C46A 
GACTGTGGTGCAGCTGAGCCTGCTTGC C→A 
codon alt. 
fdxC Rvr 
C46A 
GCAAGCAGGCTCAGCTGCACCACAGTC C→A 
codon alt. 
fdxC Fwd 
C50A 
GAGCCTGCTGCCCCAGTTGAG C→A 
codon alt. 
fdxC Rvr 
C50A 
CTCAACTGGGGCAGCAGGCTC C→A 
codon alt. 
pH588 Fwd TGACCGACTTGATCAGCG n/a 
pH588 Rvr CCTGTCGACATATGGAATCCCTCCATGAGAAAAAT
TTTGTG 
Sal1/Nde1 
metH_seq_01 GCAGATTCACCGCGCCTACTTTGAG n/a 
metH_seq_02 TGGCGATGCCTTTTTGATTGAGACTGC n/a 
metH_seq_03 AGGTCTTCCTGTCCTGGGTAAAAACG n/a 
metH_seq_04 TTCCATGATCGGTGAGCGCACCAACTCC n/a 
metH_seq_05 TGAAGACGGCGATGGCCCTGAGTCC n/a 
metH_seq_06 CCACACCACCCTGGGTCTGTCCAATATTTCC n/a 
metH_seq_07 ATCAACGAGGACCTTCTCAACGGCATG n/a 
metH_seq_08 TGAACAACGCCGGCGCATCCAATTACC n/a 
metH_seq_09 CCTTGATGAGCGCGCCTTGTTCATGG n/a 
metH_seq_10 TTGTTCGCAGCCAATGAATACC n/a 
Table 2.3: Primers used in this study. 
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2.1.5: Media and solutions for bacterial work 
2.1.5.1: Brain/Heart Infusion (BHI) 
Glucose   10g 
NaCl    2.5g 
Urea    2g 
Peptone   10g 
Yeast Extract   5g 
Brain/Heart Infusion  5g 
The broth was made up to 1l with dH2O and autoclaved. 
 
2.1.5.2: BHI agar 
22 g of Bacterial agar were added to 1l BHI broth before autoclaving. 
 
2.1.5.3: Electroporation recovery media 
Glucose   10g 
NaCl    2.5g 
Urea    2g 
Peptone   10g 
Yeast Extract   5g 
Brain/Heart Infusion  5g 
Sorbitol (0.4M)  10ml 
The broth was made up to 1l with dH2O and autoclaved. 
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2.1.5.4: CG-13 
ACES    54g 
(NH4)2SO4   10g 
K2HPO4   1g 
KH2PO4   1g 
MgSO4.7H2O   0.25g 
CaCl2    1mg 
Take to 600ml with dH2O, then pH to 7 with NaOH and filled to 920ml. Solution 
autoclaved. Then: 
Glucose 50% (w/v)  80ml 
Catechol (30g/l)  1ml 
Trace element soln.  1ml 
Na2MoO4.2H2O (20g/l) 1ul 
Vitamin soln.   1ml 
Of filter sterilised solutions was added. 
 
2.1.5.5: Trace element solution (CG-13) 
FeSO4.7H2O   1g 
MnSO4.H2O   1g 
ZnSO4.7H2O   0.2g 
CuSO4    20mg 
The solution was made up to 100ml with dH2O and filter sterilised. 
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2.1.5.6: Vitamin solution (CG-13) 
Cobalamin   1mg 
Thiamine   3mg 
Pyridoxal HCl   10mg 
Biotin    1mg 
The solution was made up to 10ml with dH2O and filter sterilised. 
 
2.1.5.7: CG-13 agar 
22 g of Bacterial agar was added to 920ml CG-13 broth before the autoclaving step. 
 
2.1.5.8: MMYE – Enhanced minimal media 
Glucose   20g 
(NH4)2SO4   10g 
Urea    3g 
Yeast Extract   1g 
K2HPO4   1g 
MgSO4.7H2O   0.4g 
FeSO4.7H2O   0.002g 
MnSO4   0.002g 
NaCl    0.05g 
The broth was made up to 1l with dH2O and autoclaved. 
After autoclaving, the following was filter sterilised and added: 
Biotin    50µg 
Thiamine   200µg 
Cobalamin   50µg 
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2.1.5.9: MMYE Agar 
22 g of Bacterial agar was added to 1l MMYE broth before autoclaving. 
 
2.1.5.10: Luria-Bertani (LB) broth 
Tryptone   10g 
Yeast extract      5g 
NaCl        5g 
The broth was made up to 1l with dH2O and autoclaved. 
 
2.1.5.11: Super LB broth 
Tryptone   32g 
Yeast extract   20g 
NaCl      5g 
The broth was made up to 1l with dH2O and autoclaved.  
   
2.1.5.12: Luria-Bertani agar 
15 g of Bacterial agar was added to 1l LB broth before autoclaving. 
2.1.5.13: LB Glucose 
Tryptone   10g 
Yeast extract      5g 
NaCl        5g 
Glucose   10g 
The broth was made up to 1l with dH2O and autoclaved. 
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2.1.5.14: LB Glucose agar 
15 g of Bacterial agar was added to 1l LB Glucose broth before autoclaving. 
 
2.1.5.15: NZY+ broth 
NZ amine    10g 
(casein hydrolysate) 
Yeast extract      5g 
NaCl       5g 
dH2O was added to final volume of 1l and adjusted to pH 7.5 using NaOH.  This was 
autoclaved. The following filter-sterilised supplements were added prior to use: 
1 M MgCl2         12.5ml 
1 M MgSO4         12.5ml 
20% (w/v) glucose           20ml 
 
2.1.5.16: SOC 
Tryptone    20g 
Yeast Extract    5g 
NaCl     0.5g 
Broth was made up to 950ml with dH2O and autoclaved. 
KCl (0.25M)    10ml 
MgSO4 (1M)    10ml 
MgCl2 (1M)    10ml 
Glucose (1M)    20ml 
After autoclaving, the above was added after filter sterilisation.  
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2.1.5.17: M9 salts (10x stock) 
Na2HPO4              60 g 
KH2PO4              30 g 
NH4Cl               10 g 
NaCl                 5 g 
This was made up to 1l with dH2O and then autoclaved.  
 
2.1.5.18: Minimum media broth 
10 x M9 salts          100 ml 
Glycerol              2 ml 
1 M MgSO4              2 ml 
0.1 M CaCl2              1 ml 
1 mg/ml CoCl2 x 6 H2O 1 ml 
dH2O           880 ml 
All solution were made up separately and autoclaved before being mixed, except for 
antibiotics which were filter sterilised.  
 
2.1.5.19: Calcium chloride solution, 1M 
CaCl2.2H20            29.4 g 
This was made up to 200 ml with dH2O and then autoclaved. The solution was diluted 
1:10 with sterile dH2O and used for minimum media and for the preparation of 
competent cells. 
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2.1.5.20: IPTG solution, 1M 
2.38 g of IPTG were dissolved in 10 ml dH2O, filter sterilised (0.2 µm), aliquoted in to 
0.4 ml and stored at -20°C. The final working concentration was 0.4mM. 
 
2.1.5.21: X-gal solution, 20 mg/ml 
X-gal was dissolved in dimethylformamide and stored in the dark at –20 °C. 
 
2.1.5.22: Antibiotics: 
Antibiotic Stock concentration Final concentration 
Ampicillin 100mg/ml in dH2O 100µg/ml 
Chloramphenicol 35mg/ml in Ethanol 35µg/ml 
Kanamycin 50mg/ml in dH2O 50µg/ml 
Table 2.4: Antibiotics used in the growth of E. coli and C. glutamicum for plasmid 
selection. 
 
2.1.6: Media and solutions for DNA work 
2.1.6.1: TE Buffer 
Tris-HCl, pH 8.0  10mM 
EDTA, pH 8.0   1mM 
 
2.1.6.2: DNA Loading Buffer (6x stock) 
Bromophenol blue  0.25% 
Glycerol   50% 
TE Buffer   50% 
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2.1.6.3: Molecular size marker Hyperladder I (Bioline) 
 
Figure 2.1: 5µl Hyperladder I applied to a 1% agarose gel. 
 
2.1.7: Media and solutions for protein work 
2.1.7.1: Ammonium sulphate cuts 
Tris-HCl pH8.0        20mM  
 
2.1.7.2: Hydrophobic interaction chromatography 
Loading Buffer  Tris-HCl pH7.2   20mM 
    NaCl     400mM 
 
Wash 1   Tris-HCl pH7.2   20mM 
    NaCl     300mM 
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Wash 2   Tris-HCl pH7.2   20mM 
    NaCl     275mM 
 
Wash 3   Tris-HCl pH7.2   20mM 
    NaCl     250mM 
 
Wash 4   Tris-HCl pH7.2   20mM 
    NaCl     225mM 
 
Wash 5   Tris-HCl pH7.2   20mM 
    NaCl     200mM 
 
Wash 6   Tris-HCl pH7.2   20mM 
    NaCl     175mM 
 
Wash 7   Tris-HCl pH7.2   20mM 
    NaCl     150mM 
 
Wash 8   Tris-HCl pH7.2   20mM 
    NaCl     100mM 
 
Wash 9   Tris-HCl pH7.2   20mM 
    NaCl     50mM 
 
Wash 10   Tris-HCl pH7.2   20mM 
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Column clean wash  Tris-HCl pH7.2   20mM 
 
2.1.7.3: Ion exchange chromatography 
Loading Buffer  Tris-HCl pH7.2   20mM 
 
Wash 1   Tris-HCl pH7.2   20mM 
    NaCl     50mM 
 
Wash 2   Tris-HCl pH7.2   20mM 
    NaCl     100mM 
 
Wash 3   Tris-HCl pH7.2   20mM 
    NaCl     150mM 
 
Wash 4   Tris-HCl pH7.2   20mM 
    NaCl     175mM 
 
Wash 5   Tris-HCl pH7.2   20mM 
    NaCl     200mM 
 
Wash 6   Tris-HCl pH7.2   20mM 
    NaCl     225mM 
 
Wash 7   Tris-HCl pH7.2   20mM 
    NaCl     250mM 
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Wash 8   Tris-HCl pH7.2   20mM 
    NaCl     275mM 
 
Wash 9   Tris-HCl pH7.2   20mM 
    NaCl     300mM 
 
Wash 10   Tris-HCl pH7.2   20mM 
    NaCl     400mM 
 
Column clean wash  Tris-HCl pH7.2   20mM 
    NaCl     4M 
 
2.1.7.4: Immobilised metal ion affinity chromatography (pH8) 
Charge Buffer I  NiSO4     100mM 
 
Charge Buffer II  CoCl2.6H2O    100mM 
 
Charge Buffer III  ZnCl2.4H2O    100mM  
     
Binding Buffer  Tris-HCl, pH8.0              20mM 
    NaCl         0.5 M 
    Imidazole          5mM 
 
Wash Buffer I   Tris-HCl, pH8.0   20mM 
    NaCl     0.5M 
    Imidazole    15mM 
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Wash Buffer II  Tris-HCl, pH8.0   20mM 
    NaCl        0.5 M 
    Imidazole    25mM 
 
Wash Buffer III  Tris-HCl, pH8.0   20mM 
    NaCl     0.5 M 
    Imidazole    50mM 
 
Wash Buffer IV  Tris-HCl, pH8.0   20mM 
    NaCl     0.5 M 
    Imidazole              100mM 
 
Elute Buffer   Tris-HCl, pH8.0   20mM 
    NaCl     0.5 M 
    Imidazole              400mM 
 
Strip Buffer   Tris-HCl, pH8.0   20mM 
    NaCl     0.5 M 
EDTA               100mM 
 
2.1.7.5: Immobilised metal ion affinity chromatography (pH7) 
Charge Buffer I  NiSO4     100mM 
 
Charge Buffer II  CoCl2.6H2O    100mM 
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Charge Buffer III  ZnCl2.4H2O    100mM  
     
Binding Buffer  Tris-HCl, pH7.0              20mM 
    NaCl         0.5 M 
    Imidazole          5mM 
    Glycerol    10% (v/v) 
 
Wash Buffer I   Tris-HCl, pH7.0   20mM 
    NaCl        0.5 M 
    Imidazole    25mM 
    Glycerol    10% (v/v) 
 
Wash Buffer II  Tris-HCl, pH7.0   20mM 
    NaCl     0.5 M 
    Imidazole    50mM 
    Glycerol    10% (v/v) 
 
Wash Buffer III  Tris-HCl, pH7.0   20mM 
    NaCl     0.5 M 
    Imidazole              100mM 
    Glycerol    10% (v/v) 
 
Elute Buffer   Tris-HCl, pH7.0   20mM 
    NaCl     0.5 M 
    Imidazole              400mM 
    Glycerol    10% (v/v) 
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Strip Buffer   Tris-HCl, pH7.0   20mM  
NaCl     0.5 M 
    EDTA               100mM 
    Glycerol    10% (v/v)  
 
2.1.7.6: Solutions for protein acrylamide gels 
10x Running Buffer:  Tris-HCl    30 g/l 
    Glycine    144 g/l 
 
 
SDS Sample Buffer:  0.5 M Tris-HCl, pH 6.8  6 ml  
    Glycerol    4.8 ml 
    10% SDS    9.6 ml 
    0.05% Bromophenol blue  1.2 ml 
    dH2O     24 ml 
Add 14 µl β-Mercaptoethanol/ml 2x SDS-Buffer. 
 
 
Native Sample Buffer: 0.5 M Tris-HCl, pH 6.8  1 ml 
    Glycerol    0.8 ml 
    0.05% bromphenol blue  0.2 ml 
    dH2O     6 ml 
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Denaturing molecular mass marker Dalton VII 
 
 
Figure 2.2: banding pattern of the SDS-7 Dalton VII marker used for denaturing gels 
examining low or medium molecular weight proteins. 
Protein     Molecular mass (Da) 
Bovine serum albumin   66,000 
Ovalbumin     45,000 
G-3-P dehydrogenase   36,000 
Carbonic anhydrase    29,000 
Trypsinogen     24,000 
Trypsin inhibitor    20,100 
α-Lactalbumin    14,200 
 
 
 
 
 
 
 
 
66kDa 
 
45kDa 
36kDa 
 
29kDa 
24kDa 
20.1kDa 
 
14.2kDa 
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High molecular weight marker: 
 
Figure 2.3: banding pattern of the SDS6H2 marker used for denaturing gels examining 
high molecular weight proteins. 
Protein    Molecular mass (Da) 
Rabbit muscle myosin   200,000 
E. coli β-Galactosidase  116,000 
Rabbit Phosphorylase B  97,400 
Bovine serum albumin  66,000 
Egg serum albumin   45,000 
Bovine Carbonic Anhydrase   29,000 
 
 
Coomassie blue stain 
Trichloracetic acid (100%)  250 ml 
Coomassie blue R250      0.6 g 
SDS        0.1 g 
Tris-HCl      0.25 g 
Glycine     0.15 g 
Made up to 500 ml with dH2O. 
 
200kDa 
 
116kDa 
97.4kDa 
 
66kDa 
 
45kDa 
 
 
 
29kDa 
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2.1.7.7: Composition for SDS gels  
SDS GELS 
Running gels 8% 10% 12.5% 15% Stacking gel 5% 
dH2O (ml) 5.7 4.7 3.4 2.2 dH2O (ml) 3.4 
30% Acrylamide (ml) 4 5 6.3 7.5 30% Acrylamide 
(ml) 
1.5 
1.5 M Tris-HCl,  
pH 8.8 (ml) 
3.8 3.8 3.8 3.8 0.5 M Tris-HCl, 
pH 6.8 (ml) 
1.9 
10% SDS (ml) 1.5 1.5 1.5 1.5 10% SDS (ml) 0.75 
10% APS (ml) 0.15 0.15 0.15 0.15 10% APS (ml) 0.075 
TEMED (ml) 0.01 0.01 0.01 0.01 TEMED (ml) 0.01 
Table 2.5: Denaturing gel composition 
 
2.1.7.8: Solutions for Western blotting 
Transfer Buffer 
Trizma base    25mM 
Glycine    200mM 
Methanol    20% (v/v) 
 
Phosphate buffered saline – PBS 
NaCl     140mM 
KCl     3mM 
Na2HPO4    10mM 
K2HPO4    2mM 
 
Tris-NaCL pH 7.5 wash buffer 
NaCl     150mM 
Trizma base    50mM 
The components were mixed and the pH adjusted to pH 7.5 before adjusting the final 
volume. 
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TBST Buffer 
Tris-HCl (pH 7.6)   25mM 
NaCl     150mM 
Tween     0.05% (v/v) 
 
Amido black stain 
Napthol blue black   0.1% (w/v) 
Methanol    10% (w/v) 
Acetic acid    2% (v/v) 
 
2.1.7.9: Solutions for cobalamin-dependent methionine synthase assay 
Homocysteine 
50mg of L-homocysteine thiolactone was dissolved in 1.7ml of ddH2O, before addition 
of 0.83ml of 0.8M NaOH and bubbling with argon for 5 minutes. After deoxygenating, 
the solution was heated to 45ºC for 6 minutes before acidification with 5M acetic acid 
to pH5. The solution was then diluted to 3.3ml with argon-deoxygenated ddH2O and 
stored in aliquots of 50µl at -80ºC. 
 
Methyltetrahydrofolate 
(6R,S)5-methyltetrahydrofolate monoglutamate (calcium salt) was prepared to 4.2mM 
in 8mM sodium ascorbate. Deoxygenated with argon before aliquoting into 500µl 
volumes and stored at -20ºC. 
 
SAM 
S-adenosyl-methionine was dissolved to a final concentration of 3.8mM in 1mM HCl 
and stored in 50µl aliquots at -80ºC. 
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2.1.7.10: Solutions for HPLC 
Eluent A 
Na2HPO4 pH 6.8   40mM 
Solution was prepared with ddH2O and filtered. 
 
Eluent B 
Methanol    45% 
Acetonitrile    45% 
ddH2O     10% 
Solution was prepared using filtered ddH2O. 
 
2.1.7.11: Solutions for HPLC-MS 
Eluent A 
Ammonium acetate pH 6.0      50mM 
Solution was prepared with ddH2O and filtered. 
 
 
Eluent B 
Methanol                   25% 
Solution was prepared using filtered ddH2O. 
 
2.1.7.12: Solutions for EPR experiments 
Buffers as otherwise listed for protein purification were deoxygenated by argon gas 
before use. 
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2.1.7.13: Solutions for MALDI-TOF 
Colloidal coomassie blue stain 
Ammonium sulphate   1.3 M 
Methanol    34% (v/v) 
Coomassie blue G250   1 g/l 
 
Matrix solution 
Acetonitrile    33.3% (v/v) 
Trifluoroacetic acid   66.6% (v/v) 
Dihydrobenzoic acid   20 mg/ml 
 
2.2: Microbiological methods  
2.2.1: Sterilization 
If not stated otherwise all media and buffers were sterilised for 15 min at 121° C and 1 
bar pressure in the autoclave. Temperature sensitive substances were filtered sterilised 
(pore diameter 0.20 µm). 
2.2.2: Storage of Bacteria 
For long-term storage of bacteria, glycerol stocks were prepared. Glycerol was added to 
an overnight bacterial culture to a final concentration of 15% (v/v). The culture was 
incubated on ice for 30 min before storage at -80°C. 
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2.2.3: Plate cultures 
Bacteria were usually streaked directly from a glycerol stock. Antibiotics were added 
where required. The agar plates were incubated overnight at 37° C. 
 
2.2.4: Liquid cultures 
Liquid cultures were inoculated with a single colony from an agar plate culture. The 
medium was supplemented with the antibiotics where required. Aerobic cultures were 
shaken at ~200 rpm in baffled flasks. Anaerobic cultures were pre-cultivated aerobically 
before overlaying the culture with mineral oil. 
 
2.2.5: Preparation of competent cells 
Competent E. coli cells were prepared based on the method described by Sambrook et 
al. (1989). A bacterial overnight starter culture derived from a single colony was 
inoculated into 100 ml fresh LB broth and grown to an OD600 of 0.3. The cells were 
cooled on ice for 15 minutes and centrifuged at 3,000 rpm at 4°C. The pellets were 
gently resuspended in 50 ml of ice-cold 0.1 M CaCl2 and pelleted again by 
centrifugation. After gentle re-suspension of the cells in 25 ml of 0.1 M CaCl2 and 
incubation on ice for 30 min the cells were collected by centrifugation. Finally the 
collected cells were re-suspended in 0.25 ml of 0.1 M CaCl2 containing 15% glycerol 
(v/v). Aliquots of 30µl were frozen rapidly and placed at -80°C. 
 
2.2.6: Transformation of competent cells 
Competent cells were de-frosted on ice for 10 min before adding 1µl of plasmid DNA. 
The mixture was incubated on ice for 15 min and then heat-shocked by incubation at 
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42°C for 50 sec before rapid transfer on ice. After the addition of 250µl NZY+ broth the 
cells were incubated at 37°C for 20 to 60 min to allow antibiotic resistance expression. 
The mixture was then spread on a LB plate containing the required antibiotics and 
incubated at 37°C overnight. 
 
2.2.7: Production of recombinant protein 
The E. coli strains BL21 (DE3) pLysS and Rosetta (DE3) pLysS were transformed with 
a vector containing the gene of interest cloned in frame. The recombinant strain was 
grown in LB or super LB with ampicillin and chloramphenicol at 37°C and shaken 
vigorously to an OD600 of approximately 0.6. Protein expression was induced with 
0.4mM IPTG overnight at 16°C. The cells were collected by centrifugation at 4,000 rpm 
for 15 min at 4°C. The pellet was re-suspended in 2ml/g of binding buffer and stored at 
-20°C until protein purification. 
 
2.2.8: Growth of C. glutamicum 
The strain was grown in BHI or other Corynebacterium media with kanamycin if 
required for plasmid selection and shaken vigorously at 30ºC to an OD600 of 
approximately 0.6. To obtain optimum aeration, 400ml cultures were shaken in 2 litre 
baffled flasks. If the strain was inducible, 1mM IPTG was added and growth allowed to 
continue overnight at 30ºC. The cells were harvested by centrifugation at 4,000RPM for 
15 minutes at 4ºC. The pellet was resuspended in 2ml/g of 20mM Tris pH7.2 or 
whichever buffer was deemed necessary and stored at -20ºC until protein purification. 
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2.2.9: Sonication of bacteria 
Harvested cells were defrosted and lysed by sonication using a Sonics Vibracell 
Ultrasonic processor, with an output watt of between 20 and 30 in bursts of 6 times 30 
sec with 30 sec breaks. The sonicated cells were centrifuged at 18,000 rpm for 20 min at 
4°C. 
 
2.3: Molecular Biological methods 
2.3.1: PCR reactions 
All PCR reactions were performed in an Eppendorf AG 22331 PCR machine.  
The basic PCR reaction and the cycles used are outlined as follows: 
 
 with DMSO without DMSO 
ddH2O 32.5µl 37.5µl 
10 x PCR buffer (Roche, 
containing 18mM MgCl2) 
5µl 5µl 
DMSO 5 µl - 
5mM dNTPs 2µl 2µl 
10 µM 5’ primer 2µl 2µl 
10 µM 3’ primer 2µl 2µl 
DNA template 1µl 1µl 
Taq polymerase 0.5-1µl 0.5-1µl 
Table 2.6: basic PCR reaction. 
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Time Step Temp 
Roche Taq Hotstar Taq 
Cycles Function 
1 95°C 2 min 15 min 1 Initial Denaturation of the 
chromosomal DNA 
2 95°C 30 sec 20 sec Denaturation of the amplified 
DNA 
3 55-
58°C 
30 sec 20 sec Annealing of the primers 
4 72°C 1 min per 1,000bp  
 
35 
Elongation 
5 72°C 5 min 10 min 1 Final elongation 
Stop 4°C Hold 
Table 2.7: temperature protocol for PCR reaction. 
Once the PCR reaction was completed the product was subjected to agarose gel 
electrophoresis. 
 
2.3.2: Electrophoresis of DNA  
The DNA fragments were separated by agarose gel electrophoresis. 
 
2.3.2.1: Agarose gel 
The agarose gel percentage was chosen according to the size of the DNA fragments to 
be separated [0.5 – 2% (w/v) agarose in TAE buffer]. A 1% aragose gel was routinely 
used. Agarose gels were set with the appropriate amount of agarose in 1x TAE buffer 
with the addition of ethidium bromide to a final concentration of 0.5µg/ml. The DNA 
samples containing 20% DNA loading buffer were loaded into the agarose gel wells and 
electrophoresis was carried out at ~ 60 V for approximately 90 minutes. 
 
2.3.2.2: Visualization under UV 
UV radiation (312 nm) is absorbed by the ethidium bromide and re-emitted at 590 nm in 
the red-orange wavelength range. Ethidium bromide is a fluorescent dye that 
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intercalates between the base pairs, allowing visualization of the DNA under UV light. 
Therefore, the DNA was visualized by placing the gel onto an UV transilluminator. The 
gel was then photographed through a red filter. 
 
2.3.3: Isolation and purification of a DNA fragment  
2.3.3.1: From an agarose gel 
The DNA band of interest was carefully excised from an agarose gel using a scalpel 
blade. Purification was carried out using Qiagen QIAquick® gel extraction kit 
according to the protocol for using a microcentrifuge as stated in the handbook. 
 
2.3.3.2: From solution 
DNA fragments resulting from a PCR reaction or from a restriction digest were purified 
using Qiagen QIAquick® gel extraction kit according to the handbook section stating 
the protocol for QIAquick® PCR purification. 
 
2.3.4: Ligation of DNA 
Vector and insert were digested with the relevant restriction enzymes as described in the 
relevant sections. The ligation of DNA fragments into the vector was carried out at 
either room temperature for 1 hour or at 4ºC overnight. 
Typical ligation protocol 
Insert     2.5µl 
Vector     1.5µl 
2x Rapid Ligation buffer (Promega) 5µl 
T4 DNA Ligase (Promega)  1µl (= 1 U/10µl) 
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2.3.5: Isolation of plasmid DNA 
2.3.5.1: Qiagen E. coli miniprep (spin) 
A Qiagen QIAprep® miniprep kit was used for the purification of plasmid DNA. Refer 
to the QIAprep® miniprep handbook for the protocol, QIAprep® Spin Miniprep Kit 
using a microcentrifuge. 
 
2.3.5.2: Qiagen C. glutamicum miniprep 
Qiagen have available on their website a user-developed protocol for the isolation of 
plasmids from C. glutamicum. This protocol is as follows: 
5 ml of a culture of C. glutamicum was harvested by centrifugation at 6000 x g for 5 
min. The supernatant was completely removed. Cells were resuspended in 1 ml Buffer 
B, and transferred to a clean microcentrifuge tube before centrifuging for 2 min. 
Supernatant was removed again. The pellet was resuspended in 0.3 ml Buffer P1 
containing 15 mg/ml lysozyme, ensuring that RNase A (100 µg/ml) had been added to 
Buffer P1. This was incubated at 37°C for 2-3 hours, mixing gently occasionally. 0.3 ml 
of Buffer P2 was added and mixed thoroughly by gently inverting 4-6 times. This was 
incubated at room temperature for 5 min. 0.3 ml of chilled Buffer P3 was added and 
mixed immediately by inverting 4-6 times. The resulting solution was incubated on ice 
for 15 min. The prep was centrifuged at maximum speed for 10 minutes and the 
supernatant removed again. A Quagen-tip 20 was equilibrated by addition of 1ml buffer 
QBT and allowed to empty by gravity flow before application of the prep supernatant. 
The column was then washed with 4ml of buffer QC and DNA eluted by 0.8ml of 
buffer QF. DNA was precipitated by addition of 0.56ml of ice cold isopropanol and 
centrifuged at >10000g for 30 minutes in a microfuge. Supernatant was removed, taking 
care not to disturb the DNA pellet. DNA pellet was washed with 1ml of 70% ethanol 
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and centrifuged again for 10 minutes at >10000g. After decanting ethanol, pellet was 
allowed to air dry for 5-10 minutes before redissolving in elute buffer. 
 
Medium and buffer composition  
Buffer B:  
50 mM glucose  
10 mM CDTA 
25 mM Tris·Cl, pH 8.0  
 
2.3.5.3: Modifications to Qiagen spin miniprep system for application 
to C. glutamicum 
The Qiagen QIAprep® miniprep kit was used for the purification of plasmid DNA. 
Refer to the QIAprep® miniprep handbook for the protocol, QIAprep® Spin Miniprep 
Kit using a microcentrifuge with the following additions for its use with C. glutamicum: 
An incubation/wash step with Buffer B (described above) for three minutes between the 
removal of growth medium and addition of Qiagen buffer P1. 15mg/ml of lysozyme 
was added (along with 100µg/ml RNase A) to buffer P1 before application to C. 
glutamicum cell pellet. 
 
2.3.6: Restriction digest of DNA 
Plasmid DNA was digested using the relevant enzymes and the optimal buffer chosen 
according to either the Promega or New England Biolabs information provided. The 
reactions were incubated for 2 hours at the temperature required by the restriction 
enzyme before being subjected to electrophoresis. 
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 Single digest Double digest 
ddH2O 5µl 5µl 
Restriction enzyme 1 1µl 0.5µl 
Restriction enzyme 2 - 0.5µl 
10 x Buffer 1µl 1µl 
Plasmid DNA 3µl 3µl 
Table 2.8: typical restriction enzyme digest protocol. 
 
2.3.7: Cloning into vectors 
2.3.7.1: Cloning into pGEM®-T Easy - Indirect cloning 
Genes of interest obtained from PCR reactions were cloned using the pGEM®-T Easy 
vector system from Promega. 2µl PCR product was mixed with 1µl pGEM®-T Easy 
vector and ligated overnight. Competent E. coli JM109 were transformed with the 
ligation mixture and recombinants were identified by blue/white screening when plating 
the cells on LB plates containing ampicillin, 0.5mM IPTG and 80 µg/ml X-Gal. Refer to 
the pGEM®-T technical manual for more detail. The gene was subsequently sub-cloned 
into the NdeI and BamHI sites of pET vectors.  
2.3.7.2: Cloning into pET-3a, pET-14b and pET-23b vectors 
The vectors and the genes of interest were digested at their NdeI and BamHI restriction 
sites, which were introduced into the PCR product of the gene via the 5’ and 3’ primers 
respectively (Section 2.1.3:). When a natural BamHI restriction site occurred in a gene 
the primers were designed with a BglII restriction site, which has a compatible cohesive 
end with BamHI. After isolation and purification of the required DNA fragments vector 
and gene were ligated together (Section 2.3.4:). Competent JM109 were transformed 
with the ligation mixture and plated onto appropriate media. Single colonies were 
selected, grown and the recombinant plasmids amplified and sequenced to verify the 
DNA sequence. In pET-14b, the N-terminus of the encoded recombinant protein is 
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fused to the C-terminus of a short peptide sequence containing a stretch of six 
consecutive histidine residues. In pET-23b the C-terminus of the encoded recombinant 
protein is fused to the N-terminus of a short peptide sequence containing a stretch of six 
consecutive histidine residues. In pET-3a the encoded recombinant protein is not fused 
to a His-tag. In pLysS the encoded recombinant proteins are not His-tag fusions. 
 
2.3.7.3: Cloning of fdxA, fdxB and fdxC mutants 
The mutations created in this study FdxA (C9A, C17A, C20A, C25A, C40A, C43A, 
C46A, C50A), FdxB (C40A, C46A, C49A, C82A, C87A) and FdxC (C9A, C17A, 
C20A, C25A, C40A, C43A, C46A, C50A) were generated using the QuikChange® II 
Site-Directed Mutagenesis Kit from Stratagene. Briefly the method is described as 
follows: the QuikChange® II site-directed mutagenesis kit can be used to introduce 
point mutations that switch amino acids as well as delete and insert single or multiple 
base pairs. The mutagenesis method was performed using PfuUltraTM high-fidelity 
(HF) DNA polymerase. The basic procedure utilizes a supercoiled double-standed DNA 
(dsDNA) vector with an insert of interest and two synthetic oligonucleotide primers, 
both containing the desired mutation. The oligonucleotide primers, each complementary 
to opposite strands of the vector, were extended during temperature cycling by PfuUltra 
TM HF DNA polymerase. Extensions of the oligonucleotide primers generated a 
mutated plasmid containing staggered nicks. Following temperature cycling, the product 
was treated with DpnI. The DpnI endonuclease (target sequence: 5’-GmATC-3’) is 
specific for methylated and hemimethylated DNA and was used to digest parental DNA 
template and to select for mutation-containing synthesized DNA. The nicked vector 
DNA containing the desired mutations was then transformed into XL1-Blue 
supercompetent cells and the nicks were repaired. Mutant plasmids were purified and 
sequenced to verify the correct mutation. 
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2.4: Biochemical methods 
2.4.1: Standard purification procedures 
2.4.1.1: Ammonium sulphate precipitation 
All ammonium sulphate precipitation work was carried out in a cold room at 4ºC, 
meaning that solution saturation of ammonium sulphate is 3.93M. Given that 100% 
saturation is 4.1M at 25ºC (which is what Table 2.9 assumes) the amount of ammonium 
sulphate to be added to the solution at 4ºC can be calculated by multiplying the requisite 
quantity (in grams) by 0.9585. Ammonium sulphate was ground by pestle and mortar 
until a fine powder, and added slowly to the stirred solution over the course of 30 
minutes to avoid ‘hotspotting’ – having one area of the solution at a higher 
concentration than another – which causes protein precipitation to be unpredictable. The 
solution was then stirred for a further 45 minutes before being centrifuged at 10000g for 
15 minutes to pellet the precipitated protein. The supernatant was decanted into a clean 
beaker and placed back on the stirrer if addition of more ammonium sulphate was 
necessary for another round of precipitation. The protein pellet was resuspended in PBS 
or Tris buffer for assays and gels. 
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Table 2.9: Quantities of ammonium sulphate necessary to increase concentration to a 
given percentage, given that the volume of liquid is 100ml, provided by Dr. A. A. 
Brindley, based upon (Green and Hughes 1955). 
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2.4.1.2: Hydrophobic interaction chromatography 
Hydrophobic interaction chromatography relies on the hydrophobicity of proteins to 
bind them to the column. As such, it starts at high salt concentrations and gradually 
works toward zero salt present in the solution. Washes were stepped, as detailed above 
in section 2.1.7.2, wash volumes were 50ml and concentrated down for assays or gels. 
 
2.4.1.3: Ion exchange chromatography 
Ion exchange relies on the charges of proteins to bind them to the stationary phase of a 
column. Washes were stepped up from zero salt to 400mM, as detailed in section 
2.1.7.3, wash volumes were 50ml and concentrated down for assays or gels. 
 
2.4.1.4: Fast protein liquid chromatography (FPLC) 
The FPLC was set up following the Amersham manual for ion exchange 
chromatography using a 1ml Mono-Q column using default settings where possible with 
the following exceptions; a flow rate of 1ml/min, fraction size of 5ml, equilibration 
volume of 25ml, wash 1 volume of 10ml, elution volume of 600ml and a final wash 2 
volume of 50ml. 
 
2.4.1.5: Immobilized metal-ion affinity chromatography (IMAC) 
The His-tag sequence of the fused protein has affinity for transition metals such as Co2+, 
Ni2+, Cu2+, Zn2+ and Fe3+. Chelating SepharoseTM Fast Flow resin loaded with the 
suitable metal ion will therefore selectively retain protein with exposed histidines, 
which form complexes with the metal ions. The bound protein can be isolated by 
competitive elution with increasing concentrations of imidazole. Proteins were purified 
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at room temperature, but were kept on ice as much as possible. Columns containing 
approximately 3 to 5 ml of the resin were used to purify proteins from a 1l culture. The 
resin was initially rinsed with water, charged with NiSO4 (Charge buffer I) and 
equilibrated with 50 ml Binding buffer. Cell pellets were defrosted and sonicated and 
the protein containing soluble cell extract was separated from the cell debris by 
centrifugation. The supernatant was applied to the resin and allowed to flow through by 
gravity. Unbound proteins were washed away with 50 ml of Binding buffer, 25 ml of 
Wash buffer I and finally 25 ml of Wash buffer II. Elution buffer was applied to the 
column to recover the protein, which was collected in 2 ml fractions. The resin was 
regenerated with 15 ml Strip buffer and washed with water. The composition of the 
buffers can be found above (Section 2.1.7). 
 
2.4.1.6: Urea IMAC 
Urea was added to all buffers and solutions for an IMAC column to a final 
concentration of 8M. Aside from the urea addition, standard IMAC protocol was 
followed. 
 
2.4.2: Buffer exchange 
Purified protein was desalted on a pre-packed disposable Sephadex G25 column (PD-
10, bed volume 8.3 ml). In brief the method consists of the following steps: (1) column 
equilibration with 25 ml of buffer into which the protein was to be exchanged: (2) 
application of 2.5 ml protein (3) elution of protein sample in 3.5 ml buffer: (4) 
restoration of column in dH2O. 
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2.4.3: Bradford protein assay 
The Bradford assay relies on the dye coomassie blue G250 binding to proteins, and 
most readily to arginyl and lysyl residues. The absorbance maxima of the dye shifts 
from the red cationic form (470 to 650 nm) to the blue anionic form (590 to 620 nm) in 
the presence of protein. Thus, the quantity of the protein can be estimated by measuring 
the amount of dye in the blue form at 595 nm (Bradford 1976). The protein assay dye 
from BioRad was added to diluted protein solution. The reaction was left at room 
temperature and the OD595 was measured. A standard curve was generated with bovine 
serum albumin (5, 10, 15, 20 and 25 mg) at the same time. Refer to the BioRad 
instruction manual for details. 
 
2.4.4: A280 protein concentration estimation 
Protein concentrations were estimated by the method described by Warburg and 
Christian (Warburg 1941). The OD280 was recorded and the concentration estimated 
from the calculated extinction coefficient for the protein using the following equations. 
The Beer/Lambert law: 
A280 = Concentration x Extinction coefficient x Path length  
To convert to mg/ml: 
mg/ml protein = Molecular mass x Concentration 
 
2.4.5: Polyacrylamide gel electrophoresis 
2.4.5.1: SDS-PAGE 
The composition of the gel, buffers and stain were previously described in Section 
2.1.7. Polyacrylamide gels were run according to Laemmli (Laemmli 1970). The sample 
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was denatured by 1:1 addition of SDS sample buffer and boiling for 5 minutes. Between 
5 to 20µg denatured sample was loaded into each well and 7µl of Dalton VII molecular 
mass marker was run on each gel to estimate the relative molecular mass of the protein 
of interest. Electrophoresis was performed at a constant voltage of 200 V using an Atto 
Dual Mini Slab AE6450 electrophoresis apparatus and an Atto Mini Power 
electrophoresis power supply SJ1082, both obtained from GRI Ltd. The gel was stained 
with coomassie blue stain and de-stained by boiling in water. Finally, for storage the gel 
was dried between two cellophane sheets (BioRad). 
 
2.4.5.2: Urea SDS-PAGE 
Urea SDS-PAGE was carried out based on the methods of Arvan et al. (Liu et al. 2003; 
Zhang et al. 2003) and Schagger (Schagger and von Jagow 1987). The sample was 
denatured by 1:1 addition of SDS sample buffer and boiling for 5 minutes. Between 5 to 
20µg denatured sample was loaded into each well and 7µl of Dalton VII molecular mass 
marker was run on each gel to estimate the relative molecular mass of the protein of 
interest. Electrophoresis was performed at a constant voltage of 200 V using an Atto 
Dual Mini Slab AE6450 electrophoresis apparatus and an Atto Mini Power 
electrophoresis power supply SJ1082, both obtained from GRI Ltd. The gel was stained 
with coomassie blue stain and de-stained by boiling in water. Finally, for storage the gel 
was dried between two cellophane sheets (BioRad). 
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2.4.6: Western Blotting 
2.4.6.1: Western blotting (alkaline phosphatase) 
Proteins separated on a denaturing polyacrylamide gel (Section 2.4.6.1) were transferred 
onto Hybond-P, hydrophobic polyvinylidene difluoride (PVDF) membrane from 
Amersham Biosciences (Towbin et al. 1979). The PVDF membrane was briefly soaked 
in 100% methanol before immersing in transfer buffer. The polyacrylamide gel, PVDF 
membrane, blotting paper and gauze pads were all soaked in transfer buffer for 10 
minutes before the blot was constructed. 
 
The ‘sandwich’ was placed in the Western Blot transfer tank (BioRad) along with an ice 
block and filled with cold transfer buffer before being electrophoresed at 100 V for 75 
minutes using a BioRad power pac 300. Once electrophoresis was complete the PVDF 
membrane was incubated with 5% non-fat dry milk in PBS for at least 2 hours to block 
non-specific sites before probing with antibodies. All solutions used for any Western 
blotting method used can be found in Section 2.1.7.5. 
 
To probe for His-tagged recombinant proteins, the His-tag monoclonal antibody (Ab) 
obtained from Novagen is used as the primary Ab. The epitope for this mouse 
monoclonal Ab is a penta-histidine residue motif (HHHHH), and binding is not 
dependent on sequence context. The secondary Ab used is the goat anti-mouse IgG 
alkaline phosphatase conjugate also from Novagen. 
 
Once the membrane had been incubated in the 5 % milk solution in PBS, it was rinsed 
briefly three times with PBS and incubated for 1 to 2 hours at 4°C with the primary Ab, 
His•Tag monoclonal Ab, at a working dilution of 1:1,000. After thoroughly rinsing the 
membrane three times with PBS and a further two times with Tris-NaCl wash buffer, 
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the membrane was incubated with the secondary Ab for 1 hour at room temperature at a 
working dilution of 1:5,000. The membrane was again washed thoroughly with Tris-
NaCl wash buffer before proteins were detected by incubating with Sigma Fast™ 
BCIP/NBT buffered substrate reagent, containing 0.15 mg/ml BCIP, 0.30 mg/ml NBT, 
100 mM Tris buffer and 5 mM MgCl2. 
 Alkaline Phosphatase + BCIP    BCI + PO4, pH 9.5 
  BCI + NBT  insoluble, blue colour 
The colour was allowed to develop and the reaction stopped by immersing the 
membrane in water. The blots were allowed to dry for ease of storage. 
 
2.4.6.2: Western blotting (horseradish peroxidase) 
This process used the Supersignal® West HisprobeTM Kit from Pierce Biotechnology. 
Proteins separated on a denaturing polyacrylamide gel (Section 2.4.6.1) were transferred 
onto Hybond-P, hydrophobic polyvinylidene difluoride (PVDF) membrane from 
Amersham Biosciences (Towbin et al. 1979). The PVDF membrane was briefly soaked 
in 100 % methanol before immersing in transfer buffer. The polyacrylamide gel, PVDF 
membrane, blotting paper and gauze pads were all soaked in transfer buffer for 10 
minutes before the blot was constructed. The ‘sandwich’ was placed in the Western Blot 
transfer tank (BioRad) along with an ice block and filled with cold transfer buffer before 
being subjected to electrophoresis at 100 V for 75 minutes using a BioRad Power PAC 
300. Once electrophoresis was complete the PVDF membrane is incubated in 25 mg/ml 
BSA dissolved in TBST buffer (25 mM Tris pH 7.6, 0.15 M NaCl, 0.05 % Tween) for 
one hour at room temperature. The membrane was then subjected to two 10 minute 
washes in TBST. The blot was subsequently incubated with 10 ml of HisProbe-HRP 
working solution (Pierce Biotechnology) for one hour with shaking. The blot was 
washed again four times with TBST for 10 minutes per wash before incubation with 
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SuperSignal West Pico Substrate Working Solution (Pierce Biotechnology) for 5 
minutes. The blot was removed from the solution and excess liquid removed with tissue. 
The blot was then kept in a dark environment and transferred to a darkroom where it 
was placed on photographic film for 10 seconds before development. 
 
2.4.7: MALDI-TOF SDS-PAGE analysis 
2.4.7.1: Reduction and desalting 
To attempt identification of recombinantly expressed His-tag fusion proteins, purified 
proteins were subjected to SDS-PAGE. The gel was removed from the running buffer 
and fixed with a fixing solution for 1 hour. The gel was stained with colloidal 
coomassie stain and individual protein bands were excised and prepared for MALDI-
TOF as follows.  
Bands of interest were excised with a clean scalpel, cut into small squares (1 x 1 mm) 
and transferred to a microfuge tube. The gel pieces were then washed with 100 µl of 50 
mM NH4HCO3/acetonitrile (1:1) for 15 minutes and the centrifuged to remove the 
liquid. The gel pieces were shrunk by the addition of 100 µl acetonitrile and left to stand 
for 15 minutes. The samples were spun down and the liquid removed before incubation 
at 56 °C for 30 mins in 50 µl of 10 mM DTT and 50 mM NH4HCO3. The gel pieces 
were centrifuged, the liquid removed and the samples shrunk briefly again in 
acetonitrile. The acetonitrile was subsequently removed and the samples incubated in 55 
mM iodoacetamide and 50 mM NH4HCO3 for 20 minutes in the dark. Iodoacetamide 
solution was removed and gel pieces washed twice for 15 minutes in 50 mM NH4HCO3. 
The gel pieces were then shrunk again in acetonitrile and acetonitrile removed and the 
samples dried in a vacuum centrifuge. 
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2.4.7.2: In-gel Digestion 
The gel pieces were rehydrated in in 20µl digestion buffer (10mM NH4HCO3, 0% 
acetonitrile) containing 10 ng/µl of trypsin at 4°C (on ice) for 30 min. After 30 minutes, 
the supernatant was removed and 10µl of the digestion buffer without trypsin was added 
to keep gel pieces wet during enzyme cleavage and the samples were left at 37°C 
overnight. 
 
2.4.7.3: Extraction of peptides 
5 µl of acetonitrile was added to each sample before sonication in an ultrasonic bath for 
15 minutes. The supernatant was then removed and stored in a microfuge before the 
addition of 10 µl of 50 % acetonitrile with 5 % formic acid and another sonication for 
15 minutes in an ultrasonic bath. The supernatant was removed and combined with the 
previous supernatant and the samples analysed by MALDI on a Bruker Ultraflex 
machine. A matrix solution was used consisting of one part acetonitrile and two parts 
trifluoroacetic acid containing 20 mg/ml dihydrobenzoic acid.  
 
2.4.8: Anaerobic techniques 
Anaerobic work was carried out under the nitrogen environment of the glove box (Belle 
Technologies) containing less than 3 ppm oxygen. Liquids such as water and buffer 
stocks were degassed under argon prior to transfer into the glove box. Chemicals were 
taken into the glove box as powders and were made up with degassed water once inside. 
Resins such as PD-10 columns and DEAE columns were brought into the glove box 24 
hours prior to use and equilibrated with at least 50 ml of anaerobic buffer. 
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2.4.9: UV/visible spectrophotometry 
All UV/visible spectra were recorded on a Hewlett-Packard 8452A diode array 
spectrophotometer or a Varian Cary 50 Bio UV/visible spectrophotometer over a range 
of 300 – 800 nm. 
 
2.4.10: Cobalamin-dependent Methionine Synthase assay 
For each assay mix, the following was added to 2ml Eppendorf tubes: 
dH2O    494µl 
KPO4 pH7.2   80µl 
500mM DTT   40µl 
3.8mM SAM   4µl 
100mM L-homocysteine 4µl 
Hydroxycobalamin  80µl 
Sample   50µl 
After incubation at 37ºC for 5 minutes, 48µl of methyltetrahydrofolate was added, 
inverted gently to mix and incubated for a further 10 minutes. The assay was stopped by 
addition of 200µl of 5M HCl/60% formic acid, mixed by inversion and heated to 80ºC 
for 10 minutes. Precipitated protein was pelleted by centrifugation at 10,000g for 5 
minutes, then the supernatant decanted into a cuvette and the samples absorbance at 
350nm tested in a Cary 50 UV/Visible spectrophotometer. 
Blanks were run for each sample – a homocysteine negative blank for crude extracts, or 
a water sample blank for purified protein. 
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2.4.11: HPLC 
2.4.11.1: HPLC (Methionine/Homocysteine determination) 
The assays were run on an Agilent 1100-series HPLC with a Zorbax Eclipse C18 
column with inline diode array and fluorescence detectors. An automated pre-column 
mixing program was utilised to make certain that derivitisation only occurred when the 
sample was about to be applied to the column. The vial positions were as follows: vial 
1: borate buffer (0.4M, pH10.2), vial 2: water (for needle wash, vial not sealed with lid), 
vial 3: OPA reagent (20mM), vial 4: water (capped), vial ‘x’: sample, where ‘x’ is any 
position other than 1-4 in the autosampler tray. The derivitisation routine was as 
follows: draw 4µl from vial 1; draw 4µl from sample vial (e.g. position 7); mix 6µl in 
air, maximum speed, twice; incubate for 30 seconds; draw 0µl from vial 2 (needle 
washing step); draw 1.5µl from vial 3 (OPA); mix 7µl in air, maximum speed, six times; 
draw 0µl from vial 2 (needle wash step); draw 40.5µl from vial 4; mix 40µl in air, 
maximum speed, twice; inject. To avoid over-pressurising the column, a flow rate of 
1ml/min was used. 
2.4.11.2: HPLC-MS (Cobalamin determination) 
10 µl of the reaction mixtures described in Section 5.4.2 were injected on to an Ace 5 
AQ column (2.1 x 150 mm, 5 µm, Advanced Chromatography Technologies) that was 
attached to an Agilent 1100 series HPLC coupled to a micrOTOF-Q (Bruker) mass 
spectrometer and equipped with online diode array and fluorescence detectors and run at 
a flow rate of 0.2 ml/min. Cobalamins were separated using a gradient of methanol in 1 
% acetic acid. The concentration of methanol was increased in a linear gradient from 5 
to 70 % over 20 minutes and then back to the starting conditions over a further 10 
minutes. The reaction products were identified based on retention time, spectral 
characteristics and mass spectrum. 
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2.4.11.3: HPLC-MS (Flavin determination) 
The bound flavin cofactor was extracted from FprA by incubation of the protein at 100 
ºC for 10 minutes. Subsequently, the precipitate was removed by centrifugation leaving 
a yellow supernatant. Of this, 10 µl was injected on to an Ace 5 AQ column (2.1 x 150 
mm, 5 µm, Advanced Chromatography Technologies) that was attached to an Agilent 
1100 series HPLC coupled to a Bruker micrOTOF-Q mass spectrometer and equipped 
with online diode array and fluorescence detectors and run at a flow rate of 0.3 ml/min. 
Flavin cofactors were separated isocratically using 25 % methanol in 50 mM 
ammonium acetate pH 6.0 as the eluent.  The absorption at 455 nm and fluorescence 
emission at 525 nm (excitation wavelength 450 nm) were recorded. The retention time, 
spectral characteristics and mass spectrum of the cofactor extracted were compared to 
authentic standards of FMN and FAD. Under these conditions FAD and FMN eluted 
with retention times of 3.2 and 4.0 minutes respectively. 
 
2.4.12: Electron Paramagnetic Resonance Spectroscopy (EPR) 
EPR spectra were recorded in collaboration with Dr. Steve Rigby (Queen Mary, 
University of London). Protein samples were prepared as described in the text and 
300µl injected into quartz EPR sample tubes. These were then frozen in liquid nitrogen 
at 250µM for ferredoxins, 50µM for flavoproteins and 16µM for cdMS. EPR 
experiments were performed on a Bruker ELEXSYS E580 spectrometer operating at X-
band (9.5GHz) employing a Super High Q cylindrical cavity (Q factor ~16,000) 
equipped with an Oxford Instruments ESR900 liquid helium cryostat linked to an 
ITC503 temperature controller.  
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2.4.12.1: For study of 2[4Fe4S] centre proteins 
The iron-sulphur spectra were recorded at 12ºK employing a microwave power of 1 
mW, modulation frequency of 100 kHz and modulation amplitude of 5 G with a centre 
field of 3340G and a sweep width of 600G. 
 
2.4.12.2: For study of 2Fe2S centre proteins 
Iron-sulphur spectra were recorded at 12ºK, with confirmation of the 2Fe2S nature at 
60ºK, employing a microwave power of 1 mW, modulation frequency of 100 kHz and 
modulation amplitude of 5 G with a centre field of 3340G and a sweep width of 600G.  
 
2.4.12.3: For study of flavoproteins 
The flavin spectra were recorded at 12ºK employing a microwave power of 1 mW, 
modulation frequency of 100 kHz and modulation amplitude of 5 G with a centre field 
of 3340G and a sweep width of 75G.  
 
2.4.12.4: For study of Co2+-cobalamin containing proteins 
The Co2+ spectra were recorded at 12 K employing a microwave power of 1 mW, 
modulation frequency of 100 kHz and modulation amplitude of 5 G with a centre field 
of 3400G and a sweep width of 700G. 
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3: Cobalamin-dependent Methionine Synthase in the native C. 
glutamicum system 
3.1: Introduction 
As described in chapter 1, C. glutamicum is a Gram-positive bacterium native to the soil 
in many parts of the world. Originally isolated in Japan by Kinoshita (Kinoshita 1959) it 
has been used as an industrial source for production of a range of amino acids, including 
methionine and lysine. The first isolate produced high concentrations of glutamate – 
hence it’s name of ‘glutamicum’ – while later strains were engineered to produce 
substantial quantities of other amino acids such as leucine, isoleucine and tryptophan 
(Ikeda and Katsumata 1992; Keilhauer et al. 1993; Jetten et al. 1994; Patek et al. 1994; 
Morbach et al. 1996; Sahm et al. 1996). More recently work has been put into 
improving amino acid production further (Eggeling et al. 1998; de Graaf et al. 2001; 
Hartmann et al. 2003; Ikeda et al. 2006) but this mostly focuses on improvements to 
lysine biosynthesis as it, like methionine, is of great importance as an additive in animal 
feed, predominantly for poultry.  
 
Despite C. glutamicum having simpler methionine cycle feedback and inhibition 
systems than that of E. coli, the creation of C. glutamicum methionine overproducing 
mutant strains has met with mixed success (Kumar and Gomes 2005). Investigation into 
the pathway (Ruckert et al. 2003) by knockouts and complementation provided an 
overview of each component of the pathway.  
 
In an alternative approach to directly improving methionine production or cdMS 
activity, work has been carried out examining methionine export (Trotschel et al. 2005) 
which would make obtaining methionine produced by biotechnological means much 
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easier. With this method production would be carried out by continuous fermentation 
with timely changes of broth as the amount of extracellular methionine increased in 
concentration. However, when a similar approach of export is applied to glutamate 
production (Uy et al. 2003) it causes significant fluctuations in many cellular processes.  
 
Nonetheless, in an attempt to improve methionine production in C. glutamicum the 
cdMS was targeted. In this case it was hoped that the cdMS could be engineered with 
more favourable kinetic traits. Specifically the kinetic and physical characteristics of 
cdMS were probed and purification of the active enzyme was sought from strains 
producing increased quantities of the enzyme. It was hoped that it may be possible to 
engineer the cdMS with biotechnologically favourable properties such as a higher kcat. 
 
3.2: Results 
3.2.1: Growth curves of the different C. glutamicum strains 
We received a number of strains of C. glutamicum from BASF which had been 
modified for enhanced methionine synthase activity or production. It was reported that 
when grown under optimum conditions, the level of cdMS could be as high as 20% of 
the total intra-cellular protein in this strain (Schroeder, H., private communication). 
‘Optimum conditions’ relied on the use of continual culture fermentation, where 
bacteria are provided with a steady consistent supply of nutrients for prolonged growth, 
which was not an option available at any point in this study. Instead batch cultures were 
used. Thus, cells were grown in 400ml brain-heart infusion media in 2 litre baffled 
flasks at 200RPM for optimum aeration, as detailed in section 2.2.8. All of the strains of 
C. glutamicum provided by BASF grow at broadly the same rate (as exemplified in Fig. 
3.1 with strain OM257). OM246 (∆metE ∆metH) reached exponential phase slightly 
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before the other strains in conditions where it is not limited by lack of methionine or 
threonine. All of the plasmid-based over-expressing strains reached exponential growth 
more slowly than the wild-type or other strains, but it was only a minor growth rate 
decrease.  
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Figure 3.1: Growth curve taken over 13 hours of C. glutamicum strain OM257. 
Optimum time for induction is after approximately 6 hours (blue marker) and harvesting 
is after approximately 8 hours (red marker) of growth.  
 
For the purification of cdMS, strain OM257 was used as the source of the enzyme since, 
after induction, levels of cdMS activity are higher when compared to the other strains 
(Table 3.1). Alternative media such as CG-13, MMYE or LB glucose (Section 2.1.5) 
had no impact on the produced levels or activity of cdMS, although they did have a 
marked impact on cell density obtained within a given timeframe. 
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Strain Corrected A350 Activity 
(nmol/min) ± 
Std. Dev. n=3 
Lu1479 0.14 0.529 ± 0.011 
Lu1479 H170 0.16 0.603 ± 0.006 
OM246 0.02 0.075 ± 0.008 
OM257 0.28 1.056 ± 0.029 
OM246 H588 0.22 0.830 ± 0.012 
Table 3.1: Corrected A350 values and calculated activity, following the protocol 
described in 2.4.10, of the cdMS activity assay on crude extracts of five different strains 
of C. glutamicum provided for use in this study by BASF. 
 
3.2.2: cdMS assay with C. glutamicum 
All cdMS catalyse the transfer of a methyl group from methyl-tetrahydrofolate (THF) to 
homocysteine to generate methionine and THF, in the following reaction: 
                       + Hcy  + Met       
 (CH3-THF + Homocysteine  THF + Methionine)  …. 
To monitor the activity of the enzyme a number of assays have been developed 
including both radioactive and non-radioactive methods. The non-radioactive method is 
the procedure that has been used extensively in this current research. This non-
radioactive assay (Drummond et al. 1995; Jarrett et al. 1997) does not examine the 
formation of methionine directly, but rather a product formed in the reaction; it studies 
the generation of reaction-demethylated THF after treatment with formic acid to 
generate methenyl-THF, as shown in the following reaction: 
 
C19H23N7O6 + CH2O2  C20H24N7O6+ + 2H2O 
    (THF + Formate  CH+-THF + 2H2O) 
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At acidic pH, this methenyl-THF has an extinction coefficient of 26500M-1cm-1 at 
350nm. The cdMS assay allows calculation of activity in nmol/min, from the corrected 
A350 values (corrected A350 = A350assay – A350blank) the extinction coefficient of CH+-THF, 
the volume of the reaction and the length of time of the reaction: 
 
 
The effect of varying MTHF and enzyme concentration in the assay was examined. All 
cdMS activity assays were repeated five times for reproducibility with the two extremes 
discarded for the purposes of averaging. For all assays but the crude quantity assay, 
protein concentration was maintained at the same level. The volume of the assay was 
kept consistent by varying the volume of water. Increasing the concentration of MTHF 
does not have a linear relationship with increase in activity (Table 3.2). The optimum 
MTHF concentration is approximately 250µM (Fig. 3.2). Likewise, the effect of varying 
sample quantity is not linear (Table 3.3). The optimum sample quantity is 50-60µl (Fig. 
3.3). 
 
MTHF Corrected A350 Activity 
(nmol/min) ± 
Std. Dev. n=3 
0µl 0.00 0.000 ± 0.001 
12µl (62.5µM) 0.054 0.204 ± 0.04 
24µl (125µM) 0.076 0.287 ± 0.009 
48µl (250µM) 0.122 0.460 ± 0.001 
96µl (500µM) 0.137 0.517 ± 0.03 
192µl (1mM) 0.184 0.694 ± 0.004 
Table 3.2: tabulated results of the A350 of the cdMS assay when varying concentrations 
of MTHF. It is important to note that doubling the amount of MTHF present does 
increase absorbance obtained, but does not double it. 
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Figure 3.2: results of the cdMS assay when varying concentration of MTHF. The ‘base’ 
value of 48µl of 4.2mM MTHF in the assay mix results in a final concentration of 
252µM (504µM for 96µl, 1008µM for 192µl) optimum concentration of MTHF is 
~250µM. This shows well that decreasing the concentration of MTHF in the assay has a 
more significant impact in the results obtained than increasing the concentration. 
 
Crude Corrected A350 Activity 
(nmol/min) ± 
Std. Dev. n=3 
0µl 0.00 0.000 ± 0.01 
12.5µl  0.071 0.268 ± 0.015 
25µl 0.095 0.358 ± 0.003 
50µl 0.122 0.460 ± 0.01 
100µl 0.172 0.649 ± 0.017 
200µl 0.216 0.815 ± 0.04 
Table 3.3: tabulated results of the A350 of the cdMS assay when varying the quantity of 
crude extract in the assay. It is important to note that doubling the amount of MTHF 
present does increase activity, but does not double it. 
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Figure 3.3: corrected A350 results of the cdMS assay when varying quantities of crude 
extract, displayed as absolute results. 
 
3.2.3: Purification of cdMS from source 
Initial reports from BASF stated that recombinantly expressed cdMS was inactive; for 
this reason purification of cdMS from the native organism was attempted. 
 
Given the different activity of the strains of C. glutamicum (Table. 3.1) gels of the 
whole cells were run as described in section 2.4.5. This was to investigate whether there 
was any obvious difference in the 1D PAGE protein signatures between the strains; for 
example, a more pronounced band at 135kDa which could potentially correspond to 
cdMS. Figure 3.4 shows a 1D SDS-PAGE gel of the crude extract of each of the C. 
glutamicum strains provided by BASF when grown in BHI media. While OM257 has 
significantly increased assay activity, there is no protein band which appears more 
pronounced around 135kDa. 
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Figure 3.4:  (Left) 8% SDS-PAGE gel of diluted crude extracts from BASF provided 
C. glutamicum strains Lu1479 (wild type), Lu1479 H170, OM257 and OM246. The 
proteome exhibited by each of these strains differs slightly. Lane 1; high molecular 
weight marker, lane 2; Lu1479 (wild type) proteome, lane 3; Lu1479 H170 proteome, 
lane 4; OM257 proteome, lane 5; OM246 proteome. (Right) 8% SDS-PAGE gel of 
diluted crude extracts from BASF provided C. glutamicum strains OM246 H588, 
OM246 H589 and OM246 H587. As they are transformed strains based upon the 
metE/metH knockout strain, the proteomic fingerprint is the same. Lane 1; high 
molecular weight marker, lane 2; OM246 H588 proteome, lane 3; OM246 H589 
proteome, lane 4; OM246 H587 proteome. 
 
As shown in Table 3.1, there is activity in crude extracts. The knockout strain (OM246) 
has very little activity when compared with the wild-type or cdMS-over-expressing 
strains. The wild-type (Lu1479) generates approximately 0.5nmol/min of methionine, 
while the strain containing the constitutive plasmid has a specific activity of 
approximately 0.68nmol/min and the OM257 IPTG-inducible over-expresser produces 
1nmol/min (Table 3.1).  
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3.2.4: Ammonium sulphate precipitation 
Ammonium sulphate precipitation is a classical technique for protein purification which 
functions by altering protein solubility. Utilising ammonium sulphate disrupts 
interaction with water molecules surrounding proteins, thus causing proteins to 
aggregate and precipitate. Ammonium sulphate precipitation purification of cdMS was 
attempted, initially using 30%, 50% and 70% ‘cuts’ as described in Part 2.4.1.1. The 
pellets were collected by centrifugation and dialysed overnight against a buffer 
containing 20mM Tris pH7.2. When analysed by SDS-PAGE the ammonium sulphate 
fractions were found to contain a large number of proteins across the size spectrum. 
There is no obvious cdMS band. There is a strong band at 220kDa (Fig. 3.5) but this 
band is approximately 85kDa too large to be cdMS. In fact, most of the protein 
precipitated with the 50% cut. Assaying fractions pre- and post-dialysis show loss of 
cdMS activity (Table 3.4). 
 
Figure 3.5: 8% SDS-PAGE gel of ammonium sulphate precipitation attempting to 
purify cdMS from C. glutamicum strain OM257, showing the ammonium sulphate 
fractions. Lane 1; high molecular weight marker, lane 2; 30% ammonium sulphate cut, 
lane 3; 50% ammonium sulphate cut, lane 4; 70% ammonium sulphate cut, lane 5; the 
rest of the soluble protein after 70% ammonium sulphate cut. 
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Ammonium sulphate (AMS) 
fraction 
Corrected A350 Activity (nmol/min) ± 
Std. Dev. n=3 
Crude extract 0.25 0.944 ± .0019 
30% AMS 0.02 0.075 ±  0.008 
50% AMS 0.01 0.038 ± 0.173 
70% AMS 0.04 0.151 ± 0.056 
30% AMS de-salted 0.01 0.038 ± 0.031 
50% AMS de-salted 0.00 0.000 ± 0.009 
70% AMS de-salted 0.00 0.000 ± 0.0012 
>70% AMS 0.03 0.113 ± 0.044 
>70% AMS de-salted 0.01 0.038 ± 0.0115 
Table 3.4: tabulated summary of the corrected A350 values obtained with the non-
radioactive cdMS activity assay on ammonium sulphate precipitation purification steps. 
 
Interestingly, while the 30% and 50% ammonium sulphate precipitation cuts gave 
slightly increased activity above the blank assay, upon buffer exchange this apparent 
activity decreased. From Table 3.4 it is evident that activity is lost upon treatment with 
ammonium sulphate for protein purification and while Figure 3.5 displays a strong large 
band in the 50% cut column, the band is running approximately level with the 220kDa 
marker and so certainly not cdMS. The inactivation of cdMS by ammonium sulphate 
negates this as a suitable purification strategy. 
 
3.2.5: Hydrophobic interaction chromatography 
Hydrophobic interaction chromatography (HIC) can be considered similar to 
ammonium sulphate precipitation as it again functions by using salt to alter the 
solubility of proteins. A column matrix with exposed hydrophobic groups (such as 
phenyl groups) binds to hydrophobic areas of proteins, rather than proteins aggregating 
and precipitating, however. As the concentration of salt in the buffer decreases, binding 
to the column decreases. The more hydrophobic a protein, the less salt needed to 
promote column binding. HIC was employed as a technique to isolate cdMS using a 
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phenyl sepharose column as described in section 2.4.1.2. Upon application of the crude 
extract to the column, some protein did appear to bind as washing the column left an 
orange tint (cob(II)alamin can appear orange to the naked eye). This colour washed off 
as the gradient continued, though no fractions had an appreciable UV/visible spectrum 
aside from protein absorbance at A280. There is no activity in any of the fractions (Table 
3.5). Because of this, it is impossible to determine if there is a potential cdMS band in 
any of the fractions (Fig. 3.6). 
 
 
Figure 3.6: 8% SDS-PAGE of fractions obtained from a hydrophobic interaction 
chromatography experiment. Lane 1; high molecular weight marker, lane 2; column 
flow-through, lane 3; high-salt buffer wash, lane 4; empty, lane5; 300mM NaCL wash, 
lane6; 250mM NaCL wash, lane 7; 200mM NaCl wash, lane 8; 150mM NaCl wash, 
lane 9; 100mM NaCl wash, lane 10; high molecular weight marker, lane 11; 0mM NaCl 
wash. 
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Hydrophobic interaction 
column fraction 
Corrected A350 Activity (nmol/min) ± 
Std. Dev. n=3 
Crude extract 0.28 1.056 ± 0.02 
Flow through 0.04 0.151 ± 0.03 
High-salt wash 0.02 0.075 ± 0.013 
300mM wash 0.03 0.113 ± 0.039 
250mM wash 0.01 0.038 ± 0.017 
200mM wash 0.00 0.000 ± 0.07 
150mM wash 0.00 0.000 ± 0.012 
100mM wash 0.01 0.038 ± 0.011 
0mM wash 0.01 0.038 ± 0.01 
Table 3.5: tabulated summary of the corrected A350 values obtained with the non-
radioactive cdMS activity assay on hydrophobic interaction chromatography 
purification fractions. 
 
3.2.6: Ion exchange chromatography 
Ion exchange chromatography is a classical procedure in protein purification, utilising 
the fact that most proteins carry a net charge at physiological pH. For cdMS, crude 
extract was applied to an anion exchange resin (Fig. 3.7) and washed with 20mM Tris 
pH7.2 with increasing NaCl gradient. Assays were run with protein in the presence of 
the step gradient fraction they were eluted by and after buffer exchange into 20mM Tris 
pH7.2 and showed no change in activity after salt was removed. Assays after 
purification show that activity is completely lost (Table. 3.6). 
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Figure 3.7: 8% SDS-PAGE of an ion exchange chromatography purification of cdMS 
from C. glutamicum. Lane 1; high molecular weight marker, lane 2; 0mM NaCl wash, 
lane 3; 50mM NaCl wash, lane 4; 100mM NaCl wash, lane5; 125mM NaCl wash, lane 
6; 150mM NaCl wash, lane 7; 175mM NaCl wash, lane 8; 200mM NaCl wash, lane 9; 
225mM NaCl wash, lane 10; 250mM NaCl wash, lane 11; 275mM NaCl wash, lane 12; 
300mM NaCl wash, lane 13; 2M NaCl wash. 
Ion exchange column 
fraction 
Corrected A350 Activity (nmol/min) ± 
Std. Dev. n=3 
Crude extract 0.30 1.132 ± 0.03 
Flow through 0.08 0.302 ± 0.0009 
0mM wash 0.01 0.038 ± 0.013 
50mM wash 0.006 0.023 ± 0.01 
100mM wash 0.008 0.030 ± 0.0001 
150mM wash 0.002 0.008 ± 0.0002 
175mM wash 0.00 0.000 ± 0.003 
200mM wash 0.001 0.004 ± 0.003 
225mM wash 0.00 0.000 ± 0.0005 
250mM wash 0.003 0.011 ± 0.0043 
275mM wash 0.005 0.019 ± 0.0044 
300mM wash 0.00 0.000 ± 0.04 
2M wash 0.01 0.038 ± 0.005 
Table 3.6: tabulated summary of the corrected A350 values obtained with the non-
radioactive cdMS activity assay on ion exchange chromatography purification fractions. 
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3.2.7: FPLC 
Fast Protein Liquid Chromatography (FPLC) can be considered similar to High 
Performance Liquid Chromatography (HPLC) and is used to purify proteins or other 
biomolecules from complex mixtures in a highly controlled and repeatable fashion. For 
the attempted FPLC purification of cdMS, an Amersham Biosciences high-capacity 
MonoQ anion exchange column was used, as described in Section 2.4.1.4. As all the 
other procedures that had been investigated for the purification of C. glutamicum cdMS 
had resulted in inactive enzyme it was decided to try a more rapid purification 
methodology in the form of FPLC. Through the use of a MonoQ anion exchange 
column, it is unsurprising that the gel fractions look similar to those obtained with the 
step-gradient ion exchange purification (Fig. 3.9) and loss of activity post-column in 
assay (Table. 3.7). The protein absorbance trace is shown in Figure 3.8. 
 
 
Figure 3.8: Trace showing the elution profile of an attempted MonoQ purification of 
cdMS from native source.  
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Figure 3.9: 8% SDS-PAGE gel of fractions showing absorbance at A280 from an inline 
UV/Visible spectrophotometer in an AKTA FPLC from purification on a Mono-Q high-
affinity column. Lane 1; high molecular weight marker, lane 2; wash fraction, lane 3; 
fraction A6, lane 4; fraction A7, lane5; fraction A8, lane 6; fraction A9, lane 7; fraction 
A10, lane 8; fraction A11, lane 9; fraction A12, lane 10; fraction B1, lane 11; fraction 
B2, lane 12; fraction B3, lane 13; fraction B4. 
 
 
FPLC column fraction Corrected A350 Activity (nmol/min) ± 
Std. Dev. n=3 
Crude extract 0.21 0.793 ± 0.044 
A10 0.03 0.113 ± 0.09 
A11 0.02 0.075 ± 0.013 
A12 0.00 0.000 ± 0.00 
B1 0.01 0.038 ± 0.0008 
B2 0.01 0.038 ± 0.001 
Table 3.7: tabulated summary of the corrected A350 values obtained with the non-
radioactive cdMS activity assay on FPLC MonoQ purification fractions. 
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The overall theme remains the same as with other purifications: activity is present in the 
crude extract with no activity post column application. While FPLC purification allows 
for greater control and accuracy of the gradient than a simple step gradient, this loss of 
activity makes it impossible to follow cdMS through purification. 
3.2.8: Cobalamin-affinity chromatography 
Cobalamin affinity chromatography, like all affinity chromatography, relies on proteins 
ability to form specific stable and reversible complexes with other biomolecules through 
the common molecular forces such as Van der Waals interaction, hydrophobic 
interaction, dipole-dipole interaction, electrostatic interaction or hydrogen bonding. 
Being a cobalamin-dependent enzyme, it was reasoned that purifying cdMS based on its 
cobalamin binding ability may be possible, perhaps stabilising the enzyme. In this 
approach crude cell extract was applied to a column containing 2ml of resin with a 
binding capacity of between 1.6-3mg of protein. The column was then thoroughly 
washed prior to the elution of any cobalamin-binding proteins by application of free 
cobalamin. SDS-PAGE of the cobalamin affinity purification fractions (Fig. 3.10) 
revealed significant binding. Assays of the cobalamin affinity fractions displayed no 
activity (Table 3.8). 
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Figure 3.10: 8% acrylamide SDS-PAGE of a cobalamin-affinity column as a further 
attempt to purify C. glutamicum cdMS from native organism. Lane 1; high molecular 
weight marker, lane 2; crude extract, lane 3; column wash, lane 4; 500µM cobalamin 
elution, lane 5; 1mM cobalamin elution, lane 6; empty, lane 7; 10mM cobalamin 
elution, lane 8; column reloading, lane 9; 250µM cobalamin elution, lane 10; 500µM 
cobalamin elution, lane 11; 1mM cobalamin elution, lane 12; empty, lane 13; high 
molecular weight marker. 
 
Cobalamin affinity column 
fraction 
Corrected A350 Activity (nmol/min) ± 
Std. Dev. n=3 
Crude extract 0.29 1.094 ± 0.025 
Flow through 0.02 0.075 ± 0.03 
Wash 0.00 0.000 ± 0.004 
B12 elution 1 0.01 0.038 ± 0.007 
B12 elution 2 0.02 0.075 ± 0.0045 
Table 3.8: tabulated summary of the corrected A350 values obtained with the non-
radioactive cdMS activity assay on cobalamin-affinity chromatography purification 
fractions. 
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cdMS appears to be rapidly inactivated upon attempt at purification. Whilst activity is 
present in the crude extract, during purification this activity is lost irrespective of 
purification technique utilised. 
3.2.9: HPLC analysis of the cdMS assay 
The lack of enzyme activity in any of the protein separation fractions suggests that C. 
glutamicum cdMS is very sensitive and is rapidly inactivate, possibly due to oxidative 
stress or displacement of the zinc cofactor. However, an alternative explanation is that 
the assay is not actually monitoring methionine synthase activity but is instead giving a 
false positive with a folate derivative present in the crude extract. This should be 
avoided by the ‘blank’ method used (use of sample in blank lacking homocysteine) but 
it was considered best to make certain. To demonstrate that the assay is really producing 
methionine, the non-radioactive cdMS assay was modified so that methionine 
generation could be measured. 
 
The assays were run as described in section 2.4.10, but the final acidification step was 
not used, and the reaction instead stopped by heating to 80ºC for 15 minutes to denature 
proteins before quenching in liquid nitrogen. Samples from these non-acidified assays 
were run on an Agilent 1100-series HPLC with a Zorbax Eclipse C18 column with 
inline diode array and fluorescence detectors using 40mM Na2HPO4 as buffer A and 
45% methanol 45% acetonitrile as buffer B. Samples were derivitised using the 
autosampler injection mixer system, for derivitisation immediately before application to 
the column as described in Section 2.4.11.1. To avoid over-pressurising the column, a 
flow rate of 1ml/min was used. Figure 3.11 shows the full HPLC trace of the cdMS 
assay adapted for HPLC analysis using strain Lu1479 – note the large methionine spike 
at 14.7 minutes. The shift in retention time for methionine (a decrease of approximately 
6 seconds) for the methionine spike peak can be attributed to the pH shift caused by 
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using 1mM HCl to aid solubility of the spike. Figure 3.12, utilising the Lu1479 H170 
strain (wild-type C. glutamicum with a secondary constitutively-controlled metH 
plasmid expression source) demonstrates a minute increase in methionine generation at 
14.7 minutes above the wild-type strain. The knockout strain OM246 (Fig. 3.13) shows 
no generation of methionine at all, as expected of a knockout strain. The IPTG-
inducible OM257 strain (Fig. 3.14) again demonstrates increased levels of methionine 
in compared to the wild-type or constitutively controlled strains, while the OM246 
H588 strain (Fig. 3.15) demonstrates methionine levels elevated above those of the 
wild-type and constitutive strains, but not as great as OM257. When the methionine 
peak for the OM257 sample was integrated, it was determined that 9nmol of methionine 
is generated in 10 minutes, which given that the calculated amount of methionine 
generated by OM257 cdMS in the non-radioactive assay is 1.05nmol/min would 
indicate that the HPLC modification would be suitable as a non-radioactive assay. 
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Figure 3.11: Full HPLC trace of assays studying methionine generation by the Lu1479 
strain. The black trace is the blank assay, the blue trace is the complete assay, and the 
red trace is the post-assay methionine-spiked run. Methionine peak is at 14.7 minutes. 
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Figure 3.12: Full HPLC trace of the cdMS assay methionine peak generated by the 
Lu1479 H170 strain. Methionine peak is at 14.7 minutes. Despite the presence of a 
constitutively-controlled cdMS expressing plasmid in the wild-type strain, Lu1479 
H170 does not generate quantities of cdMS significantly elevated above those of the 
wild-type strain. 
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Figure 3.13: Full HPLC trace of the cdMS assay methionine peak generated by the 
OM246 strain. As expected from a knockout strain, methionine generation is zero (at 
14.7 minutes). 
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Figure 3.14: Full HPLC trace of the cdMS assay methionine peak generated by the 
OM257 strain. Methionine peak is at 14.7 minutes. 
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Figure 3.15: Full HPLC trace of methionine generation by the OM246 H588 strain. 
Methionine peak is at 14.7 minutes. 
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3.3: Discussion 
In this chapter the growth of the BASF provided strains of C. glutamicum has been 
examined. Also investigated were the potential basic proteomic differences between the 
strains. Based on this strain OM257 was chosen to work with as activity of cdMS was 
enhanced above that of other strains. 
 
A study of the non-radioactive methionine synthase assay devised by the Matthews 
laboratory (University of Michigan, Ann Arbor, Michigan) (Drummond et al. 1995; 
Jarrett et al. 1997) was carried out. This assay has several advantages above the original 
HPLC-based radioactive assay for methionine synthase activity, not least of which is the 
removal of the necessity to use radio-labelled substances and a significant decrease in 
the length of time taken for each assay to be run.  
 
Despite this, the non-radioactive assay suffers from some drawbacks; the fact that this is 
an anaerobic assay carried out in an aerobic environment – oxidative stress is the cause 
of the Co3+/Co1+ cycling being derailed to Co2+ which leads to the necessity of 
reactivation, yet carrying out this assay in an anaerobic chamber is impractical. As such, 
there must be some way of ‘scrubbing’ the dissolved oxygen out of the assay mix, thus 
maintaining the anaerobic state. In the standard assay this is carried out by dithiothreitol 
(Cleland’s reagent, DTT) and free hydroxycobalamin, which is functional but produces 
protein-damaging H2O2 as a byproduct. The DTT reduces the hydroxycobalamin from 
Co3+ to Co2+, which is then oxidised by the dissolved oxygen, using up the oxygen. This 
free hydroxycobalamin and DTT react with any dissolved oxygen in the assay mix, 
keeping the sample anaerobic even when in open air – at least until the DTT is used up. 
The ‘scrubbing’ effect can be visualised by mixing hydroxycobalamin and DTT at the 
requisite concentrations for the assay (see Part 2, section 2.4.11) as in preparation of the 
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master mix for the assay, and sealing it in a Falcon tube in the dark to avoid potential 
photolysis of the cobalamin. After a few minutes, the red tint of the hydroxycobalamin 
begins to shift toward orange as it is reduced and uses up the dissolved oxygen to 
oxidise – when it runs out of oxygen it will stay the orange/red colour. DTT is not 
capable of reducing Co2+ cobalamin to Co1+ cobalamin; as such it is not present in the 
assay mix for the regeneration of the derailed Co2+ state cdMS.  
 
This ‘scrubbing’ of dissolved oxygen from the assay has one significant side effect; the 
generation of H2O2, which builds up slowly over the course of the assay and begins to 
damage the protein being studied. This is one of the causes of the time sensitivity of the 
assay, aside from the obvious fact that running the assay for varying lengths of time 
would create variation in the amount of THF generated by methyl-group donation to the 
active cdMS. The longer the assay runs for, the more damaged the protein becomes, 
which means that generation of THF is not constant throughout the assay, but slowly 
decays, meaning inconsistent results if timing is not rigidly adhered to.  
 
The final drawback of the non-radioactive assay is the product that it is examining to 
provide information about the amount of methionine produced; it examines the quantity 
of methenyl-THF, by absorbance at 350nm. Unfortunately, a range of other molecules 
that are normally present in a healthy cell also absorb at or around 350nm, such as 
NADH and NADPH, flavins, corrins and iron-sulphurs. Crude-extract assay blanks 
should account for these other absorbing species, however. 
 
The cdMS assay has been optimised well during initial development, as the effect of 
concentration of MTHF on the A350 obtained is not linear against concentration. 
Increasing the homocysteine or SAM quantities in the assay has no effect on the activity 
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and therefore absorbance obtained. This does make sense as it is the quantity of 
methenyl-THF which is observed by the assay. Due to the fact that no fractions through 
any of the cdMS purifications from C. glutamicum having any activity in this assay 
(Section 3.4) obtaining any data requires the use of crude extract prior to application on 
a column. This means that actual concentrations of cdMS in the assay cannot be 
determined as the precise quantity of cdMS in the cytosol is unknown. It is acceptable 
to assume that active cdMS protein is present evenly throughout the same crude extract, 
and that therefore one sample of crude extract will have the same activity as another 
from the same pool of crude extract; this was confirmed by running multiple assays 
from the same pool of crude extract.  
 
Like varying MTHF concentration, when varying crude extract quantity, increased 
homocysteine or SAM concentration had no effect on the activity of the assay. For the 
purposes of determining between active protein and inactive protein the assay is 
acceptable. The assay could be made less time dependent by one alteration: the addition 
of a catalase, which while it generates oxygen in the process of generating water from 
H2O2, turns over so quickly it would still be able to clear the build-up of peroxide while 
allowing the assay to be made anaerobic, as with the classic glucose 
oxidase/glucose/catalase combination for making a solution anaerobic.  
 
Many techniques were utilised in an attempt to purify cdMS from the native organism. 
Following the purification itself proved to be a challenge as the protein lost activity 
upon purification. With all techniques, simply passing a clarified crude extract through 
a column was sufficient to remove activity. When the column was eluted and no activity 
is noted in any of the fractions at all, it became clear that it was not all of the protein 
binding to the column, but the enzyme becoming damaged.  
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This damage could be one or both of the cofactors being pulled out of the enzyme. The 
zinc ion which coordinates the binding of homocysteine in the first domain is not 
covalently bound and so it is possible that it is competitively displaced by the increasing 
concentrations of salt. Initially step-gradient ion exchange chromatography was used, 
but this expanded into ammonium sulphate precipitation, hydrophobic interaction and 
cobalamin-affinity purification being tried. None of these purification techniques were 
successful in isolating active cdMS.  
 
In theory the cobalamin binding third domain of cdMS would bind to the cobalamin 
covalently bound to the column stationary phase, in much the same way as any other 
cobalamin-binding protein would (Zak et al. 1989). In practice, however, there are two 
potentially significant reasons why cdMS would not bind well to the cobalamin-affinity 
column (Croft, M., private communication); if cobalamin is already tightly bound in the 
active site of the binding domain it will not be displaced by the covalently bound 
matrix-ligated cobalamin, or if the matrix-ligated cobalamin is bonded to the column in 
the wrong manner for allowing binding inside the cdMS cobalamin binding site 
(allowing movement of the lower axial ligand) it would not bind at all.  
 
After difficulty with purification of cdMS it was suggested that the crude activity being 
displayed was in fact a false positive caused by other molecules in the cytosol. While 
the use of sample blanks should have avoided this, confirmation was sought via 
modification of medical amino-acid determination techniques. 
 
HPLC (high-performance liquid chromatography) was initially used for cobalamin-
dependent methionine synthase assays by the Matthews laboratory (Drummond et al. 
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1995) in a radioactive assay observing the transfer of a C14 isotope from the methyl 
donor (methyl-tetrahydrofolate) to the sulphur of a zinc-coordinated homocysteine. A 
non-radioactive alternative was sought (Drummond et al. 1995) and further refined 
(Jarrett et al. 1997) that would allow faster assaying of cobalamin-dependent methionine 
synthase. This is the assay utilised throughout this investigation for the study of C. 
glutamicum cdMS activity.  
 
However a modified HPLC assay was attempted to examine methionine synthesis 
during cdMS turnover. To this end, two HPLC assay possibilities were explored; the 
first, examining the loss of the methyl group from SAM during cdMS reactivation was 
not attempted due to the background breakdown of SAM to SAH (S-adenosyl 
homocysteine) under normal conditions. Discussion concluded that there was not 
sufficient confidence in being able to measure background breakdown of SAM to SAH 
to the degree of accuracy needed to determine the rate of SAM used through cdMS 
reactivation.  
 
The second HPLC assay is a modification and extension of the non-radioactive 
methionine synthase assay developed by Drummond (Drummond et al. 1995) and 
refined by Jarrett et al. (Jarrett et al. 1997). Instead of quenching the reaction with a 
combination of strong acids (HCl and HNO3), amino acid derivitisation was attempted. 
HCl/HNO3 also serve a second and equally important role of acidifying the 
tetrahydrofolate (THF) in the assay that has donated its methyl group to the cobalamin 
to form methenyl-THF, which is detected spectrophotometrically. This acid treatment is 
not required to detect methionine, however. The reaction was heat inactivated by 
heating to 80ºC for 15 minutes then rapid frozen in liquid nitrogen. 
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This avoiding of the acid treatment step was so that the OPA (ortho-phthalaldehyde) 
derivitisation could take place, for when derivitisation was attempted in the completed 
non-radioactive assay (ie: in the presence of HCl and HNO3) no fluorescent derivate 
was formed. Originally the intention was to also detect homocysteine usage by this 
same HPLC method, however the fluorescence signal from homocysteine when 
derivitised with OPA is quenched by the thiol component of the amino acid. Treatment 
with iodoacetic acid (IAA) which reacts with the thiol reveals the homocysteine-OPA 
derivate fluorescence signal, but the IAA also reacts with the methionine, resulting in 
loss of the methionine-OPA derivate signal. As the objective of this assay is to provide 
an alternative to the Drummond and Jarrett non-radioactive assay, by examining the 
generation of methionine directly rather than a by-product of reaction, addition of IAA 
to the sample was abandoned.  
 
The methionine-detecting HPLC assay was created based upon amino acid analysis 
systems used for determining free amino acid content of fish (Antoine et al. 1999), 
plasma amino acid levels (Schwarz et al. 2005) and a semi-automated Reversed-Phase 
method (Bartolomeo and Maisano 2006). It must be noted that the methionine-OPA 
derivate ‘standard’ of pure methionine elutes slightly before the methionine-OPA 
derivate in the assay samples at 12.6 minutes retention time rather than the 14.7 minute 
retention time of the assay-run samples. This is attributed to both the assay (mix and 
process) itself, the pH of the standard varying from that of the assay mix and to the fact 
that crude extracts were used as it is in crude extracts only that activity of C.glutamicum 
cdMS can be guaranteed. Because of this, the ‘standard’ was useful more for a test of 
whether the HPLC pre-column derivitisation would work sufficiently well to be 
functional for the assay than as a real marker of when methionine-OPA would elute.  
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It is for this reason that (aside from duplicate runs) all samples were run with an ‘assay 
blank’ with no homocysteine added to the assay mix, a complete run of the assay, and a 
complete run of the assay spiked with the methionine standard after the assay was run to 
completion. The methionine spike was added after the assay was run to avoid the 
possibility of product inhibition effecting the reaction. The most pressing issue with the 
HPLC study of methionine generation in this assay is the presence of large amounts of 
contaminants due to the use of crude extract. If used with purified enzyme (presuming 
that activity can be restored) then there would be little issue. Also, despite examining 
many similar protocols for amino-acid separation and identification via HPLC (Antoine 
et al. 1999; Schwarz et al. 2005; Bartolomeo and Maisano 2006) attempts to replicate 
these precisely met with results that differed from those published, particularly with 
respect to homocysteine. We were unable to create a fluorescent OPA derivative of 
homocysteine without treatment with iodoacetic acid to stop a thiol fluorescence 
quenching effect.  
 
Due to the crude extract, there are low levels of free methionine in the assay as is 
normal for cell cytoplasm. Integration of the peak between 14.7 and 15 minutes should 
allow calculation of the amount of methionine generated, which can then be compared 
to the calculated amount of methionine via the ‘normal’ cdMS assay looking at 
methenyl-tetrahydrofolate generated in the assay course of MTHF donating a methyl 
group to homocysteine – the acidification by formic acid of free THF. Doing this for 
OM257 yielded an approximate methionine yield of 9nmol, which is close to the value 
which could be expected of 10nmol, of a protein producing 1nmol/min of methionine 
for 10 minutes. 
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However, due to the extra complexity and time taken for HPLC analysis of this non-
radioactive cdMS assay it is difficult to acknowledge it as a possible method for 
improving some of the drawbacks of the non-radioactive cdMS assay by studying direct 
methionine output. Evidently, a colorimetric assay would be of further assistance, and 
there are clinical colorimetric assays available for homocysteine levels which assay at 
660 or 750nm (Matsuyama et al. 2001) but the desirability of a linked assay is not high, 
and direct colorimetric assay of methionine does not appear to be available currently. 
There is one (McCarthy and Sullivan 1941) but it is not specific (thus undesirable for 
assays involving crude extract) and appears to have fallen out of favour as an amino 
acid assay. This HPLC assay has no advantage over the standard non-radioactive cdMS 
assay aside from examining directly the methionine produced during turnover. It does, 
however, have several drawbacks. Still, the cdMS assay developed by Drummond 
(Drummond et al. 1995) remains the favourite until a simple colorimetric assay can be 
developed. This modified HPLC assay does however confirm that the activity present in 
the crude extracts is not a false positive. 
 
This leads to chapter 4, where cdMS is expressed, purified and characterised 
recombinantly. 
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4: Characterisation of C. glutamicum cobalamin-dependent 
Methionine Synthase and its associated reactivation proteins 
4.1: Introduction 
For a bacterium with such biotechnological importance for amino acid production, C. 
glutamicum has had relatively little public investigation into the pathways of many of its 
amino acids. There are two completed genome sequences for C. glutamicum, however.  
 
With the knowledge gained from E. coli cdMS in how it reacts and its interactions with 
both its cofactors and substrates, understanding the interactions and behaviour of C. 
glutamicum becomes more important as it does not share a similar reductase. X-ray 
crystallographic structures of E. coli cdMS have been obtained (Drennan et al. 1994; 
Dixon et al. 1996) although due to the highly flexible and modular nature of cdMS a full 
length structure has yet to be solved. More detailed studies of binding specificities 
(Fleischhacker and Matthews 2007; Datta et al. 2008) have also been carried out with E. 
coli cdMS.  
 
Based on sequence similarity, it is proposed that C. glutamicum cdMS shares a similar 
overall mechanism to E. coli cdMS (Fig. 4.1) including a similar reactivation 
mechanism (Fig. 4.2) although not sharing the same physiological methionine synthase 
reductase (MSR) as there is no E. coli flavodoxin ‘MSR’ homologue in C. glutamicum. 
However, studying the C. glutamicum cdMS is all very well if interactions with the 
physiological partners are still unknown – as is the case of the methionine synthase 
reductase of C. glutamicum. Examining the interactions of C. glutamicum cdMS with 
cofactors will also aid in understanding of differing evolutionary paths toward the same 
end when comparing cofactor interaction with that of E. coli cdMS. 
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Figure 4.1: Cobalamin transitions caused by normal turnover of cdMS, with cobalamin 
cycling from a Co3+ state to a Co1+ state by donation of a methyl group to homocysteine 
for form methionine, followed by the remethylation of the Co1+ by 
methyltetrahydrofolate. During normal turnover, the path of the methyl group can be 
followed within cdMS from the second (pterin binding) domain to the third (cobalamin 
binding) domain to the first (homocysteine binding) domain. 
 
 
Figure 4.2: Reactivation of the derailed cdMS by MSR, with a single electron donation 
taking the cobalamin from a Co2+ state to the Co1+ supernucleophile state for 
methylation by the secondary methyl source, SAM. 
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By developing a greater understanding of the mechanism of cobalamin dependent 
methionine synthase in C. glutamicum, it can not only provide potential insights into the 
enzyme itself but some insights into the whole pathway of methionine biosynthesis, 
along with aiding understanding of the alternative mechanisms used by other bacteria in 
methionine biosynthesis. The aim of this chapter was to characterise C. glutamicum 
cdMS, the candidate MSRs, and any other necessary components of the reactivation 
mechanism. 
 
4.2: Results 
4.2.1: Identification of candidate reactivation factors 
When C. glutamicum cdMS was initially expressed recombinantly in a knockout strain 
of E. coli by BASF, it was observed to be inactive. Hence attempts to purify cdMS from 
native source in chapter 3. Bioinformatics revealed no equivalent to E. coli MSR in the 
C. glutamicum genome. This implied that there was not a homologue present in E. coli 
that could play the role of C. glutamicum MSR. Prior to the start of this investigation 
BASF identified several candidate redox proteins which might act in the role of MSR. 
These genes were annotated as FdxA, FdxB and FdxC. 
 
4.2.2: Cloning of fdxA, fdxB and fdxC 
After identification of three candidate MSRs, E. coli strains were obtained from BASF 
containing plasmids encoding putative ferredoxins A, B and C individually. The genes 
were cloned into the standard multi-site cloning vector pET-14b as described in section 
2.3.7.2. PCR amplification of fdxC, as described in section 2.3.1, from the pQE-30-fdxC 
plasmid and ligation into pET-14b proved a simple matter, but cloning of fdxA and fdxB 
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failed. In the end, attempting to clone from the BASF provided plasmids was abandoned 
and genomic DNA from wild-type C. glutamicum was used. These PCR amplifications 
and DNA ligations into pET-14b were successful. 
 
4.2.3: Production of FdxA, FdxB and FdxC 
E. coli BL21(DE3)pLysS cells were transformed with a pET14b construct containing 
the C. glutamicum fdxA, fdxB or fdxC gene. Each of the resulting strains was grown at 
37 ºC in LB medium supplemented with appropriate concentrations of ampicillin and 
chloramphenicol. Once the cell density reached OD600 ≈ 0.6 protein overproduction was 
induced with the addition IPTG to a final concentration of 0.4mM and the cells were 
left to continue growth overnight at 16 °C before harvesting by centrifugation. 
 
4.2.4: Aerobic purification of FdxA, FdxB and FdxC 
Initially the putative ferredoxins were purified aerobically. The harvested cells were 
lysed by sonication and debris removed by centrifugation. The soluble fraction was 
applied to a column charged with Ni2+ and washed with increasing imidazol 
concentrations as described in Section 2.4.1.1. A light brown band could be observed at 
the top of the resin that faded as time passed. Protein progressed towards the bottom of 
the column as the concentration of imidazol was increased until it could be eluted from 
the column in 400 mM imidazol. Once eluted, the protein was kept at 4ºC. If left at 
room temperature the eluted protein would become cloudy as it precipitated. This 
precipitated protein was easily removed by centrifugation of the protein solution and 
discarding the resulting pellet.  
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4.2.5: Western blotting of FdxA, FdxB and FdxC 
To confirm that the bands of greatest size were the proteins they were supposed to be, a 
combined gel was run with elution fractions from all of the protein purifications, 15µg 
of each sample. This was then subjected to Western analysis using an anti-His antibody 
as described in section 2.4.6. This revealed three bands of approximately 24kDa (Fig. 
4.3) which is where the ferredoxins run on SDS-PAGE despite their 13kDa size. 
 
                     
Figure 4.3: 15% SDS-PAGE gel of FdxA, FdxC and FdxB (left) and a Western blot of 
an identically loaded gel (right).  Why there should be so much extra signal on the 
Western blot is unknown. Every attempt was made to avoid overexposure of the x-ray 
film. Lane 1; FdxA, lane 2; FdxB, lane 3; FdxC, lane 4; Dalton VII marker. 
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4.2.6: Anaerobic purification of FdxA, FdxB and FdxC 
Colouration of the putative ferredoxins suggested the presence of iron-sulphur centre 
cofactors. Proteins with 4Fe4S clusters have a brown appearance and 2Fe2S clusters 
have a brick red appearance. Such clusters are often highly sensitive to oxidation by 
molecular oxygen. For this reason, it was necessary to purify the ferredoxins in the 
absence of oxygen by performing the purification in an anaerobic glove box (Belle 
Technology). To this end, the protein was purified by nickel affinity chromatography 
from 4 litres of recombinant culture under anaerobic conditions using buffers 
deoxygenated with argon.  In contrast to the aerobic purification of the ferredoxins, a 
strong dark brown/black band was observed at the top of the metal affinity column for 
ferredoxins A and C, which began to migrate down the column as the imidazol 
concentration in the wash buffers was increased. For FdxB, a brick red band developed 
at the top of the column and was eluted as imidazol concentration increased. The 
presence of the brown colouration for FdxA and FdxC suggests the presence of a 4Fe4S 
iron-sulphur cofactor. The brick red colouration of FdxB suggests the presence of a 
2Fe2S iron-sulphur cofactor. In agreement with this suggestion, anerobically purified 
ferredoxins showed a different UV-visible spectrum to the aerobic purification. The 
anaerobic UV-visible spectrum possessed no spectral signature outside of that of the 
protein A280. Iron-sulphur centres have a ‘table-like’ spectral signature below 420nm. 
When the brown protein was removed from the anaerobic environment, the protein lost 
its brown colour. Figure 4.4 shows a complete gel of FdxA wild-type purification, 
where the dominant band is running higher than anticipated. Figure 4.5 shows a 
complete gel of FdxB wild-type purification, where again the dominant band is running 
higher than anticipated given calculated size of the protein. Figure 4.6 shows a complete 
gel of FdxC wild-type purification. The protein is approximately 11kDa, which is 
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13kDa when the 2kDa hex-His tag is taken into consideration, yet is again running 
higher than it should. This will be discussed below. 
 
Figure 4.4: SDS-PAGE of FdxA protein purification. Light streaks are due to light 
reflection from the dried down gel on the scanner glass. Lane 3; binding-buffer wash, 
lane 4; imidazol wash, lane 5; elution fraction 1, lane 6; elution fraction 2, lane 7; 
elution fraction 3, lane 8; elution fraction 4, lane 9; elution fraction 5, lane 10; elution 
fraction 6, lane 11; Dalton-7 SDS marker, lane 12; empty. 
 
 
Figure 4.5: SDS-PAGE of FdxB protein purification. Light streaks are due to light 
reflection from the dried down gel on the scanner glass. Lane 1; Dalton-7 SDS marker, 
lane 2; crude extract, lane 3; column flow through, lane 4; binding buffer wash, lane 5; 
imidazol wash, lane 6; elution fraction 1, lane 7; elution fraction 2, lane 8; elution 
fraction 3, lane 9; elution fraction 4, lane 10; elution fraction 5, lane 11; elution fraction 
6. 
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Figure 4.6: SDS denaturing gel of the wild-type FdxC purification from within a Belle 
anaerobic glovebox. Lane 3; binding-buffer wash, lane 4; imidazol wash, lane 5; elution 
fraction 1, lane 6; elution fraction 2, lane 7; elution fraction 3, lane 8; elution fraction 4, 
lane 9; elution fraction 5, lane 10; elution fraction 6, lane 11; elution fraction 7, lane 12; 
Dalton-7 SDS marker. 
 
4.2.7: Characterisation of FdxA, FdxB and FdxC 
Before interactions of the candidate reactivation factors and cdMS were carried out, 
better characterisation of the putative ferredoxins was essential. Characterisation was 
carried out in an anaerobic glovebox. Aerobic purification of each protein demonstrated 
that they were not stable in an aerobic environment, losing the distinctive colouration of 
an iron-sulphur protein as they bound to the IMAC column. All further work on the C. 
glutamicum ferredoxins A, B and C was carried out in anaerobic conditions. 
 
FdxA and FdxC proved impossible to collect redox potential data on, beyond an 
approximation given their behaviour when exposed to reducing agents. These two 
proteins proved to have extremely electronegative reduction potentials – such that 
sodium dithionite did not reduce them sufficiently to obtain reduced EPR spectra of the 
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proteins. After a particularly troublesome set of EPR sample runs, the use of sodium 
borohydride as a reductant was decided upon. This resulted in large losses of protein 
upon application, but allowed the obtaining of a signal by reducing the otherwise EPR-
silent oxidised FeS cluster. The quality of EPR spectra obtained from FdxA and FdxC 
using this method were far from perfect, but deemed acceptable. 
 
The ferredoxins were highly oxygen sensitive, losing their characteristic golden brown 
colour (in the case of FdxA and FdxC) or brick red colour (in the case of FdxB) in 
minutes if removed from the anaerobic environment of the glovebox. They would 
precipitate if left at 20ºC overnight, but were stable when kept at 4ºC for less than 24 
hours. The FdxB purified reduced, indicating that the electronic potential of E. coli 
cytoplasm was negative enough to reduce this cluster. They all bound poorly to a nickel 
IMAC column (whether N- or C-terminally hex-His tagged) which necessitated 
lowering the imidazol eluent concentration for washes. 
 
Due to the size anomaly of the ferredoxins when run on SDS-PAGE, further 
confirmation of their identity was sought. To this end, MALDI mass spectrometry based 
peptide mass fingerprinting was utilised with digests of the proteins as described in 
section 2.4.7. This yielded some interesting results, as none of the ferredoxins would 
gain a positive hit as a C. glutamicum ferredoxin in the Matrix Science MASCOT 
database. The closest result was a completely unrelated C. glutamicum enolase. In silico 
trypsin digests of the protein sequences yielded the same results as those obtained 
experimentally when the digests were input into the MASCOT search engine. Ion spray 
mass spectrometry of aerobically purified ferredoxin C gave a mass spectrum 
comparable with the protein with a His-tag (Fig. 4.7).  
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Figure 4.7: Electrospray mass chromatogram (left) of purified FdxC and the 
deconvoluted spectrum (right). The 13508.9 peak corresponds with the size of FdxC 
(11.5kDa) with His-tag (2kDa). 
 
While this electrospray mass spectrometry confirmed the size of FdxC, it also allowed 
the aggregation state of FdxC to be investigated by mass spectrometry. The His-tagged 
protein in 10 mM ammonium acetate pH 7.5 was directly injected into an ion trap mass 
spectrometer operation in positive electrospray mode at a rate of 50µlmin-1. 
Electrospray mass spectrometry is a ‘soft’ ionisation technique, which should provide a 
gentle transfer of ions from the solution into the gas phase making it possible to study 
proteins in their native form. Despite the molecular mass of most proteins being outside 
the normal operating range of an ion trap, proteins generally contain a large number of 
ionisable groups and thus readily form multiply charged states, which appear as 
envelopes of related peaks. Electrospray of FdxC led to the detection of one envelope of 
peaks, observed between 2000 and 3500 m/z. Deconvolution of the MS spectra gave 
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one peak at 13.5kDa. This supports FdxC being present as a monomer in solution, but 
confirmation by size-exclusion filtration would also have been desirable. 
 
4.2.8: Sequence analysis and modelling of FdxA, FdxB and FdxC 
Ferredoxin A, cg3275, was identified as a putative ferredoxin by sequence analysis (Fig. 
4.8) and homologous modelling (Fig. 4.9) as the first of two 2[4Fe4S] cluster 
ferredoxins. It is a small 11.7kDA 107 residue protein with a pI of 3.75.  
 
When modelled it is fairly similar to Pseudomonas aeruginosa ferredoxin 1 structurally 
(Fig. 4.9) but shares little sequence similarity (Fig. 4.8) outside of the conserved 
cysteine residues. While only a model, it highlights the dominant features of the protein: 
the two 4Fe4S clusters in the N-terminal and the large alpha-helix in the C-terminal of 
the protein.  
 
The model also highlights one of the possible reasons for the poor binding of the protein 
to an IMAC column: the N-terminal appears to be tucked inside the protein folds, 
shielded by the alpha-helix and the 4Fe4S clusters. The overall structural similarities are 
striking; it is possible that an actual crystal structure of FdxA holoenzyme would reveal 
a more compact shape as the 4Fe4S clusters would play a role in conformation. 
 
Pseudo          MSLKITDDCINC--DVCEPECPNGAISQGEEIYVIDPNLCTECVGHYDEPQCQQVCPVDC 58 
FdxA            MTYTIAQPCVDVLDRACVEECPVDCIYEGKRMLYIHPDECVDCG------ACEPVCPVEA 54 
                *: .*:: *::    .*  *** ..* :*:.:  *.*: *.:*        *: ****:. 
 
Pseudo          IPLDDAN-------VESKDQLMEKYRKITGKA--------------------- 83 
FdxA            IFYEDDVPHEWWDYTGANAAFFDDLGSPGGAASLGPQDFDAQLVAVLPPQNQN 107 
                *  :*         . ::  :::.  .  * *                      
Figure 4.8: Alignment of the Pseudomonas aeruginosa ferredoxin 1 compared to C. 
glutamicum FdxA. Conserved cysteine residues are highlighted in red. 
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Figure 4.9: Stereo view of the x-ray crystal structure of Pseudomonas aeruginosa 
ferredoxin 1, PDB code 2FGO (Giastas et al. 2006) and a SWISS-MODEL (Schwede et 
al. 2003) of C. glutamicum FdxA, demonstrating the structural similarities between the 
two proteins.  
 
C. glutamicum Ferredoxin B, gene number cg0640, is a 106 amino acid residue 2Fe2S 
iron sulphur cluster redox protein. When modelled (Fig. 4.11) it bears a strong degree of 
structural similarity to that of Rhodobacter capsulatus ferredoxin 6 chain A. It bears 
little sequence similarity (Fig. 4.10) to this R. capsulatus protein.  
 
It has a pI of 4.28, making it less acidic than FdxA or FdxC, but still charged enough to 
alter behaviour when run on SDS-PAGE. FdxB also has a classic 2Fe2S EPR spectrum 
(Fig. 4.18). As one of the candidate C. glutamicum cdMS reactivation factors proposed 
by BASF it was characterised as well as possible.  
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R.cap_fdx6_ch_A      -AKIIFIEHNGTRHEVEAKPGLTVMEAARDNGVPGIDADCGGACACSTCHAYVDPAWVDK 59 
fdxB                 MSTIHFIDHAGKTRTIEATVGDSVMETAVRNGVPGIVAECGGSLSCATCHVFVDPAQYDA 60 
                      :.* **:* *. : :**. * :***:*  ****** *:***: :*:***.:****  *  
 
R.cap_fdx6_ch_A      LPKALPTETDMIDFAYEPNPATSRLTCQIKVTSLLDGLVVHLPEKQI 106 
fdxB                 LPPMEEMEDEMLWGAAVDREDCSRLSCQIKVTEGMD-LSLTTPETQV 106 
                     **     * :*:  *   .   ***:******. :* * :  **.*: 
Figure 4.10: FASTA alignment of Rhodobacter capsulatus ferredoxin 6 chain A 
against C. glutamicum FdxB, with cysteine residues highlighted in red. It demonstrates 
that out of the five cysteine residues present and conserved in the C. glutamicum FdxB 
sequence; four are conserved in R. capsulatus.  
 
 
Figure 4.11: Stereo view of R. capsulatus ferredoxin 6 chain A (left) PDB accession 
code: 1E9M (Armengaud et al. 2001) and C. glutamicum FdxB (right), demonstrating 
the structural similarities exhibited. 
 
Ferredoxin C, gene number cg1252, is a protein of 105 amino acid residues totalling 
11.5kDa with a pI of 3.79. Like both FdxA and FdxB, it runs anomalously high with 
SDS-PAGE. Both Ferredoxin C and ferredoxin A are a golden brown when purified, 
even at higher concentrations. Sequence analysis (Fig. 4.12) and structural modelling 
(Fig. 4.13) imply the presence of twin 4Fe4S clusters, and this was confirmed to be the 
case by EPR.  
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Myco_smeg       MTYVIGRPCVDVKDRACVDECPVDCIYEGARMLYIHPDECVDCGACEPVCPVEAIYYEDD 60 
FdxC            MTYTIAQPCVDVLDRACVEECPVDCIYEGKRMLYIHPDECVDCGACEPACPVEAIFYEDD 60 
                ***.*.:***** *****:********** ******************.******:**** 
 
Myco_smeg       LPEDLQPYQEENAKFFTDVLPGRAQPLGSPGGAAKLGVVDADTPMVAELPPQGD 114 
FdxC            VPDEWLDYNDANAAFFDD--------LGSPGGAAKLGPQDFDHPMIAALPPQA- 105 
                :*::   *:: ** ** *        ***********  * * **:* ****.  
Figure 4.12: Alignment of C. glutamicum ferredoxin C against the 7Fe8S ferredoxin 
from Mycobacterium smegmatis, highlighting conserved cysteine residues. 
 
 
Figure 4.13: Stereo view of SWISS-MODEL (Schwede et al. 2003) of C. glutamicum 
FdxC and X-ray crystral structure of ferredoxin A from Mycobacterium smegmatis 
(Ricagno et al. 2007) a 7Fe8S ferredoxin which bears significant structural similarity to 
the modelled structure of C. glutamicum ferredoxin C. This demonstrates neatly the 
structural similarities of the M. smegmatis ferredoxin A and C. glutamicum FdxC. 
 
4.2.9: UV/visible spectrophotometry of FdxA, FdxB and FdxC 
Aside from the indication that colouration of a protein can provide about cofactors, 
UV/visible spectrophotometry can provide significant insight into potential cofactors. 
UV/visible spectra were recorded as described in section 2.4.9. C. glutamicum FdxA 
shares a slightly odd (Fig. 4.14) UV/Visible spectrum with ferredoxin C, although the 
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haem-like peak at 412nm is more pronounced with ferredoxin C. The double-cluster 
arrangement appears to be quite difficult for E. coli to construct, as the ratio of protein 
to iron-sulphur is fairly poor for both 2[4Fe4S] proteins. Protein/FeS ratio is 
approximately 6:1, which means that ~16% of the over-expressed protein is actually 
holoenzyme. This is taken into account during any assays by calculating concentrations 
of enzyme from amount of FeS, rather than protein. As E. coli does not possess any 
2[4Fe4S] cluster proteins, this is understandable. 
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Figure 4.14: UV/Visible spectrum of FdxA, showing the 430-330nm ‘table’ 
characteristic of 4Fe4S cluster UV/Visible spectra.  
 
 
When purified in an anaerobic environment, FdxB has the classical brick red colour of a 
2Fe2S protein and UV/visible spectrum (Fig. 4.15). Protein/FeS ratio is approximately 
5:1, which means that only 20% of the over-expressed protein is actually holoenzyme. 
This is taken into account during any assays by calculating concentrations of enzyme 
from amount of FeS, rather than protein. 
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Figure 4.15: UV/Vis spectrum of wild-type FdxB, displaying the characteristic 
‘shoulder’ of an iron-sulphur cluster.  
 
The classic ‘table’ of iron-sulphur UV/Visible spectra is partially evident, but the 
spectrum of FdxC is dominated by a haem-like peak at 412nm (Fig. 4.16). Protein/FeS 
ratio is approximately 4:1, which means that only 25% of the over-expressed protein is 
actually holoenzyme. This is taken into account during any assays by calculating 
concentrations of enzyme from amount of FeS, rather than protein. 
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Figure 4.16: UV/Vis spectrum of purified FdxC, showing the haem-like peak at 412nm.  
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4.2.10: EPR of FdxA, FdxB and FdxC 
Electron paramagnetic resonance (EPR) spectroscopy is a valuable technique for 
studying the electronic structure and environment of molecules which contain one or 
more unpaired electrons. EPR has been used to investigate the nature of the putative 
iron-sulphur clusters present in the ferredoxins as described in section 2.4.12.  
 
EPR of wild-type FdxA (Fig. 4.17) revealed some interesting characteristics. There is a 
splitting between the two g┴ (g-perpendicular) factors for the FeS clusters, one at the 
FeS ‘standard’ g-factor of g=1.94, the second shifted upfield slightly to g=1.92. The g┴ 
at g=2.005 is spot on for a radical signal as most radicals are present at g=2, potentially 
caused by excess borohydride reducing agent. The g║ (g-parallel) for the two linked FeS 
clusters are g=2.02 and g=2.04 respectively, with the g┴ of a copper contaminant 
present at g=2.07. This data tallies with the structural models – two 4Fe4S clusters in 
close proximity to one another but due to protein folding itself not in identical 
environments and shares similarities to previously reported 2[4Fe4S] clusters. There 
was no signal when the FdxA sample was oxidised. 
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Figure 4.17: X-band EPR spectrum of wild-type C. glutamicum FdxA reduced with 
sodium borohydride. Spectrum measured as described in section 2.4.12.1. Sample 
concentration 250µM, no signal when oxidised. 
 
Electron paramagnetic resonance (EPR) spectroscopy of wild-type FdxB (Fig. 4.18) 
revealed standard 2Fe2S cluster characteristics; a g┴=1.94 and a g║=2.02. 
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Figure 4.18: X-band EPR spectrum of wild-type FdxB. The 2Fe2S nature of the FeS 
cluster is fully evident with an extremely strong signal. Spectrum measured as described 
in section 2.4.12.2. Sample concentration 250µM, no signal when oxidised. 
 
Electron paramagnetic resonance (EPR) spectroscopy of wild-type FdxC (Fig. 4.19) 
revealed some interesting characteristics; there is a splitting between the two g┴ (g-
perpendicular) factors for the FeS clusters, one at the FeS ‘standard’ g-factor of g=1.94, 
the second shifted upfield slightly to g=1.92. The g┴ at g=2.005 is spot on for a radical 
signal, potentially caused by excess borohydride reducing agent. The g║ (g-parallel) for 
the two linked FeS clusters are g=2.02 and g=2.04 respectively, with the g║ of a copper 
contaminant present at g=2.07, although this contamination is at a much lower level 
than in the FdxA wild-type spectrum. This data tallies with the structural models – two 
4Fe4S clusters in close proximity to one another but due to protein folding itself not in 
identical environments – hence the splitting of the clusters signals.  
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Figure 4.19: X-band EPR spectrum of wild-type C. glutamicum FdxC, reduced with 
sodium borohydride, showing the g values of both clusters and a borohydride radical. 
Spectrum measured as described in section 2.4.12.1. There was no signal when sample 
was oxidised, protein concentration was 250µM. 
 
4.2.11: Site directed mutagenesis of FdxA, FdxB and FdxC 
In order to investigate the nature of the FeS centres in the ferredoxins, it was decided to 
mutate the conserved cysteine residues thought to be responsible for co-ordinating the 
iron-sulphur centre by site directed mutagenesis. Each targeted cysteine was mutated to 
an alanine residue, which cannot co-ordinate Fe-S centres correctly.  
 
Constructs showing single amino acid substitutions (C9A, C17A, C21A, C25A, C40A, 
C43A, C46A and C50A for ferredoxins A and C, and C40A, C46A, C49A, C82A and 
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C87A for ferredoxin B) were generated by use of the Quikchange II site directed 
mutagenesis kit (Stratagene), as described in Section 2.3.7.3. Constructs showing 
double amino acid substitutions failed to transform into the XL-1 Blue ultracompetent 
cells. The mutants were prepared using pET-14b-fdxA, pET-14b-fdxB or pET-14b-
fdxC plasmids as a template and primers listed in Table 2.3. The sequences were 
confirmed as correct by sequencing the inserts in both directions using the T7 promoter 
and T7 terminator as primers. 
 
4.2.12: Production of mutants of FdxA, FdxB and FdxC 
E. coli BL21(DE3)pLysS cells were transformed with a pET14b construct containing 
the C. glutamicum fdxA C9A, C17A, C21A, C25A, C40A, C43A, C46A or C50A 
cysteine to alanine knockout mutants, fdxB C40A, C46A, C49A, C82A or C87A 
cysteine to alanine knockout mutants or fdxC C9A, C17A, C21A, C25A, C40A, C43A, 
C46A or C50A cysteine to alanine knockout mutant genes as described in section 
2.3.7.3. Each of the resulting strains was grown at 37 ºC in LB medium supplemented 
with appropriate concentrations of ampicillin and chloramphenicol. Once the cell 
density reached OD600 ≈ 0.6 protein overproduction was induced with the addition IPTG 
to a final concentration of 0.4mM and the cells were left to continue growth overnight at 
16 °C before harvesting by centrifugation. 
 
4.2.13: Purification of mutants of FdxA, FdxB and FdxC 
The harvested cells were lysed by sonication and debris removed by centrifugation. The 
soluble fraction was applied to a column charged with Ni2+ and washed with increasing 
imidazol concentrations as described in 2.1.7.3. Figure 4.20 shows elution fractions of 
each of the FdxA single-knockout mutants, in which yields of desired protein are poor 
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for all of the mutants. Mutants C17A, C40A and C43A had no appreciable colouration 
on the column. Figure 4.21 shows elution fractions of each of the FdxB single-knockout 
mutants. Yields of desired protein are, again, extremely poor for all of the mutants.  
 
None of the FdxB mutants exhibited the brick red colouration of a 2Fe2S cofactor. The 
extremely faint fifth lane is due to sample spill-over from lane six and is not a sample. 
Figure 4.22 shows elution fractions of each of the FdxC single-knockout mutants. 
Protein yields are poor for all of the mutants, although the C9A, C25A, C43A and 
C46A mutants have better yields than the C17A, C21A, C40A and C50A mutants. This 
increased yield is not reflected in an increased signal in the EPR spectra obtained from 
the knockouts, indicating that while protein levels might have increased, iron-sulphur 
centre yields have not. All FdxC mutants exhibited a similar brown colouration on 
bound to the IMAC column and when in solution. 
 
 
Figure 4.20: SDS denaturing gel of the eight FdxA single-knockout cysteine mutants. 
Lane 1; C9A single knockout mutant, lane 2; C17A single knockout mutant, lane3; 
C21A single knockout mutant, lane 4; empty, lane 5; Dalton-7 SDS marker, lane 6; 
C25A single knockout mutant, lane 7; C40A single knockout mutant, lane 8; C43A 
single knockout mutant, lane 9; C46A single knockout mutant, lane 10; c50A single 
knockout mutant. 
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Figure 4.21: SDS denaturing gel of the five FdxB single-knockout cysteine mutants. 
Lane 1; C40A single knockout mutant, lane 2; Dalton-7 SDS marker, lane 3; C46A 
single knockout mutant, lane 4; C49A single knockout mutant, lane 5; sample spill-over 
from lane 4, lane 6; C82A single knockout mutant, lane 7; C87A single knockout 
mutant. 
 
 
 
Figure 4.22: SDS denaturing gel of the eight FdxC single-knockout cysteine mutants. 
Lane 1; C9A single knockout mutant, lane 2; C17A single knockout mutant, lane3; 
C21A single knockout mutant, lane 4; 25A single knockout mutant, lane 5; Dalton-7 
SDS marker, lane 6; C40A single knockout mutant, lane 7; C43A single knockout 
mutant, lane 8; C46A single knockout mutant, lane 9; C50A single knockout mutant. 
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4.2.14: EPR of mutants of FdxA, FdxB and FdxC 
Studying the mutant clusters by EPR was hoped to shed light on their interactions, 
possibly revealing whether each cluster was reducible individually, or whether one was 
reduced first in preference to the second. EPR spectra were collected as described in 
section 2.4.12.1 and 2.4.12.2.  
 
The spectra exhibited by the single-cysteine knockout mutants of FdxA (Fig. 4.23) aside 
from contaminants, are for the most part similar to the wild-type FdxA EPR spectrum. 
As there is no signal exhibited when oxidised, this rules out the possibility of a 3Fe4S 
cluster forming from the single cysteine knockout. There are a few notable exceptions – 
knocking out a single cysteine residue from the protein appears to shift the midpoint 
reduction potential to a point where sodium dithionite (which is unable to reduce the 
wild-type enzyme) can act as a reducing agent. All of the knockouts have a decreased 
signal intensity compared to the wild-type enzyme, but this is likely due to an already 
moderately unstable protein losing one of the points holding the FeS clusters together. 
The C17A, C40A and C43A mutants have next to no visible 4Fe4S signal when reduced 
either by dithionite or borohydride. The most common contaminants are copper (C21A) 
and manganese (all spectra). The knockouts did not shift g factors from the wild-type 
values (Fig. 4.17). Manganese was found frequently in many EPR spectra but there was 
no contaminating manganese or copper in any buffer when empty protein-free buffer 
EPR spectra were run. 
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Figure 4.23: X-band EPR spectra of FdxA single cysteine knockout mutants, the 
cysteine knockout is labelled by each spectrum (x-axis; field in G). All knockouts 
exhibited manganese contamination (the six evenly spaced lines). The C17A, C40A and 
C43A knockouts did not show any appreciable 4Fe4S signal. The C21A mutant 
exhibited some copper contamination while it and the C9A mutant displayed a smaller 
4Fe4S signal than the C25A, C46A and C50A mutants. 
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The FdxB single cysteine knockout mutants all lack the classical brick red 2Fe2S 
colouration, indicating a loss of the 2Fe2S cluster. This is supported by EPR (Fig. 4.24) 
in which none of the mutants possess an FeS signal as remotely intense as the wild-type 
protein. 
 
Figure 4.24: X-band EPR spectrum of FdxB single cysteine knockout mutants, the 
cysteine knockout is labelled by each spectrum (x-axis; field in G). There is little to no 
appreciable FeS signal in the spectrum when compared to the intensity of the wild-type 
FdxB. All FdxB mutants show this loss of 2Fe2S cluster signal.  
C40A 
C46A 
C49A 
C82A 
C87A 
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The spectra exhibited by the single-cysteine knockout mutants of FdxC (Fig. 4.25) aside 
from contaminants are similar to the wild-type FdxC EPR spectrum. None of the 
knockouts lost FeS signal in the manner of three of the FdxA knockouts. The two most 
common contaminants are copper and manganese. Manganese was found frequently in 
many EPR spectra but there was no contaminating manganese or copper in any buffer 
when empty protein-free buffer EPR spectra were run. As with the FdxA wild-type and  
mutants and the FdxC wild-type there was no indication of a 3Fe4S signal, 
demonstrating complete cluster loss upon mutation of a single cysteine residue ligand. 
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Figure 4.25: X-band EPR spectra of FdxC single cysteine knockout mutants, the 
cysteine knockout is labelled by each spectrum (x-axis; field in G). Unlike FdxA, there 
was far lower manganese contamination in the FdxC mutants. The C25A, C40A, C43A 
and C46A knockouts show significantly less 4Fe4S signal than other knockouts. On 
those samples where cluster splitting was not visible the 4Fe4S signal appeared greater 
(C21A knockout) than in those samples where there was evidence of cluster splitting 
still occurring (C9A, C17A, C40A, C43A, C50A). 
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4.2.15: Recombinant C. glutamicum cdMS 
When it became evident that purification of cdMS from native source was always 
causing loss of assay activity, it was decided to attempt to clone cdMS from C. 
glutamicum and into an E. coli expression vector which was used and better understood 
within the laboratory. In short, purification of cdMS from source was abandoned in 
favour of recombinant expression in a system for easier purification and better 
understood by the laboratory. 
4.2.16: C. glutamicum plasmid purification  
With the failure of purifying cdMS from source, purification of the plasmids became a 
focus. To this end an enhanced spin miniprep was developed for use with C. 
glutamicum. As purification of C. glutamicum cdMS from the native organism proved 
to be a greater challenge than anticipated, it was decided that recombinant expression 
might yield better results, as detailed in chapter 4. To this end, cloning from genomic 
and plasmid DNA was attempted. Working with plasmid DNA first required isolation of 
the plasmids. 
 
Purification of C. glutamicum plasmid DNA by the laboratory standard Qiagen Spin 
Miniprep system yields extremely low quantities of plasmid DNA. Because of this, 
alternative methods of obtaining the plasmid DNA were sought. Qiagen do have a user 
developed miniprep system for C. glutamicum detailed on their website (detailed in 
section 2.3.12) which amounts to alcohol precipitation of the DNA (Zeugin and Hartley 
1985; Sambrook et al. 1989) with some prior treatment to weaken the mycolic cell wall 
of the Corynebacterium. After several occasions where running what should have been 
isolated plasmid on agarose gels resulted in nothing but the Hyperladder marker 
evident, an attempt to decrease the potential for loss of the DNA pellet was made by 
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adapting the C. glutamicum miniprep to the faster and less error susceptible spin 
miniprep system (Fig. 4.26).  
 
Simply applying the spin miniprep protocol to C. glutamicum resulted in little to no 
plasmid DNA yield and so the following was discovered to work acceptably in 
obtaining appropriate yields of plasmid DNA from C. glutamicum: after spinning the 
10ml culture down to pellet the cells and decanting the supernatant, the cells were 
resuspended in 1ml of buffer B, from the user developed C. glutamicum plasmid 
miniprep. The cells were then centrifuged again to pellet the cells and the supernatant 
removed, followed by addition of buffer P1 (with RNAse added to standard 
concentrations, but with 1mg/ml lysozyme added also, in a similar fashion to the 
alterations made to the spin miniprep system for Bacillus megaterium. After those 
alterations, the spin miniprep was carried out as normal. Yield of plasmid DNA from C. 
glutamicum using this altered miniprep protocol was comparable to the yield of DNA 
obtained from E. coli with the unmodified spin miniprep system. 
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Figure 4.26: 1% agarose gel analysis of plasmid DNA extracted from strain OM257. 
Lane 1; Hyperladder 1, lane 2; ethanol precipitation purification, lane 3; Qiagen spin 
miniprep purification, lane 4; Qiagen spin miniprep with buffer B treatment, lane 5; 
Qiagen spin miniprep with buffer B and lysozyme treatment. 
 
4.2.17: Cloning of cdMS 
Attempts to clone metH from genomic DNA by PCR as described in section 2.3.1 
proved to be a considerable challenge, despite multiple attempts. Correspondence with 
members of the Matthews (R.G. Matthews, Life Sciences Institute, University of 
Michigan, Ann Arbor, Michigan) laboratory revealed difficulties when originally 
cloning metH from E. coli. A strategy for the insertion of an Nde1 site at the start of the 
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metH gene into the BASF plasmid H588 (which was known to be correct) was 
determined with the aid of Dr. Evelyne Deery and carried out (Fig. 4.27). This allowed 
subcloning of the metH gene to generate the pET-14b-metH construct from which yields 
of cobalamin-dependent Methionine Synthase were very high. 
 
  
                                                                                     Apa1                           
                                                                                PspOM   |                           
                                                                               Kpn1 |   |                           
                                                                          Acc65   | |   |                           
                                              Swa1                       Apa1 |   | |   |                           
                                 Not1         Dra1                  PspOM   | |   | |   |                           
                                 Eag1BsrB1   BsaB1 Xho1    Stu1    Aat2 |   | |   | |   | Xho1      BsrB1           
                                    |    |       |    |       |       | |   | |   | |   |    |          |           
               tggcttgaccgacttgatcagcggccgctcgatttaaatctcgagaggcctgacgtcgggcccggtaccgggccccccctcgaggtcgagcggcttaaag 
            1  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
100 
               accgaactggctgaactagtcgccggcgagctaaatttagagctctccggactgcagcccgggccatggcccgggggggagctccagctcgccgaatttc 
                                                                                                                    
                      SpDon                            EcoK                                             Bcg1a       
                          |                               |                                                 |       
               tttggctgccatgtgaatttttagcaccctcaacagttgagtgctggcactctcgggggtagagtgccaaataggttgtttgacacacagttgttcaccc 
          101  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
200 
               aaaccgacggtacacttaaaaatcgtgggagttgtcaactcacgaccgtgagagcccccatctcacggtttatccaacaaactgtgtgtcaacaagtggg 
                                                                                                                    
                                      Bcg1b                           Eco57      Sal1              SpDon            
                                          |                               |         |                  |            
               gcgacgacggctgtgctggaaacccacaaccggcacacacaaaatttttctcatggagggattcatcatgtcgacttcagttacttcaccagcccacaac 
          201  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
300 
               cgctgctgccgacacgacctttgggtgttggccgtgtgtgttttaaaaagagtacctccctaagtagtacagctgaagtcaatgaagtggtcgggtgttg 
orf 1        >                                                     M  E  G  F  I  M  S  T  S  V  T  S  P  A  H  N   
                                                                                                                    
                                                                         Nco1                                       
                                                                      Nar1  |                                       
                                                                     Kas1|  |    BseY1                    BmgB1     
                                                                        ||  |        |                        |     
               aacgcacattcctccgaatttttggatgcgttggcaaaccatgtgttgatcggcgacggcgccatgggcacccagctccaaggctttgacctggacgtgg 
          301  ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
400 
               ttgcgtgtaaggaggcttaaaaacctacgcaaccgtttggtacacaactagccgctgccgcggtacccgtgggtcgaggttccgaaactggacctgcacc 
orf 1        > N  A  H  S  S  E  F  L  D  A  L  A  N  H  V  L  I  G  D  G  A  M  G  T  Q  L  Q  G  F  D  L  D  V  E 
 
 
 
Forward primer (5’  3’) (18 bases) 
TGA CCG ACT TGA TCA GCG 
 
Reverse primer (5’  3’) (mutating in Nde1 site) (41 bases) 
CCTGTCGACATATGGAATCCCTCCATGAGAAAAATTTTGTG 
 
Figure 4.27: diagram detailing how the primers for the generation of the Nde1 site in 
BASF plasmid pH588 was determined. The forward primer is fairly short, and does not 
contain any base alterations. The reverse primer contains the Nde1 site and is 41 base-
pairs long because of the adenine and thymine rich region of the plasmid just outside of 
the metH gene. Despite this A/T rich region, the PCR encountered no issues. 
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4.2.18: Production of cdMS 
E. coli BL21(DE3)pLysS cells were transformed with a pET14b construct containing 
the C. glutamicum metH gene. The resulting strain was grown at 37ºC in Super LB 
medium supplemented with appropriate concentrations of Ampicillin and 
Chloramphenicol. Once cell density had reached an approximate OD600 of 0.6, protein 
overproduction was induced with the addition of IPTG to a final concentration of 
0.4mM and the cells left to continue growth overnight at 16ºC before harvesting by 
centrifugation.  
 
4.2.19: Purification of cdMS 
The harvested cells were lysed by sonication and debris removed by centrifugation. The 
soluble fraction was applied to a column charged with Ni2+ and washed with increasing 
imidazole concentrations as described in 2.1.7.4. During purification of cdMS (Fig. 
4.28) a reddish/purple band could be observed at the top of the resin upon application of 
the spin-clarified sonicate. This reddish/purple colour migrated down the column during 
washing with the buffer imidazol steps. By the time the protein was eluted with 400mM 
imidazol, there was no colour to the protein at all; implying that any bound cofactors 
had been washed out during the purification. Once eluted, the protein was kept on ice, 
or at 4ºC for overnight storage. The purified cdMS protein could be left at room 
temperature for days at a time without any apparent ill effects such as protein 
precipitation, but it was considered best to purify it as close to use as possible – 
normally the morning of any experimental procedures. 
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Figure 4.28: SDS denaturing gel of a His-tagged cdMS purification. There is some 
cdMS protein present in the pellet fraction, but by far the largest quantity is obtained in 
the elution fractions. Light streaks are due to reflection from the gel onto the scanner 
glass. Lane 1; crude extract, lane 2; pellet, lane 3; column flow through, lane 4; binding 
buffer wash, lane 5; imidazol wash, lane 6; elution fraction 1, lane 7; high-molecular 
weight marker, lane 8; elution fraction 2, lane 9; elution fraction 3, lane 10; elution 
fraction 4, lane 11; elution fraction 5, lane 12; elution fraction 6, lane 13; elution 
fraction 7. 
 
cdMS was possibly the least troublesome protein to purify as it bound to the IMAC 
column tightly and eluted cleanly with lower contamination from other proteins than the 
ferredoxins. The purified protein was stable at temperatures ranging from room 
temperature to 4ºC provided it was kept as apoenzyme. If provided with cobalamin for a 
partial holoenzyme form it would remain stable for approximately three days before 
beginning to precipitate; stability when cobalamin and zinc were present in solution was 
significantly reduced. It would always purify as apoenzyme, requiring incubation with 
cobalamin for study of reactivation. While incubation with cobalamin and zinc was 
attempted on multiple occasions, the stability of the protein became compromised and it 
precipitated far more quickly than the partial holoenzyme. 
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4.2.20: Western Blotting of cdMS 
To confirm that the band of greatest size was cdMS, 15µg of protein sample was 
subjected to Western analysis using an anti-His antibody as described in section 2.4.6. 
This revealed a band of approximately 130-140kDa for cdMS (Fig. 4.29). The cdMS 
band looked fairly clean on the gel, but there was some cross-reaction with the His 
probe below the protein, possibly indicating some proteolysis of cdMS occurring. 
 
                                                   
Figure 4.29: 8% SDS-PAGE gel (left) of purified cdMS and Western blot of an 
identically loaded gel (right). Lane 1; cdMS, lane 2; SDS6H2 high-molecular weight 
marker. 
4.2.21: Characterisation of purified recombinant C. glutamicum cdMS 
To begin characterisation of C. glutamicum cdMS, investigation of cofactor and 
substrate binding is an essential step. As the focal point of all reactions (turnover and 
reactivation) in cdMS, the cobalamin cofactor was first investigated; binding, 
temperature-dependent environment shifts and methyl-group donation. To study the 
interactions of the substrates with cdMS, which do not affect the UV/visible spectrum 
of the enzyme, EPR was utilised. 
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4.2.21.1: cdMS binding of cobalamin 
In any experiment where studying cobalamin- bound or binding to cdMS, it must be 
ascertained first that cobalamin is capable of binding to the recombinant protein. Thus a 
method of ascertaining binding needed to be found. It is based around the idea that a 
10,000Da spin concentrator column will not allow a protein of greater than 10,000Da 
through the membrane. Given that cdMS is 135,000Da, there is little chance of it being 
able to pass through the filtration membrane. If cobalamin is binding to cdMS, it will 
not pass through – free cobalamin is approximately 1300Da molecular weight 
(depending on upper axial ligand) and so should pass through the membrane easily if 
not bound to a larger protein.  
 
Purified cdMS was incubated in the dark with cobalamin for 30 minutes. Figures 4.30 
and 4.31 show prior and post a simple spin column experiment for determining binding 
of cobalamin to cdMS. Free cobalamin passes easily through the membrane (Fig. 4.31, 
right) while cdMS-bound cobalamin fails to pass through (Fig. 4.31, left). A protein 
control of BSA was used to test whether a non-cobalamin-binding protein would 
influence the migration of cobalamin through the membrane (Fig. 4.31, middle) – while 
the BSA protein failed to pass through the membrane, it had no effect on the migration 
of cobalamin, lending further support to the fact that C. glutamicum cdMS was capable 
of binding cobalamin correctly. 
 
Figure 4.30: incubated preparations of cdMS and cobalamin, bovine serum albumin 
and cobalamin, and free cobalamin for binding experiment. 
MetH + B12       BSA + B12                  B12 
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Figure 4.31: 10,000Da molecular weight cut-off spin concentrator columns after 10 
minutes at 4000RPM. Note how free cobalamin and cobalamin in the presence of BSA 
have migrated through the 10,00Da membrane and are in the bottom of the 
concentrator, while cobalamin incubated with cdMS remains in the top, having failed to 
pass through the 10,000kDa filtration membrane – indicating that cobalamin is indeed 
binding to cdMS. 
 
In most enzymes possessing cofactors, the spectrum of the cofactor is influenced upon 
binding to the protein (Datta et al. 2008; Lawrence et al. 2008). To this end, the 
alteration of cobalamin spectrum upon binding to cdMS was examined. There are 
insignificant alterations in the spectrum of cdMS-bound hydroxycobalamin when the 
protein is denatured by treatment with SDS; a spectrum-wide absorbance decrease. Fig. 
4.32 has untreated methylcobalamin bound cdMS and 15 minutes after treatment with 
0.2% SDS. It is evident that there are no significant spectral shifts upon binding of 
cobalamin or denaturation of cdMS. 
 
MetH + B12      BSA + B12          B12 
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Figure 4.32: UV/Vis spectrum of C. glutamicum cdMS with bound hydroxycobalamin 
without addition of SDS (upper spectrum) and 15 minutes after addition of 0.2% SDS 
(lower spectrum). 
 
4.2.21.2: Temperature titrations of cdMS 
As temperature increases, proteins can change conformation. Modular proteins may 
favour particular conformations as temperatures vary, and binding of cofactors can alter, 
influencing their spectral characteristics. This is the case with E. coli cdMS (Datta et al. 
2008) where the base-off His-on conformation of the cobalamin becomes base-off His-
off as the temperature increases. C. glutamicum cdMS was incubated at 4ºC with 
hydroxycobalamin for one hour then placed in a Peltier-controlled temperature variable 
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UV/visible spectrophotometer for spectral analysis. For C. glutamicum cdMS, as the 
temperature increases, the absorbance signal of the methylcobalamin drops slightly, but 
for all temperatures approaching physiological norms for both Corynebacterium and E. 
coli, the spectra are so close as to be almost indistinguishable from one another (Fig. 
4.33). Temperatures as high as 45ºC demonstrate no temperature related spectral shift. 
 
Figure 4.33: UV/Vis temperature titration spectra of C. glutamicum cdMS with bound 
methylcobalamin. The C. glutamicum cdMS does not exhibit any significant deviance 
from a normal methylcobalamin spectrum as temperature is varied from 10ºC to 45ºC. 
There is a very slight decrease in absorbance as the temperature increases. 
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4.2.21.3: Methyl group donation enhancements of cdMS 
Methylcobalamin is photosensitive, and as such breaks down fairly quickly if light is 
present, but in a dark environment breakdown should be slowed or stopped. As cdMS is 
a methyltransferase, it was hypothesised that in the presence of cdMS, methyl group 
loss from methylcobalamin would be increased above that of free methylcobalamin in 
the same conditions. As the UV/Visible spectra of hydroxy- and methyl-cobalamin 
show significant differences (Fig. 4.34) it should be possible to create a time-dependent 
examination of methyl group loss from the cobalamin. The starting concentration of 
methylcobalamin was 1mM for both the free methylcobalamin and cdMS-bound 
methylcobalamin donation experiments. Assuming that rate of methyl group loss from 
the methylcobalamin was constant - which for the free methylcobalamin it was – it 
means that in a low light environment (a darkened room with the assay completely 
enclosed with silver foil) the rate of loss was 37µM/min for free methylcobalamin (Fig. 
4.35). For methylcobalamin in the presence of cdMS, the rate of loss was 45.5µM/min 
(Fig. 4.36). This is an increase in methyl ligand donation of 23% by addition of cdMS to 
the solution. It must be taken into consideration that this is not fully holoenzyme cdMS, 
as it does not have the homocysteine coordinating zinc ion bound in the first domain of 
cdMS and also that none of its physiological partners are present in the solution. As 
such, methyl group loss is simply into solution, rather than to a physiological acceptor. 
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Figure 4.34: UV/Vis spectra of hydroxycobalamin and methylcobalamin, 
demonstrating the spectral changes of methyl group addition to the corrin-bound cobalt. 
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Figure 4.35: UV/Vis spectrum illustrating the degradation of methyl cobalamin to 
hydroxycobalamin when in free solution in a dark aerobic environment. Obtained via a 
Varian Cary 50 UV/Vis spectrophotometer set to take one scan from 800-300nm every 
60 seconds. The time course was completed in 30 minutes, with only the last three scans 
overlapping, indicating that there was going to be no further methyl group donation in 
free solution. 
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Figure 4.36: UV/Vis spectrum illustrating the degradation of methyl cobalamin to 
hydroxycobalamin when in the presence of C. glutamicum cobalamin-dependent 
Methionine Synthase in a dark aerobic environment. Obtained via a Varian Cary 50 
UV/Vis spectrophotometer set to take one scan from 800-300nm every 60 seconds. The 
time course was completed in 30 minutes, with the final eight scans overlapping, 
indicating that the methyl group donation when methylcobalamin was bound to a 
methyltransferase is enhanced above that of free methylcobalamin. 
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4.2.21.4: EPR of cdMS with cofactors 
As EPR examines unpaired electrons, it can be used to focus on the environment in 
which the cobalt ion of cobalamin finds itself in – during different states of cdMS 
turnover or reactivation. In order to study cdMS by EPR, Co2+ cobalamin is necessary 
as it is the only cobalamin not EPR-silent due to electron pairing. All samples were 
prepared in 3mm bore quartz-glass EPR sample tubes to final concentrations of 13µM 
cdMS, 12µM Co2+ cobalamin (to make certain that all cobalamin was bound) 12µM 
SAM, 12µM MTHF, 12µM zinc and 12µM homocysteine and studied as described in 
section 2.4.12.4. The last three figures (4.46-4.48) were a second preparation of samples 
and run on a different spectrometer and so intensities cannot be directly compared to 
others. All other comparisons can be maintained, however. 
 
Apoenzyme cdMS (Fig. 4.37) should have no EPR spectrum as there is nothing bound 
or present in solution that would present an unpaired electron. There is a small amount 
of copper contamination at g║=2.07, which is decreased by reduction with dithionite 
(Fig. 4.38). 
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Figure 4.37: X-band EPR spectrum of cdMS apoenzyme; note the small Cu2+ 
contamination at g┴=2.07. 
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Figure 4.38: X-band EPR spectrum of cdMS apoenzyme when in the presence of 
sodium dithionite; note the reduction in Cu2+ contamination signal at g┴=2.07. 
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Free Co2+ cobalamin has a classic cobalt EPR spectrum, exhibiting a g┴=2.25, with 18G 
nitrogen triplet hyperfine splittings slightly upfield. The g║ is masked by the copper 
signal present in all samples, with cobalt splitting of 107G evident again further upfield 
(Fig. 4.39). When bound to cdMS (Fig. 4.40) the nitrogen splittings are better defined, 
indicating that there is potentially a shift in lower axial ligand from the DMB loop of 
cobalamin to the cobalt-coordinating histidine residue of cdMS. A difference spectrum 
of the two (Fig. 4.41) shows a significant Co2+ cobalamin signal remaining, 
demonstrating a signal quench effect of cobalamin binding to cdMS. When the normal 
turnover methyl-group donor MTHF is present (Fig. 4.42) the Co2+ signal is 
significantly reduced, implying some sort of interaction between the MTHF bound in its 
domain and the cobalamin – it is difficult to ascertain whether this is a quenching effect 
or whether the Co2+ cobalamin is being methylated. When zinc, the metal ion which 
coordinated the homocysteine binding in the homocysteine binding domain is present 
(Fig. 4.43) the spectrum alters significantly: a small but extremely sharp radical signal is 
evident at g=2.003 and the base on cobalamin conformation becomes base off – base off 
cobalamin is more open to reaction so it would make sense that there is a state where 
the dominant species is base off to allow for turnover or reactivation to occur. As soon 
as homocysteine is present (Fig. 4.44) this base off cobalamin returns to base on 
conformation, and the zinc radical is no longer present. In the presence of SAM (Fig. 
4.45) the cobalamin is still in base on form, and appears much the same as with zinc and 
homocysteine, or with MTHF. The effect of zinc, homocysteine and SAM present (Fig. 
4.46) appears to really only affect the nitrogen splitting of the signal. These nitrogen 
hyperfine splittings fade further with MTHF and SAM (Fig. 4.47) present, but return to 
similar levels as zinc, homocysteine and SAM when MTHF is added in the presence of 
zinc and homocysteine (Fig. 4.48). 
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Figure 4.39: X-band EPR spectrum of free Co2+ cobalamin, the g║ of Co2+ is hidden by 
the copper contamination at 3340G. The nitrogen splitting is caused by Co2+ interaction 
with the dimethylbenzimadazole lower axial ligand. 
 
 
 
g┴=2.25 
N splitting = 18G 
Co splitting = 107G 
Chapter 4 
 - 183 - 
-20000
-15000
-10000
-5000
0
5000
10000
15000
2300 2500 2700 2900 3100 3300 3500 3700 3900 4100 4300
Magnetic Field (Gauss)(G)
In
te
n
si
ty
 
(A
.
U
.
)
 
Figure 4.40: X-band EPR spectrum of cdMS-bound Co2+ cobalamin, the g║ of Co2+ is 
hidden by the copper contamination at 3340G. The nitrogen splitting is better resolved 
which potentially means the lower axial ligand has changed upon binding to cdMS – 
most likely the DMB ligand has been replaced with a histidine residue ligand.  
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Figure 4.41: X-band EPR spectrum showing the differences between free co(II)alamin 
and co(II)alamin bound to C. glutamicum cdMS. The predominant feature is that there 
is still a Co2+ signal, which given that concentrations were the same between samples, 
would imply a quenching effect caused by binding to cdMS. There is still a hint of 
nitrogen hyperfine couplings giving further credence to the idea that upon binding to 
cdMS the lower axial ligand is swapped from DMB to histidine. 
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Figure 4.42: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
methyltetrahydrofolate. The g║ of Co2+ is hidden by the copper contamination at 3340G 
(g┴=2.07). Attention must be drawn to the significant decrease in Co2+ signal – it is 
unknown whether this signal loss is due to interactions of Co2+ cobalamin with MTHF 
when bound to cdMS, or whether the Co2+ cobalamin has become methylated by the 
presence of MTHF (thus Co2+ becoming Co3+ and EPR silent). 
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Figure 4.43: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
zinc bound to the homocysteine binding domain site. Note the small but extremely 
sharp radical that has developed at g=2.003. Also, the majority of the Co2+ cobalamin 
signal has shifted from ‘base on’ (g=2.25) to ‘base off’ (g=2.43) conformation. 
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Figure 4.44: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
zinc bound to the homocysteine binding domain site, with homocysteine also present in 
solution. Upon addition of homocysteine, the radical present at 3340G in the sample 
above (Fig. 4.42) is no longer evident which would imply the radical is zinc interaction 
related. Further, the ‘base off’ conformation Co2+ signal has shifted completely back to 
‘base on’. The copper g┴ has shifted ever so slightly from g=2.07 to g=2.05. 
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Figure 4.45: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
SAM. The Co2+ cobalamin signal is still at g=2.25, indicating base on, and the copper 
has moved back to g=2.07. 
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Figure 4.46: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
zinc, homocysteine and SAM. The nitrogen splitting has faded, and a half-field signal 
appears to have developed, indicating a possible dimer. Unfortunately, free non-haem 
iron contamination also has appears at approximately g=4.3, leading to the possibility 
that it is not a dimer. 
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Figure 4.47: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
MTHF and SAM. The nitrogen splitting has faded further from 4.45, and a half-field 
signal remains, indicating a possible dimer. Unfortunately, free non-haem iron 
contamination also has appears at approximately g=4.3, leading to the possibility that it 
is not a dimer. 
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Figure 4.48: X-band EPR spectrum of cdMS-bound Co2+ cobalamin in the presence of 
zinc, homocysteine and MTHF. The nitrogen splitting has begun to return from the fade 
in 4.46, while the half-field signal remains, indicating a possible dimerisation. 
Unfortunately, free non-haem iron contamination also has appears at approximately 
g=4.3, leading to the possibility that it is not a dimer. 
 
4.2.22: Identification of FprA as a C. glutamicum-specific ferredoxin 
reductase 
Throughout the purification of ferredoxins A, B and C from expression in E. coli, it 
became apparent that the 2Fe2S FdxB had a redox potential sufficiently similar to other 
adrenodoxin-type 2Fe2S proteins as to be able to be reduced within the cytoplasm of E. 
coli. This was because the protein was always purified in a reduced form. To obtain the 
oxidised form of FdxB it has to be treated with ferricyanide.  
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FdxA and FdxC behaved differently; they purified oxidised and failed to be reduced by 
the reducing agent sodium dithionite (which has a reduction potential of -620mV) but 
are able to be reduced by sodium borohydride (which has a reduction potential of -
800mV). It being unlikely that the potential of C. glutamicum cytoplasm being low 
enough to reduce these extremely electronegative 2[4Fe4S] cluster proteins, there must 
be within the C. glutamicum genome a gene encoding for a ferredoxin reductase capable 
of reducing these 2[4Fe4S] cluster ferredoxins. 
 
FprA_C_Glu      MSRPLRVAVVGAGPAGIYASDLLMKS-----DTDVQIDLFERMPAPFGLIRYGVAPDHPR 55 
FprA_M_tub      -MRPYYIAIVGSGPSAFFAAASLLKAADTTEDLDMAVDMLEMLPTPWGLVRSGVAPDHPK 59 
                  **  :*:**:**:.::*:  *:*:     * *: :*::* :*:*:**:* *******: 
 
FprA_C_Glu      IKGIVKSLHNVMDKEQLRFLGNIEVGKDITVEELREFYDAIVFSTGATGDQDLRVPGSDL 115 
FprA_M_tub      IKSISKQFEKTAEDPRFRFFGNVVVGEHVQPGELSERYDAVIYAVGAQSDRMLNIPGEDL 119 
                **.* *.:.:. :. ::**:**: **:.:   ** * ***::::.** .*: *.:**.** 
 
FprA_C_Glu      EGSWGAGEFVGFYDGNPNFERN-WDLSAEKVAVVGVGNVALDVARILAKTGDELLVTEIP 174 
FprA_M_tub      PGSIAAVDFVGWYNAHPHFEQVSPDLSGARAVVIGNGNVALDVARILLTDPDVLARTDIA 179 
                 ** .* :***:*:.:*:**:   ***. :..*:* *********** .  * *  *:*. 
 
FprA_C_Glu      DNVYESLAKNQAKEVHVFGRRGPAQAKFTPLELKELDHSDTIEVIVNPEDIDYDAASEQA 234 
FprA_M_tub      DHALESLRPRGIQEVVIVGRRGPLQAAFTTLELRELADLDGVDVVIDPAELD-GITDEDA 238 
                *:. ***  .  :** :.***** ** **.***:** . * ::*:::* ::* . :.*:* 
 
FprA_C_Glu      RRDSKSQDLVCQTLESYAMRDPKGAPHKLFIHFFESPVEILGEDGKVVGLKTERTQLDGN 294 
FprA_M_tub      AAVGKVCKQNIKVLRGYADREPRPGHRRMVFRFLTSPIEIKGK-RKVERIVLGRNELVSD 297 
                   .*  .   :.*..** *:*: . :::.::*: **:** *:  **  :   *.:* .: 
 
FprA_C_Glu      G----GVTGTGEFKTWDMQSVYRAVGYRSDAIEGVPFDDERAVVPNDGGHIIDPEVGSPI 350 
FprA_M_tub      GSGRVAAKDTGEREELPAQLVVRSVGYRGVPTPGLPFDDQSGTIPNVGGRIN----GSPN 353 
                *    ....*** :    * * *:****. .  *:****: ..:** **:*     ***  
 
FprA_C_Glu      TGLYATGWIKRGPIGLIGNTKSDAKETTEMLLADHAAGSLPAPAK----PELESIIEFLD 406 
FprA_M_tub      E--YVVGWIKRGPTGVIGTNKKDAQDTVDTLIKNLGNAKEGAECKSFPEDHADQVADWLA 411 
                   *..******* *:**..*.**::*.: *: : . ..  * .*     . :.: ::*  
 
FprA_C_Glu      ERKVAFTTWDGWHLLDAAERALGEPEGRERKKIVEWNDMVRHARPEYDI 455 
FprA_M_tub      ARQPKLVTSAHWQVIDAFERAAGEPHGRPRVKLASLAELLRIGLG---- 456 
                 *:  :.*   *:::** *** ***.** * *:..  :::* .     
Figure 4.49: Alignment of C. glutamicum FprA against M. tuberculosis FprA. 
Sequence identity is 40%. 
 
Because of this, bioinformatics was used to attempt identification of a ferredoxin 
reductase present in C. glutamicum that is not present in the E. coli genome. A 
flavoprotein, FprA (gene number cg3049) annotated as a ferredoxin reductase that 
showed no sequence homology with any E. coli flavoprotein, ferredoxin reductase or 
other gene was determined. This ferredoxin reductase bears reasonably high sequence 
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(Figure 4.49) and (modelled – Figure 4.51) structural similarity to the FprA from 
Mycobacterium tuberculosis (Figure 4.50). Primers for PCR synthesis of this ferredoxin 
reductase were generated, and the gene cloned into a pET-14b vector and sequenced for 
ease of study. 
 
 
Figure 4.50: X-ray crystal structure of Mycobacterium tuberculosis flavoprotein FprA 
(Bossi et al. 2002). PDB accession code: 1LQU. 
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Figure 4.51: SWISS-MODEL of C. glutamicum FprA using default parameters, 
coloured by secondary structure. 
 
4.2.23: Production of FprA 
For overproduction of FprA, E. coli BL21(DE3)pLysS cells were transformed with a 
pET14b construct containing the C. glutamicum FprA gene as described in section 
2.2.6. The resulting strain was grown at 25ºC in Super LB medium supplemented with 
appropriate concentrations of Ampicillin and Chloramphenicol. Once cell density had 
reached an approximate OD600 of 0.6, protein overproduction was induced with the 
addition of IPTG to a final concentration of 0.4mM and the cells left to continue growth 
overnight at 25ºC before harvesting by centrifugation. 
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4.2.24: Purification of FprA 
The harvested cells were lysed by sonication and debris removed by centrifugation. The 
soluble fraction was applied to a column charged with Ni2+ and washed with increasing 
imidazole concentrations as described in 2.1.7.5. During purification of FprA (Fig. 4.52) 
a yellow band could be observed at the top of the resin that progressed towards the 
bottom of the column as the concentration of imidazole was increased until it could be 
eluted from the column in 400mM imidazole. Once eluted, the protein was kept on ice, 
or at 4ºC for overnight storage. If allowed to remain at room temperature for very long, 
some protein would begin to precipitate. If this occurred the precipitated protein was 
easily removed by centrifugation of the protein solution and discarding the resulting 
pellet. The yellow appearance of the protein suggested the presence of a flavin cofactor, 
which was confirmed first by subjecting the eluted protein to UV-visible spectroscopy 
and then HPLC to determine the flavin species. Flavin absorption peaks are found at 
380 nm and 455 nm and this pattern was present in the FprA UV-visible spectrum. 
Although protein measurements indicated that FprA was being purified at a level of 
100mg per millilitre of eluent, the SDS gel of the IMAC purified yellow fraction 
indicated a fair number of other protein bands. Determination of FprA quantity from the 
amount of flavin present indicated approximately 50mg per millilitre of eluent with 
flavin bound. The His-tagged FprA is predicted to have a molecular mass of 52 kDa (50 
+ 2 kDa) and a protein band of around 50 kDa is clearly visible in lanes that contain 
FprA. 
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Figure 4.52: SDS denaturing gel of a His-tagged FprA purification. It is evident that 
despite optimising growth conditions that still moderate quantities of the protein are 
insoluble as they are present in the pellet fraction (lane 2). Lane 1; crude extract, lane 2; 
pellet, lane 3; column flow through, lane 4; binding buffer wash, lane 5; imidazol wash, 
lane 6; elution fraction 1, lane 7; Dalton-7 SDS marker, lane 8; elution fraction 2, lane 
9; elution fraction 3, lane 10; elution fraction 4, lane 11; elution fraction 5, lane 12; 
elution fraction 6, lane 13; elution fraction 7. 
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4.2.25: Western Blotting of FprA 
To confirm that the band of greatest size was FprA it was subjected to Western analysis 
using an anti-His antibody as described in section 2.4.6. This revealed a band of 
approximately 50kDa for FprA (Fig. 4.53). 
 
                                                            
Figure 4.53: 12.5% SDS-PAGE gel (left) of purified FprA and Western blot of an 
identically loaded gel (right). The slightly lopsided and blurry nature of the gel might be 
caused by bubbles while running or a gel not completely uniform in composition. Lane 
1; FprA, lane 2; Dalton VII marker. 
 
4.2.26: Characterisation of FprA 
Having determined that ferredoxins A and C were unable to be reduced by any of the E. 
coli native ferredoxin reductases it became necessary to characterise the identified FprA 
as a candidate C. glutamicum ferredoxin reductase. To this end, determination of the 
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cofactor and the putative ferredoxin reductases ability to reduce a ferredoxin were 
investigated. 
 
FprA was the most particular of the five proteins with initial purifications demonstrating 
the protein eluting from the column with a considerable level of precipitation already 
present under standard conditions of 20mM Tris pH8.0 as the buffer in solutions. The 
protein-bound yellow flavin co-factor (Fig. 4.54) washes out of the binding site easily 
with increasing levels of imidazol. Fortunately FprA, like the ferredoxins, did not bind 
tightly to the nickel-prepared IMAC and so the concentrations of the eluent could be 
decreased. Provided that eluent concentration is not high enough to wash the flavin out 
of the protein, washing of the column could continue for as long as was required to 
remove extraneous bound protein.  
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Figure 4.54: UV/visible spectrum of purified C. glutamicum FprA, demonstrating the 
classic 350nm and 450nm flavin absorption spectrum. 
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4.2.26.1: Flavin determination 
Despite the colour and UV-visible spectrum of FprA being characteristic of a flavin 
cofactor, it is not feasible to distinguish the particular type of bound flavin on the basis 
of this information alone. However, it is possible to separate, and therefore differentiate 
between FMN and FAD by reverse phase HPLC. Flavin was extracted from the protein 
by boiling purified FprA and the precipitated protein was removed by 
microcentrifugation leaving a yellow supernatant. The ease of extraction of the flavin 
from binding with the protein when denatured would imply that it is not covalently 
bound to FprA. The resulting supernatant was then subjected to analysis by RP-HPLC 
using a C-18 column which was developed with an isocratic elution of 25% methanol in 
20mM KH2PO4 at pH 7.5, as described in section 2.4.11.3.  
 
The absorption at 455 nm and fluorescence emission at 525nm were both recorded (as 
described in Section 2.4.11). The retention time and spectral characteristics (i.e. FMN 
has approximately 10-fold higher fluorescence than FAD) of the cofactor extracted from 
FprA were compared to commercial standards of FMN and FAD. Under these 
conditions FAD and FMN eluted with retention times of 3.2 and 4.0 minutes 
respectively. A comparison of retention times identified the flavin as FAD; although 
retention times are not identical to the commercial standards (Fig. 4.55).  
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Figure 4.55: The flavin cofactor was extracted from FprA and analysed by RP-HPLC. 
The retention time was then compared to commercial standards (FMN and FAD) 
revealing the natively bound cofactor to be FAD. 
 
4.2.26.2: Fe3+ reduction by FprA 
As a candidate ferredoxin reductase, FprA would need to be able to reduce FeS clusters 
in those ferredoxins. The ability to reduce iron is a good general indicator of whether a 
candidate ferredoxin reductase has the ability to act as a reductase for FeS cluster 
proteins (Fischer et al. 2002). Ferrozine (4,4'-(3-(2-pyridinyl)-1,2,4-triazine-5,6-
diyl)phenylsulfonic acid) is a ferrous iron chelator used to determine concentration of 
Fe in medical and ecological environments (Davis et al. 1986). It does not react with 
ferric iron (Giokas et al. 2002) and upon chelation of ferrous iron develops a deep 
purple colour with a characteristic UV/Vis peak developing at 562nm (Fig. 4.56). This 
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means that it is a good potential indicator for Fe3+ reduction by FprA (Lin and Kester 
1992; Viollier et al. 2000; Sarradin et al. 2005). 
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Figure 4.56: example UV/Vis spectrum of Fe2+ reaction with ferrozine showing the 
development of a distinct peak at 562nm. Fe3+ does not react with ferrozine, leaving the 
spectrum unaltered from baseline. The presence of EDTA has no effect on the intensity 
of the peak at 562nm. 
 
The above spectrum (Fig. 4.56) shows an example titration of Fe2+ with ferrozine, with 
the ferrozine being at a concentration of 10µM while 1µM Fe2+ was titrated in 10µl 
volumes to a final concentration of 100nM. Ferrozine binds Fe2+ at a ratio of 3:1 (Huang 
et al. 2003). This can be used to determine the amount of Fe2+ generated from Fe3+ by 
FprA. For Fe3+ reduction assays, concentration of added ferrozine was 10µM, Fe3+ 
concentration was 10µM, free flavin was 2µM and NADPH concentration was 50µM. 
While NADPH facilitated increase reduction of Fe3+, NADH did not, even when in 
large excess leading to the conclusion that FprA is an NADPH dependent reductase. 
FprA was added to a concentration of 60nM. After 30 minutes incubation at 25ºC, the 
control (flavin, NADPH, no enzyme) had generated 30nM of Fe2+, while FprA had 
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generated 75nM Fe2+ (Fig. 4.57). The rate of reduction of Fe3+ by free flavin or by FprA 
is not great, although after a period of 30 minutes when protein is present the curve had 
levelled off. FprA apoenzyme yields no active Fe reduction properties. Given the rate of 
ferric reduction in this assay (25mM(min)-1(mol FAD)-1) determination of ferric 
reduction needs to be confirmed by ferricyanide and/or DPIP assay. 
 
Figure 4.57: Initial kinetics of Fe3+ reduction to Fe2+ by C. glutamicum FprA to 
demonstrate that the protein has Fe reduction ability at a greater rate than free flavin. 
The rate difference during the first two minutes in the no enzyme control reaction is 
attributed to insufficient mixing of the reaction mixture. Concentration of all assay 
constituents was maintained. 
 
4.2.26.3: Redox titrations 
Flavin cofactors are incredibly versatile mediators of redox reactions due to the 
availability of three different redox states, as described in section 1.4.1. This allows 
flavin coenzymes to participate in both one-electron and two-electron transfer reactions. 
The fully oxidised flavin (quinone) is converted to a semiquinone by a one-electron 
transfer. The semiquinone can exist in one of two states depending on the pH and the 
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effect of the protein environment on the isoalloxazine ring. A second electron transfer 
converts the semiquinone in to the completely reduced (hydroquinone) form. 
Alternately, the transition between quinone and hydroquinone can be promoted directly 
with the transfer of two-electrons. 
 
Collecting redox titration data of FprA proved to be more challenging than anticipated 
due to the temperature and buffer sensitivity of FprA. The volume of 30µM FprA was 
1ml, with 2µl of 0.5mM sodium dithionite added at each step of the titrations. With 
initial tests, a rapid titration (Fig. 4.58) provided only a few of the intermediate steps 
between oxidised flavin and fully reduced flavin, but slowing the titration down only 
meant that the protein started to precipitate (Fig. 4.59) without reducing.  
 
A flavin semiquinone can exist in one of two forms, either protonated (neutral or blue 
semiquinone) or monodeprotonated (anionic or red semiquinone). These radical species 
are easily distinguishable by their characteristic spectra. A red semiquinone can be 
identified from a strong absorbance around 370 nm whereas a blue semiquinone has a 
distinctive long wavelength absorbance around 580-620 nm. From Figure 4.58 it can be 
determined that there appears to be no flavin semiquinone generation – absolutely no 
increase in flavin absorption above 500nm throughout the reduction titration – which 
was confirmed by EPR. Carrying out the titration with NADH, which is not the natural 
electron donor for FprA yielded no reduction unless in significant (>30 times) excess. 
Titrations with NADPH at 4ºC in an attempt to prevent the protein from precipitating 
failed to indicate reduction was occurring (Fig. 4.60). However, when FprA is used to 
reduce Fe3+ (section 4.8.2) NADPH works well as an electron donor, so this may 
potentially be FprA not favouring a reduced state when no substrate is present for 
reduction by FprA.  
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Figure 4.58: Sodium dithionite redox titration of C. glutamicum flavoprotein FprA, 
flavin concentration 30µM showing no development of a semiquinone state during 
reduction. This titration was carried out rapidly, to avoid protein precipitating.  
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Figure 4.59: Sodium dithionite redox titration of C. glutamicum flavoprotein FprA 
(flavin concentration 32µM) showing the whole spectrum shifting up as the protein 
precipitates due to temperature sensitivity or possibly the addition of dithionite. 
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Figure 4.60: NADPH redox titration of C. glutamicum FprA at 4ºC. There is some 
upward shift of the whole spectrum over time again, which would indicate that FprA is 
beginning to precipitate. Each step of the reaction was measured four minutes after 
addition of 1mM NADPH (to a final assay concentration of 1µM per step addition) and 
inversion mixing. 
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4.2.26.4: EPR of FprA 
The possibility of FprA forming a single-electron semiquinone was investigated by EPR 
with both sodium dithionite and NADPH, the natural substrate of FprA. Despite there 
being no obvious colour or spectral shift aside from the normal discolouration of the 
flavin from yellow to colourless upon reduction (indicating a semiquinone intermediate 
state) it may have been possible that there was a very small quantity of semiquinone 
present in the solution to be detected by EPR. No semiquinone was in evidence when 
FprA was reduced either by dithionite or by NADPH by colouration of by EPR 
spectrum (Fig. 4.61).  
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Figure 4.61: X-band EPR spectrum of the oxidised, sodium dithionite reduced or 
NADPH reduced C. glutamicum ferredoxin reductase FprA. It is effectively noise from 
the electronics and the cavity producing the fluctuations; fully oxidised or reduced 
flavins are EPR silent. 
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4.3: Discussion 
In this chapter, the identification and characterisation of the potential components of C. 
glutamicum cobalamin-dependent methionine synthase reactivation system has been 
presented. Previous investigations into cdMS and reactivation systems have always 
focussed on the system of E. coli. This study was able to clone, express and purify the 
C. glutamicum cdMS, its candidate reactivation factors and the ferredoxin reductase 
capable of reducing these ferredoxins after the last was identified by bioinformatics.  
 
The nature of the ferredoxins was confirmed by sequence analysis, modelling and 
studied by UV/visible spectrophotometry and EPR. Attempts to identify the ferredoxins 
by peptide mass fingerprinting resulted in inaccurate results that were duplicated when 
carried out in silico. Each ferredoxin was modelled based on database-determined 
matches which resulted in modelling FdxA against P. aeruginosa ferredoxin 1, FdxB 
against R. capsulatus ferredoxin 6 chain A, and FdxC against M. smegmatis ferredoxin 
A. By EPR, ferredoxins A and C were confirmed to be 2[4Fe4S] cluster ferredoxins, 
while FdxB was confirmed to be a 2Fe2S ferredoxin.  
 
Single knockout mutants of the ferredoxins to shed further light on their FeS cluster 
characteristics confirmed the linked nature of the twinned clusters in ferredoxins A and 
C, and that all five cysteine residues appear to be essential for proper cluster formation 
in FdxB. Double residue knockouts were unsuccessful as the plasmids would not 
transform.  
 
Both FdxA and FdxC run on a denaturing gel at approximately 20-22kDa. Upon 
investigation (Guerrini et al. 2008) it was determined that small proteins with high 
numbers of acidic amino acid residues run ‘high’ on SDS gels. The acidic pI exhibited 
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by all three ferredoxins (but to varying degrees) means the protein runs ‘high’ on 
denaturing SDS-PAGE (Andrews 1986; Shi 1998; Garfin 2003) equivalent of a protein 
approximately 50% larger than the molecular weight would indicate.  
 
Modelling the FdxB protein structure using SWISS-MODEL (Schwede et al. 2003) 
(using default settings) displays an almost identical structure to that of the R. capsulatus 
ferredoxin 6 chain A, which highlights the fact that the C82 residue is not located near 
the pocket the other four surround. When examining the model of FdxB (Fig. 4.11) it 
would be reasonable to think that loss of any of the coordinating cysteine residues (C40, 
C46, C49 or C87) would result in loss of 2Fe2S signal from the EPR spectrum while the 
loss of the distant C82 residue would have little to no impact. As can be seen in the 
knockout spectra, this is not the case: loss of any of the cysteine residues from FdxB 
results in loss of the 2Fe2S cluster. Dependence of the cluster stability on the four 
coordinating cysteine residues is understandable as a 2Fe2S cluster has two cysteine 
residues orienting each iron atom – lose one of these coordination points and the iron 
will likely ‘fall out’ of ligation with the protein, closely followed by the two sulphur 
atoms. It is possible the second iron would remain ligated by two cysteine residues but 
that would result in a non-haem iron site. It is not known why loss of the C82 residue 
affects the 2Fe2S cluster, but it is obvious that it plays a role in protein structure if 
knocking it out results in the loss of a cofactor on the opposite side of the protein.  
 
The monomeric nature of FdxC was confirmed by ion-spray mass spectrometry. The 
haem-like peak visible in the FdxC UV/visible spectrum may be due to low levels of 
haem contamination. Haem possesses an extinction coefficient that makes it far more 
evident in UV/visible spectrophotometry than FeS clusters, so even miniscule levels of 
contamination have a great effect. The lack of haem evident in the EPR spectrometry 
Chapter 4 
 - 210 - 
would support this conclusion. Knocking out a single cysteine residue from FdxA or 
FdxC appears to shift the midpoint reduction potential to a point where sodium 
dithionite (which is unable to reduce the wild-type enzyme) can act as a reducing agent. 
It does not appear to alter the environment of the clusters, as would be evidenced by 
changes in the splitting between the two clusters. In those cases where splitting is lost, it 
is likely caused by loss of the second 4Fe4S cluster, rather than having both clusters in 
an identical environment.  
 
All of the knockouts have a decreased signal intensity compared to the wild-type 
enzyme, but this is likely due to an already moderately unstable protein losing one of 
the points holding the FeS clusters together. Comparison of the modelled ferredoxins 
and the mutant EPR spectra yields some interesting links. For FdxA, those cysteine 
residues that are present within, or near, secondary protein structure fail to have 
significant impact on the FeS signal when mutated. Those cysteines (C17, C40 and 
C43) which do cause the loss of most (if not all) of the FeS signal when mutated are 
found in areas of flexible protein with no secondary structure giving the protein 
additional stability. This can be directly compared to the FdxC mutants, where some 
exhibit decreased FeS signal but it is not eliminated. Comparing the modelled structure 
of FdxC to the EPR results obtained from the mutants demonstrates a protein where 
more of the cysteine residues are within or near secondary structure. This secondary 
structure evidently provides significant structural support to damaged clusters. 
 
C. glutamicum flavoprotein A (FprA) has significant sequence similarity to the 
Mycobacterium tuberculosis FprA (Fischer et al. 2002). This is not unsurprising given 
the close phylogenetic relationship that Corynebacterium and Mycobacterium share. It 
was hypothesised that the ease of extraction of the flavin from FprA was due to a 
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mutation – aspartate 255 to asparagine. Aspartate and asparagine are both polar amino 
acids with the same hydropathy index of -3.5 (Kyte and Doolittle 1982) while aspartate 
is negatively charged at pH7 while asparagine is neutral. A second PCR reaction from 
genomic DNA yielded the same mutation and the conclusion was reached that the wild 
type bacterium being worked on had a base change at that residue, or that the database 
was incorrect. Mutagenesis was performed to change the D255N mutation to database 
consensus, but the resulting plasmid did not allow growth of the transformed E. coli 
XL-1 Blue supercompetent strain. The toxicity of this aspartate 255 mutant to the cell 
might potentially be the reason for the D255N mutation.  
 
The cofactor of the ferredoxin reductase was resolved by HPLC analysis and the flavin 
was confirmed to be non-covalently bound FAD. If FprA is capable of being the 
electron-donating enzyme for reduction of 2[4Fe4S] cluster ferredoxins, it would thus 
likely need to donate two electrons (one to each 4Fe4S cluster) during each reduction. It 
was determined by redox titration that the ferredoxin reductase does not form a flavin 
semiquinone during transition from an oxidised to reduced state and this was confirmed 
by EPR. During Fe3+ reduction experiments it was determined that FprA was NADPH 
dependent, and unable to utilise NADH for reduction.  
 
The recombinant C. glutamicum cobalamin-dependent methionine synthase purifies as 
apoenzyme, so it allowed many studies of cofactor binding for the enzyme. While 
studies of fragments of cdMS have the potential to allow insight to the behaviour of the 
protein, the lack of the ability to study domains 3 and 4 of cdMS (cobalamin binding 
and reactivation domains respectively) alone does not impact this study in a negative 
fashion. Any data obtained with fragmentary cdMS would have to be verified with the 
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full length protein as the fragments would never be found functional in nature – the 
protein would always be complete, unless it was being digested by proteases.  
 
The most important step of characterising the C. glutamicum cdMS is investigating the 
nature of the binding of cobalamin. Potentially, the binding of cobalamin to a protein 
would create shifts in the observed spectra, be it UV/Vis or EPR, obtained compared to 
free cobalamin. As the presence of an upper axial ligand (methyl, adenosyl, hydroxyl, 
cyano…) alters the spectrum of cobalamin, so too does the presence or loss of a lower 
axial ligand, which in free cobalamin is the dimethylbenzimadazole (DMB) ‘tail’. In 
cdMS bound cobalamin, this DMB lower axial ligand is replaced with a histidine 
ligand. In E. coli cdMS, the spectrum of the bound cobalamin alters based on whether 
this histidine ligand is ‘base-off’ or ‘base-on’ in conformation. Unless studying the fully 
active form of the C. glutamicum enzyme during turnover, the full length cdMS remains 
stubbornly in ‘base on’ conformation. It was confirmed that the recombinant C. 
glutamicum cdMS is able to bind cobalamin when expressed in E. coli.  
 
Experimental data from cdMS shows that the full length protein does not behave in the 
same manner as truncated cdMS proteins from E. coli in either temperature sensitivity, 
or cobalamin binding. The binding of the cobalamin cofactor to C. glutamicum 
cobalamin-dependent Methionine Synthase is not accompanied by a significant 
alteration in the obtained UV/Vis spectrum of the cofactor in the way that the binding of 
some other protein-cofactor associations such as the DNA methyltransferase M.Hha1 
(Zhou et al. 2007) or the alterations in UV/Visible spectrum obtained from fragmented 
E. coli cdMS (Datta et al. 2008) when subjected to alterations in the environment.  
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The full length C. glutamicum cdMS shows none of the temperature related spectral 
alterations that are evident with the truncated domain 3+4 E. coli cdMS (Bandarian et 
al. 2003; Datta et al. 2008) with methylcobalamin bound. It is possible, given a domain 
3+4 construct of C. glutamicum cdMS that these spectral changes exhibited by the E. 
coli enzyme would be duplicated. As natively the protein is never going to be found in 
an active form with just domains 3+4, lacking 1+2, any data obtained from fragments 
would have to match data obtained from the full length enzyme before it was fully 
accurate. As there is no spectral shift in the full length enzyme, it makes this point 
rather moot. 
 
As a methyl-transferase, the whole purpose of cdMS is to facilitate the transfer of a 
methyl group from a donor molecule to a recipient – in this case, methyltetrahydrofolate 
and homocysteine respectively to generate methionine. For this reason, time-dependent 
methylcobalamin breakdown assays were attempted. Methyl-group donation 
experiments demonstrate that the presence of cdMS significantly increase the rate at 
which methylcobalamin donates the Co upper axial ligand methyl group. The 23% 
increase in methyl donation is from methylcobalamin to free solution rather than to the 
natural substrate of this methyltransferase, homocysteine, so it is possible that methyl-
group donation would further increase in rate if homocysteine was present.  
 
As the multi-domain cdMS is highly flexible by its very nature, all of the cofactors and 
substrates have the potential for contact within normal turnover or during reactivation of 
the derailed protein. By UV/Visible spectrophotometry, the cobalamin spectrum 
dominates cdMS as soon as it is present. Via EPR, more subtle interactions, particularly 
around the cobalamin binding domain and site were examined. As the cobalamin 
binding domain is arguably the ‘focal point’ of the enzyme, where transfer of the methyl 
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group occurs at each step EPR investigations into effects of cofactor binding on Co2+ 
cobalamin signal were used. These demonstrated a distinct lack of conformational 
movement – at least where the environment of the cobalamin was concerned – in most 
cofactor and substrate possibilities. The exception to this rule was in the presence of 
zinc (fully holoenzyme cdMS) which shifted the cobalamin signal from a ‘base on’ 
conformation to a ‘base off’ conformation, a rare four-coordinate intermediate that 
appears to be the catalyst for methyl group transfer to the corrin-ring ligated cobalt.  
 
Some particularly interesting interactions between the cofactors and substrates have 
been made evident by this. The work present in this chapter provides insight into the 
enzymes involved in reactivation of C. glutamicum cdMS. It is clear that much more 
work needs to be done to fully understand each of these enzymes and the reactions they 
catalyse. 
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5: Reactivation of the C. glutamicum cobalamin-dependent 
Methionine Synthase 
5.1: Introduction 
The biologically active forms of cobalamin (two of which are adenosylcobalamin and 
methylcobalamin) are frequently used by enzymes as cofactors or coenzymes in 
complex rearrangement and methylation reactions (Banerjee and Ragsdale 2003). One 
of these is the final step of methionine biosynthesis with the cdMS.  
 
The catalytic properties of the cobalamin cofactors arise from the nature of the cobalt-
carbon bond formed with the upper axial ligand. Attaching an adenosyl or methyl group 
to the central cobalt ion of cobalamin requires enzymatic reduction of the cobalt to 
Co1+. This reduction is carried out by a redox protein to facilitate the transfer of the 
adenosyl group from ATP by an adenosyltransferase such as CobA or PduO. The same 
reduction occurs to allow a methyl group from a donor such as SAM to be transferred, 
in the case of cdMS.  
 
During biosynthesis of cobalamin, this reduction is carried out by CobR. Neither E. coli 
nor C. glutamicum have the ability to synthesise cobalamin de novo although both 
possess salvage pathways to reuse cobinamide and later intermediates (Lawrence and 
Roth 1995; Rodionov et al. 2003). The CobR enzyme bears no structural similarity to 
cobalamin-dependent Methionine Synthase or its reductase, but during reactivation the 
cobalamin bound to cdMS undergoes the same Co2+ to Co1+ reduction that the substrate 
of CobR experiences, hence the comparison.  
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Although an enzyme has been purified from Pseudomonas denitrificans with 
cob(II)alamin to cob(I)alamin activity (Blanche et al. 1992), it was only recently that the 
enzyme was characterised at the genetic level in Brucella melitensis (Blanche et al. 
1992; Lawrence et al. 2008). A detailed characterisation revealed that the protein is an 
NADH-dependent flavoenzyme. CobR has a wide substrate specificity and is able to 
reduce a number of corrin based substrates from Co2+ to Co1+ by single electron 
reduction (Lawrence et al. 2008). The ability to perform the reaction is intriguing due to 
the energetically unfavourable nature of the cob(II)alamin to cob(I)alamin transition, 
which exhibits a reduction potential of -610 mV (Lexa et al. 1977; Banerjee et al. 1990). 
In E. coli cdMS holoenzyme this same cobalt reduction is carried out by a flavodoxin 
acting in the role of methionine synthase reductase (MSR)(Hall et al. 2000). It has been 
demonstrated (Olteanu and Banerjee 2001; Leal et al. 2004; Wolthers and Scrutton 
2004; Yamada et al. 2006) that the same happens in human cdMS.  
 
This remains a fascinating biochemical step as CobR, E. coli flavodoxin and human 
MSR all carry out an energetically unfavourable reaction. So long as the reduction 
potentials of the two enzymes overlap at some point in their reduction curve, it is still 
possible for electron transition to occur in the requisite direction. This leads to a 
question of the methodology used by these enzymes – in these systems, could there be 
distortion of the corrin ring to make the reaction more favourable? In the C. glutamicum 
system this question does not arise in the same fashion: C. glutamicum does not possess 
a flavoenzyme able to act in a homologous fashion to the E. coli or Homo sapiens MSR. 
Thus the use of a ferredoxin able to act as MSR was proposed. The aim of this chapter 
was to study the C. glutamicum cdMS and its interactions with its potential 
physiological partners and any reactivation that may occur. 
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5.2: Results 
5.2.1: In vivo experiments with metH, fdxA, fdxB, fdxC and fprA in a 
methionine-auxotrophic strain of E. coli 
Recombinant expression of C. glutamicum cdMS in E. coli fails to yield active protein 
when purified. Utilising a ∆metH ∆metE MTD23 E. coli strain kindly provided by 
Rowena Matthews, in vivo complementation of C. glutamicum cdMS was attempted. 
This allowed for verification that no E. coli enzyme could play the role of C. 
glutamicum MSR. Further, co-expression of the C. glutamicum cdMS with the 
candidate reactivation factors would shed some light on whether they could act in the 
role of MSR. Competent cells of strain MTD23 were generated as described in section 
2.2.5. These competent cells were transformed with separate E. coli vectors containing 
metH and a single fdx gene as described in 2.2.6. The transformed cells were grown on 
LB agar in the presence of ampicillin and chloramphenicol, as described in 2.2.3. A 
single colony was streaked onto M9 minimal media plates supplemented with B12 and 
trace element solution and left to incubate at 37ºC and 30ºC. A positive control strain 
(metE/metH functional) grew on these plates. 
 
In vivo complementation performed before the identification of FprA as this requisite 
ferredoxin reductase failed to yield any positive identification of the MSR from the 
candidates. When carried out by BASF, their ∆metE ∆metH strain of E. coli (the 
specifics as to genotype and phenotype were not revealed) displayed growth when 
transformed with C. glutamicum cdMS and FdxC, but only at 30ºC when left for 
significant lengths of time – in excess of five days. After 24 hours, confidence in the 
effectiveness of strain and plasmid selective antibiotics will greatly decrease. 
Attempting to duplicate the results described by BASF using the MTD23 double 
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knockout strain was unsuccessful. Irrespective of the constructs used, the MTD23 strain 
failed to grow without the presence of methionine (Table 5.1). Addition of 1µM 
methionine to the M9 plates allowed growth. Attempts to perform the recombinant 
complementation using a three-enzyme system of cdMS, candidate MSR and FprA 
would not transform into MTD23 competent cells. The use of electroporation to 
transform MTD23 cells with this plasmid yielded the same results. 
Strain Grows without methionine Growth with methionine 
MTD23 No Yes 
MTD23 pmetH 
(constitutive) pfdxA 
No Yes 
MTD23 pmetH 
(constitutive)  pfdxB 
No Yes 
MTD23 pmetH 
(constitutive) pfdxC 
No Yes 
MTD23 pmetH (inducible) 
pfdxA 
No Yes 
MTD23 pmetH (inducible) 
pfdxB 
No Yes 
MTD23 pmetH (inducible) 
pfdxC 
No Yes 
MTD23 pmetH/fprA pfdxA Will not transform Will not transform 
MTD23 pmetH/fprA pfdxB Will not transform Will not transform 
MTD23 pmetH/fprA pfdxC Will not transform Will not transform 
Table 5.1: summary of in vivo growth experiments. In the presence of methionine, the 
transformed strains would grow. Without methionine, they would not. 
 
5.2.2: cdMS assay of purified recombinant cdMS 
As in vivo complementation of C. glutamicum cdMS did not lead to demonstrable 
activity, reactivation was studied in vitro. The first step of this was to determine 
whether recombinantly expressed apoenzyme cdMS could be recovered to full activity.  
 
As previously discussed in chapter three, the methionine synthase assay developed by 
Drummond (Drummond et al. 1995) and refined by Jarrett (Jarrett et al. 1997) is not 
very sensitive as it relies on reading a change in absorption at 350nm – a wavelength 
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where several other biological compounds absorb. These include NADPH, all forms of 
cobalamin but particularly Co(III)alamin, flavins and iron-sulphur centres. Recombinant 
C. glutamicum cdMS produced as previously described and assayed before and after 
purification, then twice after a period of reconstitution (2 minutes and 10 minutes) with 
20µM methylcobalamin and zinc (Table 5.2). This reconstitution was carried out at 
pH6.8, as this aided zinc solubility without affecting protein stability too adversely. 
Prior to purification, the recombinant cdMS displayed activity (although not as elevated 
as in the native bacterium). After purification, cdMS was inactive; reconstitution 
returned activity to the recombinant cdMS after 10 minutes. An initial test of activity 
was carried out shortly after reconstitution of the protein began, after 2 minutes, which 
revealed much activity was already demonstrable (Table 5.2). 
 
From the corrected A350 values, activity of the cdMS before purification, after 
purification and after purification and reconstitution can be determined: 
Sample A350Corrected [cdMS] (µM) Specific activity 
(nmol/min) ± Std. 
Dev. 
Blank 0.000 0 0 ± 0.0009 
cdMS Crude 0.1668 - 0.629 ± 0.01 
cdMS Purified 0.012 0.8 0.04 ± 0.004 
cdMS reconst. (2min) 0.139 0.6 0.525 ± 0.006 
cdMS reconst. (10min)  0.164 0.6 0.619 ± 0.007 
Table 5.2: Activity of cdMS before purification, after purification and after 
reconstitution with methylcobalamin and zinc. cdMS assay of protein expressed from 
pRBS21 demonstrating that before purification there is cdMS activity in the crude 
extract and that after purification activity is lost. Upon incubation with 20µM 
methylcobalamin and 20µM zinc, activity is returned to the recombinant protein if 
assayed. 
 
From this, it can be seen that cdMS activity can be restored to purified protein. 
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5.2.3: Reactivation studies 
As the purpose of interaction of cdMS with an MSR is to restore activity to derailed 
cdMS and that the presence of bound methylcobalamin means cdMS is active, then 
determining the generation of methylcobalamin would indicate reactivation has 
occurred. Derailed cdMS possesses cobalamin in its Co2+ state, while during turnover 
the cobalamin is either methylated (Co3+ state) or prepared for methylation (short term 
highly reactive Co1+ state). Also, therefore, the loss of a Co2+ signal (in UV/visible 
spectrophotometry or EPR) would indicate the same reactivation.  
 
Thus, studying the reactivation of C. glutamicum cdMS is considerably simpler than 
watching full turnover of the enzyme, as the first (homocysteine) binding domain can be 
left empty. This allows focussing on the third and fourth domains of cdMS, the 
cobalamin binding domain and the reactivation domain, respectively.  
 
For deactivated cdMS to be reactivated, it requires two things; an electron source to 
reduce the Co2+ cobalamin, and a methyl source (SAM). It does not need the 
homocysteine-orienting zinc cofactor present. If one of the candidate ferredoxins is the 
C. glutamicum MSR, then reactivation will occur. The source of electrons for MSR 
would be NADPH, via the ferredoxin reductase FprA.  
 
On paper, examination of reactivation has several possible avenues of investigation – 
UV/visible spectrophotometry, HPLC-MS, HPLC-MS/MS and EPR. Each method 
attempts to take advantage of particular characteristics of the different states of 
cobalamin. 
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5.2.3.1: UV/Vis spectrophotometry of in vitro reactivation 
Attempting to follow cdMS reactivation via UV/Visible spectrophotometry was 
justified based upon the spectral alterations (Fig. 5.1) of cobalamin as Co2+ cobalamin is 
reduced to Co1+ cobalamin and then methylated to form Co3+ methylcobalamin. The 
Co1+ state is an extremely reactive supernucleophile and thus is short-lived and 
impossible to see via UV/Vis assays. C. glutamicum cdMS was purified and 
reconstituted with Co2+ cobalamin in an anaerobic environment and provided with 1:1 
quantities of FprA, SAM, NADPH and a 1:0.2 quantity of candidate ferredoxin. This 
limitation of ferredoxin was done in order to slow reactivation moderately so that it 
could be observed over time. 
 
Figure 5.1: UV/Visible spectrum of Co2+ and Co3+ cobalamin. The black arrow 
indicates the shift that theoretically would be observed by reactivation of methionine 
synthase occurring in the assay reaction. The blue arrow indicates the effect of a blue 
shift of the Co3+ cobalamin signal caused by the ‘base off’ conformation of cdMS. In 
the Co3+ state, the cobalamin has a hydroxyl upper axial ligand. The UV/Visible 
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spectrum of methylcobalamin can be seen in Chapter 4, Fig. 4.38, and bears significant 
differences to the hydroxycobalamin form. 
 
The UV/visible reactivation assay showed no change in spectral signature for FdxA 
(Fig. 5.2) aside from protein precipitation. There was no spectral change at all for FdxB, 
which remained consistent (Fig. 5.3). With FdxC present (Fig. 5.4) the spectrum did 
alter – at 450nm there was a decrease in absorbance while at 550nm there was an 
increase in absorbance, with an isosbestic point at 495nm, indicating that there was 
some shift of the cobalamin from Co2+ state to Co3+ (methylated) state. Increasing the 
amount of ferredoxin did not allow the reaction to continue further. 
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Figure 5.2: UV/Visible spectrum of attempted C. glutamicum cdMS reactivation. 
Contained within this assay mix; 10µM cdMS (with Co2+ cobalamin bound), 10µM 
SAM, 10µM NADPH, 10µM FprA and 2µM of FdxA. While there is some increase, it 
is evenly spread and not particularly marked, which would imply that it is not 
reactivation occurring and is in fact the protein beginning to precipitate. FdxB behaves 
in the same manner as FdxA. 
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Figure 5.3: UV/Visible spectrum of attempted C. glutamicum cdMS reactivation. 
Contained within this assay mix; 10µM cdMS (with Co2+ cobalamin bound), 10µM 
SAM, 10µM NADPH, 10µM FprA and 2µM of FdxB. 
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Figure 5.4: UV/Visible spectrum of C. glutamicum cdMS reactivation. Contained 
within this assay mix; 10µM cdMS (with Co2+ cobalamin bound), 10µM SAM, 10µM 
NADPH, 10µM FprA and 2µM of FdxC. There is a decrease of absorbance at 
wavelengths from 425-490nm, with may be indicative of decreasing Co2+ cobalamin, 
along with a slight increase in absorbance  above 500nm, which could also be indicative 
of increasing methylcobalamin levels. 
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5.2.3.2: HPLC-MS of in vitro reactivation 
Different cobalamin species can be differentiated by observing their HPLC retention 
times. HPLC mass spectrometry (HPLC-MS) was used to determine cobalamin 
presence and type from assays incubated for 10 minutes to see if methylcobalamin 
would be generated by any of these ferredoxins acting as MSR. Assays were carried out 
in an anaerobic environment but run by HPLC aerobically as described in section 
2.4.11.2. Due to this exposure to air, any Co2+ cobalamin that had not been methylated 
would form hydroxycobalamin.  
 
Each assay sample was injected onto an Ace 5 AQ column (2.1 x 150 mm, 5 µm, 
Advanced Chromatography Technologies) that was attached to an Agilent 1100 series 
HPLC coupled to a micrOTOF-Q (Bruker) mass spectrometer and equipped with online 
diode array and fluorescence detectors and run at a flow rate of 0.2 ml/min. For the 
purposes of the HPLC-MS assay, absorbance was measured at 525nm to follow the 
elution of cobalamin. Hydroxycobalamin elutes at 8.8 minutes while methylcobalamin 
elutes at 20.1 minutes (Fig. 5.5). 
 
Figure 5.5: UV/Visible 525nm trace showing methylcobalamin generated by 
reactivation of C. glutamicum cdMS with CoII cobalamin bound, with FprA, NADPH, 
FdxC and SAM (all present at 10µM). The methylcobalamin retention peak is marked 
with an arrow. 
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While a peak at 20.1 minutes is visible, it was decided that further study was required to 
make completely certain that this was methylcobalamin that was being generated. 
Ferredoxins A and B, or incomplete reactivation mixes (that do not include one or more 
components) do not generate this methylcobalamin peak. 
 
5.2.3.3: HPLC MS/MS of in vitro activation 
HPLC-MS/MS allows a mass spectrum of a peak in the HPLC elution profile to be 
obtained and examined. This should allow true determination of methylcobalamin 
generation to further clarify whether reactivation is occurring. The assay was built up 
one step at a time, thus allowing the determination of whether this reactivation can 
occur when not all of the components are present. HPLC mass spectrometry mass 
spectrometry (HPLC-MS/MS) was used to determine cobalamin presence and type 
more conclusively than HPLC-MS from assays incubated for 10 minutes to see if 
methylcobalamin would be generated by any of these ferredoxins acting as MSR. 
Assays were carried out in an anaerobic environment but run by HPLC aerobically as 
described in section 2.4.11.2. Due to this exposure to air, any Co2+ cobalamin that had 
not been methylated would form hydroxycobalamin.  
 
Each sample was injected onto an Ace 5 AQ column (2.1 x 150 mm, 5 µm, Advanced 
Chromatography Technologies) attached to an Agilent 1100 series HPLC with an inline 
micrOTOF-Q (Bruker) mass spectrometer and equipped with online diode array and 
fluorescence detectors and run at a flow rate of 0.2 ml/min. For the HPLC-MS/MS 
assay, absorbance was measured at 525nm to follow the elution of cobalamin. The 
methylcobalamin standard (Fig. 5.6) illustrates the ‘optimum’ methylcobalamin mass 
spectrum which gives the peaks generated by methylcobalamin. The reactivation assay 
with FdxA present as candidate MSR (Fig. 5.7) generated low levels of 
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methylcobalamin, with FdxB (Fig. 5.8) generating less than half that. With FdxC, 
methylcobalamin generation is much higher (Fig. 5.9) while when the mass spectrum is 
averaged off of the retention time of methylcobalamin (Fig. 5.10) there is no 
methylcobalamin in the spectrum. This ‘off retention’ spectrum was to verify that there 
was no methylcobalamin signal elsewhere in the elution. 
 
Figure 5.6: from top to bottom; Total Ion Chromatogram, UV/Vis Chromatogram (200-
800nm) and Mass Spectrum of methyl-cobalamin standard used for determination of 
retention time MS/MS spectrum. Mass spectrum averaged from retention period 19.4-
20.1 minutes. 
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Figure 5.7: from top to bottom; Total Ion Chromatogram, UV/Vis Chromatogram (200-
800nm) and Mass Spectrum of a reactivation assay containing C. glutamicum cdMS 
with bound CoII cobalamin, SAM, FdxA, FprA and NADPH. Mass spectrum averaged 
from retention period 19.4-20.1 minutes. The red star indicates the methylcobalamin 
peak where the spectrum was averaged. 
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Figure 5.8: from top to bottom; Total Ion Chromatogram, UV/Vis Chromatogram (200-
800nm) and Mass Spectrum of a reactivation assay containing C. glutamicum cdMS 
with bound CoII cobalamin, SAM, FdxB, FprA and NADPH. Mass spectrum averaged 
from retention period 19.4-20.1 minutes. The red star indicates the methylcobalamin 
peak where the spectrum was averaged. 
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Figure 5.9: from top to bottom; Total Ion Chromatogram, UV/Vis Chromatogram (200-
800nm) and Mass Spectrum of a reactivation assay containing C. glutamicum cdMS 
with bound CoII cobalamin, SAM, FdxC, FprA and NADPH. Mass spectrum averaged 
from retention period 19.4-20.1 minutes. The red star indicates the methylcobalamin 
peak where the spectrum was averaged. 
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Figure 5.10: from top to bottom; Total Ion Chromatogram, UV/Vis Chromatogram 
(200-800nm) and Mass Spectrum of a reactivation assay containing C. glutamicum 
cdMS with bound CoII cobalamin, SAM, FdxC, FprA and NADPH. Mass spectrum 
averaged from ‘off sample’ area of the period 14-15 minutes to demonstrate that there is 
no methyl-cobalamin signal outside of the peak at 19.4-20.1 minutes. The red star 
indicates where the spectrum was averaged, off the methylcobalamin peak. 
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5.2.3.4: EPR of in vitro reactivation 
The final method of studying reactivation of cdMS is electron paramagnetic resonance. 
This was justified based on the idea that Co2+ cobalamin is the only state of cobalamin 
that possesses an unpaired electron and therefore allows EPR visualisation. The 
hypothesis was that the Co2+ cobalamin signal would either reduce or disappear entirely 
as the cdMS-bound Co2+ cobalamin was reduced to Co1+ then methylated by SAM to 
form methylcobalamin. The concentrations of sample constituents were maintained 
across samples by adding water in place of a particular component in those samples 
where the component was not required. Spectra were recorded as detailed in Section 
2.4.12.4. Concentration of all components was 12µM. 
 
Using EPR to examine reductive reactivation of cdMS is focussed on the Co2+ signal 
centred at g=2.25. As reactivation occurs the Co2+ signal decreases due to reduction to 
Co1+ followed by methylation by SAM to form methylcobalamin. For all three EPR 
reactivation studies, the red spectrum contains holoenzyme cdMS, SAM, NADPH and a 
candidate ferredoxin. The blue spectrum contains holoenzyme cdMS, SAM, NADPH 
and FprA. The green trace contains holoenzyme cdMS, SAM, NADPH, FprA and a 
candidate ferredoxin. With all three, the presence of a ferredoxin when lacking a 
reductase results in no signal decrease. When both a ferredoxin and reductase are 
present, the Co2+ signal intensity drops. This decrease is greatest with FdxC, which has 
a signal decrease of 25% (Fig. 5.13). In comparison, the intensity of the signal from the 
FdxA and FdxB EPR samples drops 11% (Figs. 5.11 & 5.12). This demonstrates a loss 
of Co2+ signal which would correlate with reductive methylation of the cobalamin, with 
FdxC being most efficient. 
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Figure 5.11: X-band EPR spectra focussing on the Co2+ signal (g=2.25) of cdMS 
reactivation using FdxA as the candidate reactivation factor. Intensity (distance from 
Co2+ line maximum to line minimum) of the complete reactivation mix (green) is 
decreased compared to the intensity of the incomplete reactivation mix (red and blue), 
so the Co2+ signal has decreased. 
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Figure 5.12: X-band EPR spectra focussing on the Co2+ signal (g=2.25) of cdMS 
reactivation using FdxB as the candidate reactivation factor. Intensity (distance from 
Co2+ line maximum to line minimum) of the complete reactivation mix (green) is 
decreased compared to the intensity of the incomplete reactivation mix (red and blue), 
so the Co2+ signal has decreased. 
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Figure 5.13: X-band EPR spectra focussing on the Co2+ signal (g=2.25) of cdMS 
reactivation using FdxC as the candidate reactivation factor. Intensity (distance from 
Co2+ line maximum to line minimum) of the complete reactivation mix (green) is 
decreased compared to the intensity of the incomplete reactivation mix (red and blue), 
so the Co2+ signal has decreased. 
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5.3: Discussion 
In this chapter a thorough investigation of the reactivation of C. glutamicum cobalamin-
dependent methionine synthase has been presented, and a primary candidate for the 
systemic assignment of the previously unidentified C. glutamicum methionine synthase 
reductase has been identified in ferredoxin C.  
 
While attempts to create in vivo reactivation in a recombinant system ended in failure – 
apparently more due to plasmid toxicity than any failure of the pathway – in vitro 
reactivation assays yielded some interesting insights into this previously uncharacterised 
mechanism.  
 
The MTD23 strain used for the in vivo reactivation trials is a methionine auxotroph with 
in frame deletions knocking out both the metE and metH genes. With addition of 1µM 
methionine to the growth medium normal growth of the strain is restored, indicating 
that there are no other effects to the deletions within these genes as can often happen 
with multiple deletion mutants (for example, the OM246 double knockout strain of C. 
glutamicum is auxotrophic for both methionine and threonine).  
 
In theory, providing the knockout strain with C. glutamicum cdMS and MSR would 
restore normal growth. However, with two candidate ferredoxins that had no E. coli 
homologues and possessed extremely electronegative potentials the requisite ferredoxin 
reductase would also be required. After identification of a C. glutamicum ferredoxin 
reductase with no E. coli homologue, FprA, likely required by FdxA and FdxC for 
reduction, this was cloned into the same plasmid as cdMS with its own copies of the 
promoter and translation start site (pRBS49 and pRBS50). While these plasmids 
transformed into the laboratory standard competent cells JM109 and supercompetent 
Chapter 5 
 - 239 - 
cells XL-1 Blue, transformation of MTD23 with either pRBS49 or pRBS50 failed as no 
colonies were yielded on LB agar, LB glucose agar or the extremely rich 
Corynebacterium media BHI.  
 
It was after identification of FprA that BASF explained that with their testing inclusion 
of gene cg3049 (FprA) into the strain restored normal growth to their double knockout 
strain of E. coli. Despite many attempts at successfully transforming MTD23 with the 
cdMS/FprA combination plasmids, these results were never replicated with MTD23. 
Ideally, a plasmid containing E. coli cdMS would have been used as a control, but one 
was not available and PCR amplification was proving, like C. glutamicum cdMS, to be 
difficult.  
 
Growing the strains in LB media and running on an SDS-PAGE gel demonstrated a 
moderate band present at the correct size for cdMS, and activity assays showed activity 
when MTD23 containing a C. glutamicum metH encoding plasmid, although not at the 
same level as in C. glutamicum. This would imply that cdMS is being expressed, but 
that it is not sufficiently active – something is missing; most likely MSR.  
 
The lack of growth on minimal media plates when activity in crude extract is exhibited 
from cells grown in a rich medium can be attributed to cdMS being active until 
oxidative stress derails the Co1+/Co3+ cycling. The fact that growth does occur on 
minimal media plates, but that it is extremely slow, would indicate that the protein is 
active to some degree, but that upon cobalamin transition to Co2+, the cdMS is rendered 
inactive with no method of reactivation available. 
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Because the MTD23 strain would not transform with the metH/fprA construct, it is 
likely that what was missing was a ferredoxin reductase capable of reducing the 
2[4Fe4S] FdxA or FdxC. Despite the apparent failure of in vivo complementation to 
provide a solid answer to the question of which candidate was MSR, other methods 
proved to be more successful in providing insight into the potential novel reactivation 
system. 
 
Attempting to assay C. glutamicum cdMS expressed in E. coli suffers from the same 
issue as all other attempted assays of purified C. glutamicum cdMS – that of no activity 
in anything but pre-column crude extract. Reconstituting the enzyme by incubation with 
methylcobalamin and low concentrations of zinc are somewhat successful, but the 
acidic pH required allowing zinc to remain in solution causes slow precipitation of the 
cdMS apoprotein. Much lower concentrations of zinc can be used, which does allow a 
percentage of the purified cdMS to regain methionine synthase activity, but this is 
obviously a non ideal solution.  
 
It is fortunate that purified C. glutamicum cdMS appears stable in standard buffer 
(20mM Tris pH8) for several days without evidence of precipitation, even at room 
temperature. Upon binding of cobalamin, this stability is reduced to about 10 hours. 
Upon binding of zinc and buffer exchange, this protein stability is reduced further to no 
more than three hours. It is possible that decreasing the concentration of cdMS would 
improve holoenzyme stability, although stability may also be dependent on chaperones 
present in cytosol which is obviously absent for purified cdMS.  
 
Despite this stability as apoenzyme, all experiments were carried out on freshly purified 
cdMS, incubated with cobalamin or cobalamin and zinc as necessary. From this is can 
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be shown that, provided the protein is reconstituted with methylcobalamin and zinc, 
activity can be restored to C. glutamicum cdMS. While this should allow reconstitution 
of cdMS from the native source, with large quantities of cdMS producible 
recombinantly in a form that activity can be renewed in, it was not considered 
worthwhile to attempt further purification from source. This activity is not long lived 
since the holoenzyme stability is lower than that of the apoenzyme. It appears to be 
exclusively the presence of zinc in the homocysteine binding domain which contributes 
to the instability of the holoenzyme when purified and at higher concentrations.  
 
Studying reactivation of C. glutamicum cdMS by UV/visible spectrophotometry was 
limited by the spectral complexity of a complicated assay mixture. While all three redox 
states of cobalamin are involved in the reactivation of cdMS-bound cobalamin, the Co1+  
state is extremely short-lived. It can be trapped by acetylation with iodoacetic acid as it 
is being formed, but obtaining this in the assay mix was unsuccessful as the presence of 
IAA breaks reactivation due to protein precipitation. Following the generation of Co3+ 
cobalamin via UV/Visible spectrophotometry also proved difficult due to a blue-shifting 
of the 545nm Co3+ peak into the 480nm region of the Co2+ cobalamin UV/Vis signal 
similar to E. coli cdMS (Fleischhacker and Matthews 2007). In the assay the 
concentration of the ferredoxin was a fifth that of cdMS in the hope that it would slow 
turnover down sufficiently to be able to measure over a time period via UV/visible 
spectrophotometry, which it did.  
 
Given that the full-length C. glutamicum cdMS has not previously displayed the same 
characteristics of the E. coli cdMS (as detailed by studies on fragmentary E. coli cdMS) 
it was interesting to observe that during reactivation it appeared to exhibit the same 
cobalamin spectral blue shift as that observed during conformational studies of E. coli 
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cdMS (Fleischhacker and Matthews 2007). This blue shift is synonymous with the 
movement of the lower axial ligand from ‘base on’ conformation to ‘base off’ 
conformation (Bandarian et al. 2003). Although the broader ‘hump’ of the 
methylcobalamin 545nm λmax compared to the hydroxycobalamin spectrum may also be 
playing a role in the masking of the spectral change from Co2+ to Co3+ cobalamin.  
 
Studying reactivation of cdMS by UV/Visible spectrophotometry was far from ideal, 
because of the absorbance maxima of many of the components necessary for 
reactivation. Given the differences in Co2+ cobalamin and methylcobalamin spectra (see 
Fig. 4.38.1) particularly the λmax at 300nm in Co2+ cobalamin and the far lower λmax at 
350nm for methylcobalamin, it would be ideal to be able to examine the shift in signal 
from 300 to 350nm. However, due to the other components of the reactivation assay 
which absorb in that region (Fdx, flavin, NADPH) it was extremely difficult to see any 
spectral changes in this region. Because of this the attempt to follow the smaller 480nm 
λmax of Co2+ cobalamin shifting to the 545nm λmax of methylcobalamin was made.  
 
Fig. 5.2 showed an attempt with FdxA in the assay as a control – without the protein 
beginning to precipitate the absorbance spectrum would not have shifted at all, much as 
it failed to for FdxB, while Fig. 5.3 shows an assay with FdxC present. A shift in the 
cobalamin signal from Co2+ state to Co3+ state was noted when reactivation using FdxC 
was observed by UV/Visible spectrophotometry which was not evident when examining 
reactivation with FdxA or FdxB in the reaction mixture. Because of this, HPLC-MS was 
used to try to detect generation of methylcobalamin with this assay conditions.  
 
HPLC-MS was initially used to determine the generation of methylcobalamin by 
reactivation of derailed cdMS. To this end standards of hydroxycobalamin and 
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methylcobalamin were run by HPLC-MS to determine their retention times. Any peak 
at 20.1 minutes should equate to the presence of methylcobalamin in the sample through 
a successful reactivation of Co2+ cobalamin cdMS. It was expected that this would show 
methylcobalamin generation through reactivation. Incomplete reactivation assays (i.e.: 
those missing one of the reactivation prerequisites) failed to generate methylcobalamin 
or strong peak at 20.1 minutes. The small peak visible by HPLC-MS made it important 
to be able to see in greater detail what was eluting at 20.1 minutes. 
 
The three complete assays should have formed methylcobalamin if each ferredoxin can 
act as C. glutamicum MSR. With the FdxB assay, the baseline noise made it difficult for 
accurate determination of a peak developing at 20.1 minutes or not – if there was one, it 
was lost in the baseline. With the FdxA assay, there was a small peak developed, but a 
far greater one with the FdxC assay (Fig. 5.4). While it is undeniable that there is an 
obvious peak formed at 20.1 minutes retention time, HPLC-MS/MS would allow 
determination of whether it is actually methylcobalamin being generated by cdMS 
reactivation. While FdxC and SAM assay generated the largest peak, FdxA should not 
(at least in theory) generate any peak at all. This shows that the ability to identify a peak 
at the same retention time as a standard is not sufficient: the fact that methylcobalamin 
is generated had to be positively proven. Thus HPLC-MS/MS was utilised. 
 
The first two methods (UV/Visible spectrophotometry and HPLC-MS) for examining 
reactivation showed results that could potentially indicate that reactivation is occurring 
under conditions of Co2+ cobalamin bound to cdMS in the presence of FdxC, FprA, 
SAM and NADPH, but did not show the generation of methylcobalamin conclusively. 
While retention time alone is sufficient to differentiate between hydroxyl and methyl -
cobalamin with the slight variation in 525nm signal (see Fig. 4.38.1) it was decided that 
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HPLC-MS/MS would allow more accurate identification of methylcobalamin, and also 
allow a greater number of assays to be run.  
 
With HPLC-MS/MS, the mass spectrum of methylcobalamin was obtained, which acted 
as a ‘fingerprint’ for generation of methylcobalamin. Methylcobalamin breaks down in 
the presence of light quite swiftly, which caused the hydroxycobalamin peak visible at 
8.8 minutes (Fig. 5.5). Clearly visible are the 486, 665, 971 and 1183 m/z peaks 
indicative of methylcobalamin. Without the presence of all of the fingerprint peaks for 
methylcobalamin at the correct retention time, it was considered that methylcobalamin 
was not generated in the assay mix.  
 
All reactivation assays contained cdMS with Co2+ cobalamin bound, before building up 
the requisite associated proteins and substrates for reactivation. There was no 
methylcobalamin generated in any of the assay mixes unless the assay mix contains 
Co2+ cobalamin bound to cdMS, SAM, NADPH, FprA and a ferredoxin. This would 
indicate that without a complete system for cobalamin reduction and methylation 
reactivation is unable to occur. With the complete FdxA assay (Fig. 5.4.3.7) there was a 
methylcobalamin mass spectrum exhibited, which is also supported by the peak (red 
starred) evident in the total ion chromatogram trace. This would indicate that FdxA is 
capable of acting as C. glutamicum MSR as it is capable of generating 
methylcobalamin. Lower levels of methylcobalamin are evident in the FdxB MSR 
candidate mix also. This potentially bears similarity to the human cdMS (Wolthers and 
Scrutton 2009) which demonstrates that under certain conditions cobalamin in human 
cdMS can be reduced by redox proteins other than those designated physiological 
partners.  
 
Chapter 5 
 - 245 - 
The FdxC assays follow much a similar path to those of FdxA, with no generation of 
methylcobalamin until the mix is complete. By mass spectrum intensity it allows the 
generation of much larger quantities of methylcobalamin. When FdxC is provided with 
electrons from NADPH via FprA (Fig. 5.8) generated methylcobalamin goes up by a 
factor of five above the FdxA assay (Fig. 5.6). It is somewhat difficult to measure 
relative intensities of methylcobalamin across assays as peak heights are not always 
ratio respective. Figure 5.9 is from the FdxC assay, with the mass spectrum averaged 
‘off sample’ to show that the methylcobalamin signal is only present on the peak at 20.1 
minutes. From this, hopefully it can be determined that by far the most efficient 
ferredoxin for MSR activity is FdxC, although both FdxA and FdxB appear to be able to 
act as MSR to a limited degree.  
 
Given the sequence similarity of FdxA and FdxC, the result that both can act as MSR 
(although with FdxC being approximately 5 to 6 times more efficient than FdxA) is not 
necessarily surprising. However, the modelled structural differences do raise some 
interesting questions about the specificity of C. glutamicum cdMS for its MSR. It is also 
interesting that FdxB appears to be able to act as MSR also, but with approximately half 
the efficiency of FdxA. The human cdMS is fairly promiscuous with respect to potential 
reactivation factors (Wolthers, K., private communication) utilising a selection of redox 
active enzymes to act as MSR when no specific MSR is present, and from this it appears 
as if C. glutamicum cdMS follows the same pattern.  
 
As these three ferredoxins are the only distinct ones expressed within the C. glutamicum 
genome, it seems most likely that they serve multiple roles within the cell as many 
redox proteins do. The activity in the assays when FprA is present with a ferredoxin 
(but not when FprA is present without a ferredoxin or when a ferredoxin is present 
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without FprA) confirm that FprA is a C. glutamicum ferredoxin reductase capable of 
reducing the 2[4Fe4S] clusters in FdxA and FdxC. The lack of generated 
methylcobalamin when a ferredoxin is absent from an in vitro mix shows that FprA is 
not capable of acting as MSR in the way of E. coli flavodoxin. 
 
The EPR data supported the hypothesis that as methylcobalamin was generated the Co2+ 
signal would decrease, but the signal reduction was not as great as hoped for. It 
certainly failed to disappear completely. This was not entirely unexpected as the EPR 
samples were frozen as quickly after preparation as possible, as it was difficult to keep 
the prepared samples cold enough to avoid precipitation once they were in the sample 
tubes. The Co2+ signal decrease for all three ferredoxins (Figs. 5.10-5.12) correlate with 
the data obtained by HPLC-MS/MS, where each of the ferredoxins generate 
methylcobalamin, although to different degrees. Unlike HPLC-MS/MS, it is more 
difficult to relate this decrease in signal to generation of methylcobalamin, as 
methylcobalamin is not detectable by EPR. By intensity, the Co2+ signal decreases more 
with FdxC acting as MSR than with either FdxA or FdxB. The difference is not as 
marked when studying signal decrease with EPR than as with studying 
methylcobalamin directly with HPLC-MS/MS. Unfortunately it appeared as if there 
were no particularly interesting spectral shifts occurring during reductive reactivation 
(as with the radical in the zinc/cobalamin sample in Fig. 4.42). As it was not feasible to 
trap the reaction and watch reactivation occurring in situ in the spectrometer cavity it is 
possible that there were some spectral shifts that occur during reactivation that occurred 
upon sample preparation. Despite every attempt to freeze the reaction as swiftly as 
possible, it is probable that the reactivation reaction simply occurs too quickly to be 
trapped by rapid freezing with liquid nitrogen. 
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6: General Discussion 
With amino acids being one of the basic building blocks of all life on this planet, any 
information which gains insight into their synthesis or function represents a leap over 
yet another scientific hurdle. The identification of a novel bacterial methionine synthase 
reactivation system in C. glutamicum represents a step in further understanding of 
bacterial metabolic systems as a whole. In other studied bacterial systems, such as 
flavodoxin, the protein acting in the role of MSR is flavin-dependent - the flavodoxin of 
E. coli (Banerjee et al. 1990) to the specific MSR of H. sapiens (Wolthers and Scrutton 
2004). The cdMS reactivation system in C. glutamicum is novel because it relies on a 
ferredoxin-dependent cdMS reactivation system (Fig. 6.1) to recover from oxidative 
inactivation. 
 
cdMS is a fascinating enzyme, as in many bacteria cobalamin is necessary for the 
production of methionine, and yet cobalamin itself, like other tetrapyrrole molecules, 
requires SAM to be produced. This close link was observed as early as 1950, when a 
strain of E. coli  was observed which required either cobalamin or methionine for 
growth (Davis and Mingioli 1950). As SAM is made by MetK (Grossmann et al. 2000) 
from methionine and has so many roles within the cell (Kozarich 1988; Frey 2001) this 
creates an intriguing co-dependency which ties methionine into almost every single part 
of cellular metabolism. Because of this complexity, understanding methionine synthesis 
as completely as possible is essential for greater understanding of bacterial metabolism.  
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Figure 6.1: methionine synthase turnover (in black) and the oxidative inactivation and 
recovery pathway (in red). During normal turnover, a methyl group is transferred from 
methyltetrahydrofolate to homocysteine via cobalamin to generate tetrahydrofolate and 
methionine. During reactivation, ferredoxin reduces oxidised cobalamin to Co1+ before 
methylation by SAM, where the methyl group is then donated to homocysteine to 
generate methionine and return the enzyme to normal turnover cycling. 
 
Initial attempts at characterisation of C. glutamicum cdMS from the native organism 
demonstrated that any type of purification resulted in inactivation of the enzyme. 
Without some method of detection of the protein, in this case activity, it is nigh 
impossible to track through a purification procedure. This yielded a recombinant 
method of purifying protein necessary. This recombinantly produced protein was also 
inactive upon purification, but reconstitution of the inactive enzyme to active form with 
methylcobalamin and zinc demonstrated that obtaining active recombinant enzyme was 
possible. Furthermore, it was demonstrated by UV/visible spectrophotometry, HPLC-
MS and HPLC-MS/MS that generation of methylcobalamin is possible from inactive-
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state (Co2+) protein with recombinant enzyme when provided with the necessary 
reactivation factors of SAM and an electron source for reduction. Study of the cdMS 
protein by UV/visible spectrophotometry displayed minimal environmental alteration of 
the Co2+ cobalamin at different states when compared to the E. coli cdMS (Datta et al. 
2008) or when compared by EPR (Banerjee et al. 1990), when cdMS was provided with 
its physiological substrates. Only fully holoenzyme cdMS displays a significant shift in 
the environment of the cobalamin with the lower axial ligand (histidine) moving from a 
‘base on’ to a ‘base off’ conformation to promote reductive methylation. This occurred 
without the presence of the physiological cofactor. This ‘base off’ conformation spectral 
shift was not evident by EPR studies (data not shown) of the inactive enzyme with 
ferredoxin as it is with the E. coli cdMS/flavodoxin combination (Hoover et al. 1997). 
 
Within the identification of this novel reactivation system came the identification and 
characterisation of two 2[4Fe4S] cluster ferredoxins. C. glutamicum encodes for three 
dedicated ferredoxins that are described without specific roles within the bacterium. 
Two of these, FdxA and FdxC, are dual-cluster ferredoxins with extremely 
electronegative reduction potentials. Although exact midpoint reduction potentials were 
not determined, they exceeded the reducing power of sodium dithionite, but did not 
exceed the reducing power of sodium borohydride. This will place their reduction 
potentials between -620mV and -800mV. This is more than sufficient to reduce Co2+ to 
Co1+ for reductive reactivation of cdMS (Frasca et al. 1988; Banerjee et al. 1990) 
similarly to CobR, a corrin reductase which is capable of reducing Co2+ to Co1+ 
(Lawrence et al. 2008). This system does not exhibit the thermodynamic rift that the 
flavodoxin-based cdMS reactivation possesses for reactivation to occur; H. sapiens 
MSR (Wolthers and Scrutton 2007) does not have a sufficiently electronegative 
reduction potential to – at least on paper – reduce inactivated cdMS. This ferredoxin 
Chapter 6 
 - 251 - 
system does then, however, require the same question to be asked at a different point in 
the electron transference pathway. Unlike MSR (Wolthers and Scrutton 2009) and 
CobR (Lawrence et al. 2008), which should not be able to reduce Co2+ to Co1+, the 
ferredoxin reductase must be capable of reducing these extremely electronegative 
ferredoxins.  
 
fdxA_C_glu      MTYTIAQPCVDVLDRACVEECPVDCIYEGKRMLYIHPDECVDCGACEPVCPVEAIFYEDD 60 
fdxC_C_Glu      MTYTIAQPCVDVLDRACVEECPVDCIYEGKRMLYIHPDECVDCGACEPACPVEAIFYEDD 60 
                ************************************************.*********** 
 
fdxA_C_glu      VPHEWWDYTGANAAFFDDLGSPGGAASLGPQDFDAQLVAVLPPQNQN 107 
fdxC_C_Glu      VPDEWLDYNDANAAFFDDLGSPGGAAKLGPQDFDHPMIAALPPQA-- 105 
                **.** **..****************.*******  ::*.****   
Figure 6.2: Alignment of C. glutamicum FdxA and FdxC protein sequences, showing 
their sequence similarity. 
 
Despite the sequence similarity of FdxA and FdxC (Fig. 6.2) being >90%, FdxC 
produces considerably increased quantities of methylcobalamin when utilised as cdMS 
MSR. While only based on in silico modelling of the ferredoxins (Schwede et al. 2003) 
this is attributed to their significantly different structures (Fig. 6.3). 
 
Figure 6.3: SWISS-MODELs (Schwede et al. 2003) of C. glutamicum FdxA (left) and 
FdxC (right) demonstrating their structural differences. 
 
FdxA FdxC 
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With the identification and characterisation of two 2[4Fe4S] ferredoxins came the 
identification and characterisation of an associated ferredoxin reductase, FprA, which 
was capable of reducing these redox proteins. FprA, an FAD dependent flavoenzyme, 
was found to be essential in reducing both FdxA and FdxC in a recombinant system 
with no directly homologous ferredoxins or ferredoxin reductases. Given the midpoint 
reduction potentials of flavin (Fischer et al. 2002) the mechanism utilised by FprA to 
reduce these two 2[4Fe4S] ferredoxins remains uncertain. Despite this, the generation of 
methylcobalamin from inactivated cdMS demonstrates that reductive reactivation can 
be carried out by reduced 2[4Fe4S] ferredoxin in the C. glutamicum system utilising the 
flavoprotein FprA and NADPH to reduce the ferredoxin (Fig. 6.4) for use as C. 
glutamicum MSR. 
 
 
Figure 6.4: pathway of electrons from NADPH to reduced ferredoxin via a flavin-
dependent ferredoxin reductase. 
 
Further study of this novel system is required, however. Ideally, x-ray crystal structures 
of each of the ferredoxins and the ferredoxin reductase, along with domains 3+4 of C. 
glutamicum cdMS will aid understanding of the interactions between these proteins. As 
the reactivation domain of cdMS, domain 4 is of particular interest for direct 
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comparison to that of the E. coli and H. sapiens cdMS reactivation domains. As a novel 
system, understanding the interactions of the components is particularly critical. Further 
mutants of the ferredoxins could potentially lead to clarification of how electrons flow 
in this ferredoxin-mediated reductive reactivation system, particularly using a stopped-
flow or flash-induced reaction system combined with EPR to observe electron transfer. 
Fluorescence spectroscopy of FprA would reveal further details about the flavin 
binding. While it has been demonstrated that E. coli flavodoxin is not capable of acting 
as MSR to the C. glutamicum cdMS, given the utilisation of alternative flavodoxins by 
human MSR (Wolthers and Scrutton 2009) in some situations, it would be fascinating to 
study whether the C. glutamicum ferredoxins could act in that role – even if it is 
unlikely that reactivation would occur when mixing two such radically different 
systems. 
 
The work within this thesis has presented insights into a previously undocumented 
reactivation mechanism for cdMS. Of the three objectives laid out in chapter 1, the first 
(purification and characterisation of C. glutamicum cdMS) has been met by the 
recombinant expression and purification of the enzyme as described in chapter 4. The 
second objective has not been strictly met; however steps have been made toward this 
by the recombinant expression and reconstitution of purified protein to an active form. 
Increasing methionine export has not been achieved. This would have been of particular 
use in fermenter-based (Nakayama et al. 1978; Mondal et al. 1996) biotechnological 
production of methionine, as the molecule could have been purified from extracellular 
media rather than from cytosol. The third objective, that of gaining insight into the 
previously uncharacterised C. glutamicum cdMS reactivation mechanism, has been met 
in chapter 5, with the identification of a ferredoxin-mediated reductive reactivation 
system. 
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The identification of a previously undocumented cdMS reactivation system is of 
particular interest to the biotechnology industry as C. glutamicum is widely used for 
amino acid production (Sahm et al. 1996; de Graaf et al. 2001; Hirasawa et al. 2001; 
Ruckert et al. 2003; Kumar and Gomes 2005; Trotschel et al. 2005) as a feed additive. 
Therefore any insight into the biosynthesis of an industrially important chemical aids in 
improving yields and also potential profits. It also will be of considerable interest to the 
field of systems biology as methionine plays so many incredibly integrated and complex 
roles within the cell. To fully map and understand the many complex reactions which 
occur every second within a live cell requires knowing the different mechanisms utilised 
by cells to carry out these processes. Yet another system of reactivation may exist for 
other bacteria, such as Halorhodospira halophila, which possesses a cdMS lacking the 
reactivation domain. While it may be some time before this novel system is 
characterised to the degree of the E. coli and H. sapiens mechanisms, the revelation of a 
novel cdMS reactivation system is a first step in greater insight into the metabolic 
behaviour of bacteria as a whole. While important in a biotechnological sense, it is also 
significant in the advancement of systems biology and synthetic biology. While 
significant progress has been made in the generation of a ‘minimal’ genome both in vivo 
(Gibson et al. 2008) and in silico (Forster and Church 2006; Glass et al. 2006) there 
remain genes which are essential, yet lack explanation for precisely why. To this end, 
the identification of any novel system potentially contributes to enhancing 
understanding of overall metabolism and growth of a cell. 
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